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Neuroblastoma - a general introduction  
Neuroblastoma is the most common extracranial tumor in children, with an incidence of 10.2 
cases per million children younger than 15 years [1, 2]. In the Netherlands, approximately 25 
new patients are diagnosed with neuroblastoma every year (www.skion.nl). The majority of 
neuroblastoma tumors arise in children under the age of 10, with a median age of 18 months 
at time of diagnosis [1, 3].  
The disease course in neuroblastoma patients is highly heterogeneous, ranging from 
spontaneous regression to highly aggressive disease [1-5]. Neuroblastoma accounts for 9.1% 
of all pediatric cancer deaths [1, 2]. Over the past decades, 5-year survival rates of 
neuroblastoma patients in general have improved significantly to 74% [1]. Unfortunately, 
however, overall survival of patients with high-risk, metastatic disease remains poor (Fig. 1) 
[1-4, 6, 7]. These high-risk patients receive intensive multimodal therapy, including 
chemotherapy, surgery, radiation, and myeloablative chemotherapy with autologous stem 
cell transplantation. Treatment is often followed by retinoic acid-induced differentiation 
therapy and/or immunotherapy [1-4, 7]. Despite this intensive treatment strategy, the 5-year 
event-free survival of the high-risk patients is still only about 50% (Fig. 1) [7]. Therefore, it is 
important to increase our understanding of what drives neuroblastoma development and 




Genetic alterations in neuroblastoma     
In general, pediatric tumors have a much lower mutational burden relative to adult 
malignancies [8, 9]. Consequently, only few recurrent somatic mutations have been identified 
 
Figure 1. Overall survival probability (OS) of 
3352 high-risk neuroblastoma patients 
diagnosed between 1990 and 2010 according to 
era. Five-year OS rates + Standard Error per era 
are as follows: 1990-1994 (n=356): 29% + 0.02; 
1995-1999 (n=497): 34% + 0.02; 2000-2004 
(n=1015): 47% +0.02; and 2005-2010 (n=1484): 
50% + 0.02.  Data are derived from the Children’s 
Oncology Group Statistics and Data center. 
Graph is reproduced with permission from [7]. © 
(2020) American Society of Clinical Oncology.  All 
rights reserved.  
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in sporadic neuroblastoma at time of diagnosis [9-11]. Among the most frequently detected 
genetic alterations are amplifications of the MYCN and ALK oncogenes, as well as activating 
ALK mutations. Additionally, focal deletions and putative loss-of-function mutations in the 
potential tumor suppressors ARID1A, ARID1B and ATRX have been described in low frequency 
in primary neuroblastoma tumors [10-17]. Next to these focal copy number variations and 
mutations, gain of chromosome arm 17q and loss of chromosome arms 1p and 11q are 
recurrently detected [18-23]. While several potential tumor suppressor genes can be found 
in the smallest region of overlap on chromosome 1p, candidate oncogenes and tumor 
suppressor genes on chromosomes 17q and 11q, respectively, remain to be determined [24-
30]. Given this genetic heterogeneity and the relative scarceness of recurrent somatic 
mutations in neuroblastoma [9-11], current research efforts are aimed at identifying 
(targetable) pathways that drive neuroblastoma development and progression.  
 
The neural crest - neuroblastoma cell of origin and model for cancer progression 
Since neuroblastoma is a developmental tumor originating from poorly differentiated, 
incompletely committed neural crest cells, mechanisms controlling neural crest development 
and differentiation have been suggested to contribute to neuroblastoma development and 
progression [1, 31, 32]. Therefore, the similarities between neural crest development and 
neuroblastoma progression provide an appealing starting point to identify (targetable) 
pathways that drive neuroblastoma development and progression. 
The neural crest consists of a transient, multipotent embryonic cell population derived from 
the neuroectoderm. During normal neural crest development, neural crest progenitor cells 
arise at the neural plate border, a region at the interface between the neural plate and 
non-neural ectoderm. Upon folding of the neural plate into the neural tube (neurulation), the 
neural plate borders meet, locating the neural crest cells at the dorsal side of the tube. Neural 
crest cells subsequently migrate to various locations within the embryo, where they 
eventually differentiate and give rise to various different neural crest-derived cell types, 
including neurons, glia, smooth muscle cells, melanocytes, adrenal chromaffin cells, 
chondrocytes and odontoblasts (Fig. 2) [33-36].  
In addition to the fact that the neural crest cell is thought to be the cell of origin in 
neuroblastoma, many parallels can be seen between neural crest development/migration, 




cancer cells may reactivate programs essential during neural crest development that allow 
these cells to metastasize and escape therapeutic intervention. Therefore, in the following 
paragraphs key processes essential during neural crest development, as well as tumor cell 
behavior, will be discussed in more detail. 
 
Epithelial to mesenchymal transition is essential during neural crest development and 
cancer progression 
In order to relocate to their final destination within the embryo, neural crest cells undergo a 
reversible developmental process known as epithelial to mesenchymal transition (EMT). This 
is a complex molecular program where cells transition from an epithelial phenotype into a 
migratory and invasive, mesenchymal phenotype (Fig. 3). This allows neural crest cells to 
delaminate from the neural tube and migrate to distant locations within the embryo [34, 38, 
39].  
Next to bestowing a migratory and invasive phenotype upon neural crest cells, EMT also 
 
Figure 2. Neural crest development during gastrulation and neurulation. (A) During gastrulation, induction of the neural 
crest begins with specification of the neural plate border in response to coordinated signaling events. (B) The neural crest 
is further specified from the neural plate border as the neural plate folds into a tube. (C) During and after neural tube 
closure, pre-migratory neural crest cells undergo epithelial-to-mesenchymal transition in order to delaminate from the 




induces stem cell-like properties, preventing apoptosis and senescence while contributing to 
local immunosuppression [40-45]. Consequently, tumor cells are thought to adopt this 
developmental program, at least in part, to acquire progenitor-like properties, gain invasive, 
metastatic properties and escape therapeutic intervention [43-49]. For instance, multiple 
studies have linked the expression of EMT markers to steps in the metastatic cascade 
(reviewed in [44]) as well as poor outcome in a variety of tumor types including breast, 
ovarian, hepatocellular and colorectal carcinomas, amongst others (reviewed in [50]). 
Additionally, longitudinal studies in breast cancer patients revealed that the ratio of 
 
 
Figure 3. Epithelial to mesenchymal transition as driver of neural crest development and tumor progression. (Middle) 
Overview of the transition from pre-migratory epithelial neural crest cells or non-invasive tumor cells towards a migratory, 
invasive phenotype. (A) In response to intra- and extracellular EMT inducing signals, a transcriptional program controlled 
by EMT-transcription factors is activated. These transcription factors enhance the expression of effector genes essential for 
migration and delamination, and inhibit transcription of genes associated with an epithelial phenotype, such as proteins 
involved in cell-cell contacts. In addition, these transcription factors are involved in controlling progenitor-like features, 
such as self-renewal and anoikis resistance. (B) For an epithelial cell to become migratory, cell-cell adhesions are 
disassembled, while cells lose basal-apical polarity and establish a leading and trailing edge. (C) At the leading edge, the 
cortical actin cytoskeleton is extensively remodeled to form highly dynamic, actin-rich membrane protrusions that probe 
the environment and facilitate forward movement. (D) In addition, neural crest and tumor cells express membrane-bound 
or secreted proteinases known as matrix metalloproteinases (MMPs). These proteins further promote migration by 
remodeling the extracellular matrix (ECM) and altering cell adhesion by facilitating shedding of cell surface molecules such 




mesenchymal compared to epithelial circulating tumor cells increased progressively after the 
development of refractory disease [51]. Consistently, EMT was shown to contribute to 
chemoresistance in breast cancer as well as pancreatic cancer and neuroblastoma [52-54]. 
Mutations in genes implicated in EMT were also strongly enriched in neuroblastoma relapses 
and present in about 80% of neuroblastoma recurrences [55]. 
 
EMT-transcription factors control EMT and neural crest behavior  
Specific subsets of transcription factors tightly control the activation of neural crest EMT as 
well as directional migration, and later on cell fate decisions [33-35, 56]. For instance, 
members of the ZEB, TWIST, SNAIL and SOX families, amongst others, are key determinants 
driving EMT during neural crest development [34, 35]. Apart from activating an EMT effector 
program, EMT-transcription factors also control each other’s expression. This to ensures that 
expression of these factors is regulated both spatially and temporally during neural crest 
delamination and migration (Fig. 3A). Moreover, several of these EMT-transcription factors 
control cell survival, cell-fate decisions and maintain neural crest cells in an undifferentiated 
state [34, 35]. Hence, deregulation of this process may predispose multipotent neural crest 
cells to malignant transformation, while aberrant activation of EMT-inducers could contribute 
to malignant transformation of tumor cells [56-58]. Consistently, a variety of 
EMT-transcription factors indeed does contribute to neuroblastoma development and 
progression (as reviewed in [56]). Expression of the EMT-transcription factor FOXD3 was 
significantly lower in high stage neuroblastoma tumor samples, while high expression of 
FOXD3 correlated positively with patient survival and ectopic overexpression inhibited 
neuroblastoma cell growth and migration [59]. In addition, depletion of SNAI2, a member of 
the SNAIL family of EMT-transcription factors essential during neural crest development, not 
only enhanced the migratory and invasive potential of neuroblastoma cells ([60] and this 
thesis), but also promoted neuroblastoma differentiation while enhancing sensitivity to 
retinoic acid induced differentiation therapy (this thesis). 
 
Loss of apical-basal polarity and cell-cell adhesions 
Before they migrate, neural crest cells reside within a polarized epithelial layer that is held 
together by junctional complexes [61, 62] (Fig. 3B). Upon initiation of EMT, EMT-transcription 
factors inhibit the expression of genes involved in the maintenance of these cell-cell contacts. 
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Consequently, cells lose their apical-basal cell polarity and cell-cell adhesions dissolve [43, 61, 
63] (Fig. 3B). It was initially thought that a complete EMT, where cell-cell contacts are lost and 
mesenchymal cells migrate individually, was essential for migration. However, more recent 
evidence shows that EMT is not a binary state, but should be viewed as a spectrum of 
intermediate states that allows for a dynamic and varying cell-cell junction organization that 
dictates the degree of collective migration [46, 64-66]. While an essential component of EMT 
and neural crest migration, and linked to tumor cell migration and metastasis formation in 
general, little is known about cell-cell adhesion dynamics during neuroblastoma progression 
and this aspect falls outside the scope of this thesis.  
 
Cytoskeletal remodeling and cell migration 
During development, neural crest cells migrate to distant locations in the embryo where they 
give rise to a variety of tissues [35]. Similarly, during metastasis formation, neuroblastoma 
cells migrate away from the primary tumor to invade and colonize distant tissues. To do so, 
cells undergo complex changes in cellular architecture [67, 68] (Fig. 3). During the course of 
EMT and initiation of migration, cells extensively reorganize their cortical actin cytoskeleton 
and establish front to rear polarity. At the leading edge, highly dynamic, actin-rich membrane 
protrusions are formed that probe the environment and facilitate cell motility (Fig. 3C). These 
protrusions can be broad sheet-like lamellipodia, thin filopodia at the edge of the lamellipodia 
or proteolytic invadopodia that locally degrade the extracellular matrix. Through 
integrin-based nascent adhesions these cellular protrusions are attached to the underlying 
substrate. As the leading edge of the cell progresses forward, newly formed adhesions either 
disassemble or mature into focal complexes. Forward movement of the cell is a consequence 
of cell body contraction brought about by myosin II-mediated cytoskeletal contraction that 
generates traction forces at these adhesion sites. This high level of contractility results in the 
disassembly and detachment of the adhesions at the rear of the cell, allowing it to move in 
the direction of the leading edge. Repetition of this cycle of protrusion extension, adhesion 
formation and maturation and rear retraction allows directional cell migration [69-74].  
Given the important role of actin remodeling in cell migration, as well as intracellular 
transport, proliferation and differentiation (see Box I), several actin binding and regulatory 
proteins have been linked to invasive cell behavior and metastasis formation [75], in 




Box I – The actin cytoskeleton and actin binding proteins 
The actin cytoskeleton is a highly dynamic network of actin polymers essential for many cellular 
processes and characteristics, including cell morphology, cell motility, vesicle and organelle 
movement, cell division, and even differentiation. Coordinated polymerization of actin filaments 
produces pushing forces required for the formation of protrusive structures essential for cell 
motility, as well as the formation of axons and dendrites during neuronal differentiation. On the 
other hand, myosin II motor proteins bundle actin filaments and produce contractile forces required 
for cytokinesis, adhesion formation and cell migration [83, 84]. Moreover, both the amount of 
nuclear actin as well as changes in cytoskeletal tension regulate transcription [85, 86]. These 
versatile roles require tightly spatiotemporal controlled remodeling of the actin cytoskeleton in 
response to intra- and extracellular cues. Additionally, actin remodeling involves a variety of actin 
binding proteins and regulators, including Rho-GTPases [78, 84, 86, 87].  
 
Actin cytoskeletal remodeling is largely dictated by the dynamic polymerization and 
depolymerization of actin filaments (F-actin). These actin polymers are formed by actin monomers 
(G-actin) that assemble into polarized filaments. Addition of monomers is favored at the (+) or 
barbed end of the filament, whereas disassembly is favored at the (-) or pointed end. Many actin 
binding proteins control filament nucleation, turnover and branching [87]: 
• Actin filament nucleation is facilitated by two classes of actin nucleating proteins: formins 
and the Arp2/3 complex. Whereas formins mediate nucleation and elongation of 
unbranched actin filaments, Arp2/3 complexes facilitate filament branching 
• Actin filament severing is mediated by cofilins and gelsolins 
• Actin-monomer-binding proteins profilin and thymosin-β4 compete for actin monomers. 
By sequestering actin monomers, thymosin-β4 reduces the pool of G-actin available for 
polymerization and severs as a buffer for unpolymerized actin. Monomer binding by profilin 
inhibits nucleation and (-) end elongation without affecting (+) end polymerization.  
• Filament capping protein Capz prevents actin monomer addition at the (+) end of the 
filament, whereas tropomodulins prevent actin dissociation at the (-) end. 
• Actin filament elongation is promoted by binding of formins or Ena/VASP tetramers to 
growing (+) ends as they facilitate monomer addition and inhibit filament capping. 
• Actin filaments are stabilized by the binding of tropomyosins that prevent cofilin mediated 














dynamics and regulate actin rearrangements in response to specific signaling events [76, 77]. 
In addition to cell migration, Rho-signaling also plays an important role during neuritogenesis, 
a crucial part of neuronal differentiation of neural crest cells. During neuritogenesis thin 
actin-rich protrusions are formed extending from the neuronal cell body that eventually 
mature into axons and dendrites [78]. Mutations affecting Rho-GTPases are found in a variety 
of tumors, and in several tumor types overexpression of Rho-GTPases has been associated 
with an enhanced aggressive and invasive phenotype [79]. Moreover, as spatiotemporal 
activation of Rho-GTPases is tightly controlled by guanine nucleotide exchange factors (GEFs) 
and GTPase-activating proteins (GAPs) [76, 77, 80], aberrant expression of these GEFs and 
GAPs is found in many different tumor types [79]. Additionally, Rho-signaling has been linked 
to neuroblastoma progression, as several genetic alterations in genes associated with Rho 
signaling have been identified in primary neuroblastomas [11, 81].  
Next to aberrant Rho-signaling, abnormal expression of actin binding proteins has been 
associated with metastatic disease in a variety of tumor types [75]. In line with this notion we 
have investigated the correlation between neuroblastoma disease outcome and mRNA 
expression of various regulators of adhesion dynamics and cytoskeletal organization that 
reside within the same macromolecular complex in neuroblastoma cells ([82] & Chapter 3 of 
this thesis). Moreover, in Chapter 4 we further evaluate the correlation of the actin binding 
protein Tropomodulin 2 with event-free survival of neuroblastoma patients, as well as its role 
in neuroblastoma protrusion formation and cell migration.  
 
Remodeling of extracellular matrix 
While the extracellular environment of neural crest cells is rather permissive for emigration, 
neural crest cells still encounter physical barriers such as basement membranes and the dense 
meshwork of the extracellular matrix (ECM) during delamination and migration. To cross 
these boundaries and move to distant locations, neural crest cells produce membrane-bound 
and/or secreted proteins known as matrix metalloproteinases (MMPs) [39, 88-90]. These 
MMPs facilitate proteolytic degradation of several cell surface proteins, including cadherins 
and integrins, and extracellular matrix components encountered during migration (Fig. 3C) 
[91]. Similar to neural crest cells, migrating and invading tumor cells encounter the physical 
barriers of basal membranes and the ECM. Consistently, several MMPs are linked to 




malignant tumors [92-94]. For instance in neuroblastoma, MMP-9 and MMP-14 have been 
linked to unfavorable pathology. While MMP-9 mainly contributes to tumor vasculature, 
knockdown of MMP-14 inhibited migration, invasion and angiogenesis of neuroblastoma cells 
[95-98]. Nevertheless, little is known about how MMPs may contribute to neuroblastoma 
progression.  
 
Neural crest cell differentiation 
Following migration to different parts of the embryo and reaching their final destination, 
neural crest cells need to transform from migratory cells into lineage committed, 
differentiated neural crest derivatives. This often entails a process reciprocal to EMT, known 
as mesenchymal-to-epithelial transition (MET) [99-101]. After MET, neural crest cells 
continue differentiation into their distinct derivatives. This process is tightly controlled by 
transcription factors, including several EMT-transcription factors, that activate specific 
differentiation routes that eventually determine the differentiated phenotype. With regard 
to neuroblastoma, the subset of neural crest cells that gives rise to the sympathetic lineage is 
of specific interest. These precursors will generate the sympathetic ganglia and adrenal 
medulla, the locations where the majority of primary tumors arise [3, 32]. 
Neuroblastoma is clinically a highly heterogeneous disease where survival of neuroblastoma 
patients is strongly correlated with the degree of differentiation of the tumor. Patients 
presenting with more differentiated tumors have a better outlook compared to those with 
poorly differentiated tumors [102]. A unique subset of neuroblastoma patients presents with 
a specific pattern of metastasis and is classified as stage 4S. These patients have a very good 
prognosis as tumors of these patients can even undergo spontaneous regression [5]. While 
the precise underlying mechanism has not been identified, the regression of stage 4S tumors 
strongly resembles the process where excess neural crest-derived precursors undergo 
apoptosis at the terminal stages of sympathoadrenal maturation [103]. Additionally, the 
localized benign ganglioneuromas, are suggested to be the remnant of fully matured and 
differentiated neuroblastic tumors, further underlining the significance of differentiation in 
neuroblastoma [5, 102].  
Differentiation, or actually a block thereof, is thus thought to play an important role in 
neuroblastoma development, progression and even therapy resistance. Consistently, genes 
controlling neural crest cell differentiation, such as MYCN and PHOX2B, are often mutated or 
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overexpressed in high-risk neuroblastoma [102, 103]. On the other hand, promoting 
neuroblastoma differentiation may therefore reduce the malignant phenotype of 
neuroblastoma cells ([104-106] and this thesis). Consistently, retinoic acid-based therapies 
are successfully used as maintenance therapy to differentiate residual disease in high-risk 
neuroblastoma patients after intensive treatment [107, 108]. However, while retinoic 
acid-based therapies have increased survival rates of neuroblastoma patients, many patients 
fail to respond and relapse [107-109]. Hence, there is an urgent need to identify (targetable) 
pathways that control neuroblastoma differentiation or enhance sensitivity to retinoic acid in 
order to develop novel treatment strategies that improve patient survival. 
 
Physical cross talk between cells and the microenvironment  
Neural crest cells encounter a myriad of signals during initial development and their extensive 
journey through the embryo. Next to secreted chemoattractants and inhibitors derived from 
neighboring tissues, induction of EMT, directional migration and subsequent differentiation 
of neural crest cells depends on the physical interactions between cells, as well as with their 
direct environment [38, 39, 110-113]. For instance, physical contact via long-lasting cell-cell 
contacts or transient cell collisions control neural crest cell polarity, and the composition of 
the ECM along with the physical properties of the microenvironment are fundamental for 
neural crest cells migration [113-118]. Similarly, cancer progression is strongly influenced by 
the interaction of tumor cells with their microenvironment [66, 119]. Hence, receptor 
molecules translating environmentally derived cues into signal transduction pathways that 
modulate gene expression and control cell behavior may play key roles during development 
and cancer progression. 
 
TRP channels as integrators of environmental signals 
Members of the TRP (Transient Receptor Potential) channel family of cation channels are well 
known for their role as integrators of physical and chemical cues. The family comprises 28 
mammalian members that are subdivided into six subfamilies based on their sequence 
similarity; TRPA (ankyrin), TRPC (canonical), TRPM (melastatin), TRPML (mucolipin), TRPP 
(polycystin) and TRPV (vanilloid) [120, 121]. The first TRP channel was identified in Drosophila 




to continuous light, granting the founding member of the family with the name of Transient 
Receptor Potential (TRP) [122, 123].  
TRP channels are key players in sensory perception, including response to temperature and 
light as well as the perception of taste and pain [121, 124]. In addition, they are implicated in 
transducing mechanical stimuli [125-127]. In response to these divergent stimuli, TRP 
channels modulate their ion conductive properties and mediate the translocation of signaling 
ions across the plasma membrane. This flux of ions subsequently activates downstream 
signaling pathways, translating the initial signals into a variety of cellular responses [120, 121, 
124]. Additionally, TRP channels can regulate cell behavior in manners independent of their 
ion conducting properties ([128] and this thesis).  
While observed for the first time in Drosophila, it now appears that several mammalian TRP 
channels are part of large macromolecular complexes ([82, 128-131] and this thesis). Apart 
from localizing signal transduction, assembling into such complexes may also serve to 
enhance the rate of signal transmission [131, 132]. Similar to the situation in Drosophila, these 
complexes tether TRP channels to the actomyosin cytoskeleton, thereby allowing TRP 
channels to regulate cytoskeletal dynamics [128, 129]. Consistently, several TRP channels 
have been shown to control cytoskeletal remodeling, thereby regulating processes such as 
cell migration but also axonal outgrowth, a process essential during neuronal differentiation 
[128, 132]. 
In addition to immediate effects on cell behavior, TRP channels can produce more sustained 
effects by regulating gene expression [128, 133]. This control over gene expression can be 
achieved by regulating biosynthesis, phosphorylation/dephosphorylation or induction of 
nuclear translocation of transcription factors. For instance, several TRP channels are able to 
activate the nuclear factor of activated T cells (NFAT) and NF-κB transcription factors in a 
calcium-dependent manner [134-140]. Additionally, TRP channels can control gene 
expression in manners independent of their ion conducting properties, for instance through 
tensional regulation or through nuclear translocation of proteolytically cleaved moieties 
([128, 141] and this thesis). Hence, by both immediate and sustained control of cell behavior 
in response to a broad panel of stimuli, TRP channels play critical roles during (embryonic) 
development and tissue homeostasis [128, 142-144]. Consequently, perturbed TRP 
channel-mediated signaling underlies a variety of human pathologies, including renal failure 
and cancer [128, 143-146]. 
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The channel-kinase TRPM7 
TRPM7 is a member of the melastatin-related (TRPM) subfamily of TRP channels and is 
ubiquitously expressed [147]. Analogous to other TRP channels, TRPM7 consists of six 
transmembrane domains in between large N- and C-terminal domains that are located in the 
cytoplasm (Fig. 4). Functional TRPM channels act as homo- or heterotetramers [148-150], 
where the interaction between the monomers is mediated by the C-terminal coiled coil 
domain that is highly conserved among the TRP channels [151-153]. Whereas the channel 
domain of TRPM7 is non-selective to divalent cations, it is notably permeable to Ca2+ and Mg2+ 
ions [154]. TRPM7 channel opening is regulated in response to a variety of stimuli. For 
instance, intracellular Mg2+ ions or Mg2+-complexed nucleotides, as well as acidification of the 
cytosol inhibit channel opening [155]. Additionally, channel activity can be modulated by 
G-protein coupled receptor signaling and in response to mechanical stimuli [156-162].  
Both TRPM7 and its closest relative TRPM6 are distinct from other TRP family members as 
they feature a C-terminal α-kinase domain [163, 164]. While it was initially thought that the 
kinase-domain was predominantly involved in channel opening [165, 166], it is now well 
established that it also acts to transmit signals by phosphorylation of downstream targets 
[167-173]. Recognition and phosphorylation of these downstream substrates appears to be 
facilitated by extensive autophosphorylation of the C-terminal region of TRPM7 kinase 
domain [174-177]. Moreover, the kinase-substrate interactions seem to be Ca2+ and 
Mg2+-dependent, suggesting that ion influx in response to channel activation mediates 
kinase-substrate interactions and subsequent phosphorylation [169, 170].  
By phosphorylation of its targets, the TRPM7 kinase domain controls a variety of processes. 
For instance, TRPM7 may control rates of protein elongation by phosphorylation of the 
eukaryotic elongation factor-2 kinase (eEF2K) [167] and affect vesicle fusion by annexin 1 
phosphorylation [169]. In addition, by phosphorylation of the myosin II heavy chain isoform 
A, TRPM7 controls cytoskeletal remodeling, adhesion dynamics and cell migration by 
inhibiting myosin II induced contractility [170, 171]. Moreover, TRPM7 may control actin 
dynamics by phosphorylating the actin regulatory protein Tropomodulin 1 [168] (Box I). 
Interestingly, it was recently shown that the kinase domain of TRPM7 can be proteolytically 
cleaved from the channel domain [178, 179], after which the kinase domain translocates into 
the nucleus [179]. Here, the kinase domain directly affects transcription by binding 





Figure 4. The TRPM7 protein. TRPM7 consists of 6 transmembrane (TM) domains, with a pore forming domain between 
TM domains 5 and 6, and long C- and N-termini that reside within the cytosol. Like all TRP channels, TRPM7 is organized 
into a tetrameric structure to form a channel pore. Within the N-terminal tail there are 4 domains that are conserved 
between the TRPM subfamily. The TRP box, present in all TRP channel, resides proximal to the last transmembrane domain 
and is followed by the coiled-coil domain which is thought to be necessary for monomer interaction. An α-kinase domain 
can be found at the end of the C-terminal tail. In between the coiled-coil domain and the kinase domain a Serine/Threonine 
rich region which is heavily autophosphorylated and required for substrate interaction.  
controlling ion influx, but also by regulating a wide variety of downstream processes through 
phosphorylation of effector proteins, TRPM7 represents an important and versatile regulator 
of cell behavior in health and disease.  
 
TRPM7 function in health and disease  
A large burden of evidence implicates TRPM7 in a wide variety of physiological and 
pathophysiological processes. Using conditional TRPM7 knockout mice it has become clear 
that there is a spatiotemporal requirement for TRPM7 during development and 
organogenesis. For instance, TRPM7 expression is essential during mouse early embryonic 
development, as global deletion of TRPM7 results in embryonic lethality before day 7.5 of 
embryogenesis (E7.5) [180]. However, loss of TRPM7 after day E14.5 did not affect viability of 
embryos nor did it result in severe developmental defects [181]. Tissue-specific deletion of 
TRPM7 during early embryonic development revealed that TRPM7 is essential for correct 
thymopoiesis [180], kidney development from the metanephric mesenchyme [181], and 
proper heart development and function [182]. Interestingly, cardiac-targeted deletion of 
TRPM7 during later stages of cardiac development (>~E13) has no effect on heart 
development and viability of mice, underscoring the temporal requirement of TRPM7 [182].   
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TRPM7 also plays an important role during neural crest development. Neural crest specific 
depletion of TRPM7 during early development stages led to loss of neural crest-derived 
pigment cells and dorsal ganglion neurons in mice [181]. Similarly, in zebrafish mutants 
lacking TRPM7 expression, neural-crest derived melanophore precursors die after migration 
and fail to produce differentiated melanophores [183, 184]. Moreover, TRPM7 mutant 
zebrafish larvae are temporarily unresponsive to touch for a period of 12 hours [183-185]. 
Forced expression of TRPM7 in primary sensory neurons reverts this phenotype, suggesting a 
temporal requirement of TRPM7 for differentiation or function of these primary sensory 
neurons [185].   
In the developing rat brain, TRPM7 expression peaks two weeks after birth during the period 
associated with synaptogenesis and neuritogenesis. Overexpression of TRPM7 in cultured 
cortical neurons of rats negatively regulates neurite outgrowth, number and branching [186], 
while inhibition or siRNA mediated knock down of TRPM7 in mouse primary hippocampal 
neurons enhanced neurite growth and maturation [187]. Consistently, postnatal knockdown 
of TRPM7 reduced synaptic density and plasticity in mice. This phenotype can be restored by 
expression of the kinase domain, but not the channel domain, of TRPM7. Moreover, the 
effects of TRPM7  on synaptic density appear to depend on its control over actin remodeling, 
as it is mediated by the interaction and subsequent phosphorylation of the actin regulatory 
protein Cofilin [188] (Box I). Taken together, TRPM7 appears to guard neuritogenesis and 
control synaptogenic development, processes that are essential during neuronal 
differentiation, by regulating actin dynamics. 
Next to its role during development, TRPM7 has recently been identified as a member of the 
‘core essentialome’ (genes essential for viability or optimal fitness) in the chronic myeloid 
leukemia cell line KBM7 and its derivative HAP1, suggesting that TRPM7 is critical for cell 
survival of these cells [189]. In line with this, earlier reports showed that loss of both TRPM7 
alleles in the chicken B-cell cell line DT-40 B is not compatible with survival of these cells [165, 
190].  Similarly, disruption of TRPM7 expression and activity impairs cell proliferation, cell 
growth and cell survival of a variety of cell types (reviewed in [191, 192]). Consistently, 
overexpression of TRPM7 has been observed in a variety of different tumor types [193-195]. 
In contrast, other studies have shown that diminished expression of TRPM7, either by 
complete knockout or stable knockdown, does not influence cell proliferation or cell viability 




endothelial cells [199], and siRNA mediated silencing or pharmacological inhibition of TRPM7 
protected neuronal cells against hypoxia- and ischemia-induced neuronal cell death [200-
202]. While rather conflicting, these observations probably reflect the cell type specific 
functions of TRPM7, as well as the presence or absence of cell specific compensatory 
mechanisms. Moreover, methodological differences such as transient inhibition of TRPM7 vs. 
stable knockout and variability in obtained TRPM7 levels/reduction could also explain these 
observed discrepancies.  
In line with its involvement in regulating actin remodeling, adhesion dynamics and 
actomyosin contractility, and the direct connection between these features and cell 
migration, TRPM7 was shown to control migration in both non-malignant as well as tumor 
derived cell lines in vitro [191, 192, 194]. Moreover, TRPM7 expression has been linked to the 
clinical stage and presence/formation of distant metastasis in multiple tumor types [193, 196, 
197, 203, 204]. Interestingly, this increase in migratory and invasive behavior may find its 
basis not only in the direct effects of TRPM7 on cytoskeletal dynamics and adhesion 
remodeling, but may also involve more sustained effects mediated by TRPM7 mediated 
activation of an EMT-like program ([141, 197, 205-209] and this thesis).  
 
TRPM7 and neuroblastoma 
Considering the essential role of TRPM7 during very early embryonic and neural crest 
development, as well as its function in EMT, cell migration and cell differentiation, it is not 
surprising that TRPM7 contributes to neuroblastoma development and progression. Research 
from our group has revealed that modest overexpression of TRPM7 in the mouse N1E-115 
neuroblastoma cell line relaxes the actomyosin cytoskeleton, promotes cell spreading and the 
formation of invasive structures known as invadosomes [170]. Additionally, MYCN is thought 
to promote cell migration and enhance cell proliferation of neuroblastoma cells by 
upregulation of TRPM7 [210, 211]. We have recently shown that modest overexpression of 
TRPM7 enhances both in vitro and in vivo metastasis formation, whereas TRPM7 depletion 
reduces this neuroblastoma dissemination in vivo ([197] and unpublished data). We observed 
that TRPM7 maintains neuroblastoma cells in a progenitor-like state by transcriptional 
regulation of EMT-transcription factor SNAI2 [197]. However, the exact details or signaling 
mechanism by which TRPM7 regulates the malignant character of neuroblastoma cells has 
remained elusive. Is TRPM7, similar to its relatives in Drosophila, part of large macromolecular 
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complexes? If so, do these TRPM7-interactors contribute to malignant cell behavior and are 
they directly controlled by TRPM7 channel or kinase function? In addition, is the 
transcriptional regulation of EMT-transcription factors by TRPM7 restricted to neuroblastoma 
or does this constitute a more general function of the channel kinase? What might be the 
underlying mechanisms by which TRPM7 controls transcription of these proteins? Moreover, 
to what extend does the TRPM7 activated EMT-transcription factor SNAI2 contribute to 
malignant neuroblastoma cell behavior?  
 
Scope of this thesis 
With this thesis we try to shed light onto the mechanisms by which TRP channels regulate 
(malignant) cell behavior, specifically focusing on the role of the channel kinase TRPM7 in 
neuroblastoma.  
TRP channels are important regulators of a wide variety of physiological processes 
(proliferation, adhesion, cytoskeletal dynamics, differentiation) essential during development 
and cancer progression. While integration of signals into cellular behavior by TRP channels 
mainly depends on their ion conductive properties, there is increasing evidence that (at least 
some) TRP channels control cell behavior in channel independent manners. In Chapter 2 we 
discuss both conventional, channel dependent, and unconventional mechanisms by which 
TRP channels, including TRPM7, contribute to development, tissue homeostasis and 
pathologies. 
As TRP channels form large macromolecular complexes that may serve to organize signal 
transduction and/or enhance the rate of signal transmission, control over cell behavior may 
depend on the composition of the macromolecular complex. In Chapter 3 we show that 
TRPM7 is part of a large protein complex where the majority of interactors is involved in 
regulation of adhesion formation and cytoskeletal dynamics. Interestingly, expression of 
several of these TRPM7 interactors correlates with neuroblastoma patient survival, 
suggesting a role for this complex in regulating neuroblastoma progression. In Chapter 4, we 
follow up on these findings and demonstrate that high expression of the TRPM7-interactor 
Tropomodulin 2 positively correlates with event free survival and favorable clinical and 
molecular characteristics in two independent neuroblastoma patient cohorts. Loss of 




regulates protrusion elongation and adhesion formation, thereby restricting the migratory 
and invasive potential of these cells. Additionally, bioinformatic analyses suggest that 
Tropomodulin 2 might be a direct substrate for TRPM7 mediated phosphorylation. 
In Chapter 5 we focus on the hypothesis that TRPM7’s control over cellular tension affects 
cell behavior by regulating a gene expression program involved in cellular differentiation and 
metastasis formation. We find that, by reducing cytoskeletal tension through inhibition of 
myosin II activity, TRPM7 controls the expression of the EMT-transcription factor SOX4 in 
breast cancer cells. Moreover, loss of SOX4 functionally mirrors TRPM7 depletion in this cell 
model, skewing cells to a more epithelial-like state. These results indicate that TRPM7 
contributes to breast cancer progression by maintaining a mesenchymal phenotype through 
tensional regulation of SOX4.  
Similar to the TRPM7’s transcriptional control of the EMT-transcription factor SOX4 in breast 
cancer cells, we have previously shown that TRPM7 maintains progenitor-like features of 
neuroblastoma cells by regulating the expression of the EMT-transcription factor SNAI2. In 
Chapter 6 we demonstrate that SNAI2 controls neuroblastoma differentiation by repressing 
a gene expression program linked to neuronal differentiation. A SNAI2 dependent gene 
expression signature based on the expression of these differentiation related genes 
significantly correlates with event free survival of neuroblastoma patients. Moreover, 
depletion of SNAI2 reduces malignant behavior of neuroblastoma cells in vitro and in vivo, 
and strongly sensitizes neuroblastoma cells to retinoic acid-treatment, underlining the 
importance of SNAI2 controlled inhibition of differentiation in neuroblastoma progression.  
In Chapter 7, we discuss the findings described in this thesis in relation to the literature and 
integrate these findings into a working model describing how TRPM7 may control metastatic 
behavior and disease progression. Moreover, we will discuss how this knowledge can be 







[1] J.M. Maris, Recent advances in neuroblastoma, The New England journal of medicine, 362 (2010) 2202-2211. 
[2] D.A. Morgenstern, S. Baruchel, M.S. Irwin, Current and future strategies for relapsed neuroblastoma: challenges on the 
road to precision therapy, J Pediatr Hematol Oncol, 35 (2013) 337-347. 
[3] K.K. Matthay, J.M. Maris, G. Schleiermacher, A. Nakagawara, C.L. Mackall, L. Diller, W.A. Weiss, Neuroblastoma, Nature 
Reviews Disease Primers, 2 (2016) 16078. 
[4] V.P. Tolbert, K.K. Matthay, Neuroblastoma: clinical and biological approach to risk stratification and treatment, Cell Tissue 
Res, 372 (2018) 195-209. 
[5] G.M. Brodeur, Spontaneous regression of neuroblastoma, Cell Tissue Res, 372 (2018) 277-286. 
[6] J.R. Park, R. Bagatell, W.B. London, J.M. Maris, S.L. Cohn, K.M. Mattay, M. Hogarty, Children's Oncology Group's 2013 
blueprint for research: Neuroblastoma, Pediatric Blood & Cancer, 60 (2013) 985-993. 
[7] N.R. Pinto, M.A. Applebaum, S.L. Volchenboum, K.K. Matthay, W.B. London, P.F. Ambros, A. Nakagawara, F. Berthold, G. 
Schleiermacher, J.R. Park, D. Valteau-Couanet, A.D.J. Pearson, S.L. Cohn, Advances in Risk Classification and Treatment 
Strategies for Neuroblastoma, Journal of Clinical Oncology, 33 (2015) 3008-3017. 
[8] B. Vogelstein, N. Papadopoulos, V.E. Velculescu, S. Zhou, L.A. Diaz, K.W. Kinzler, Cancer Genome Landscapes, Science, 339 
(2013) 1546. 
[9] S.N. Gröbner, B.C. Worst, J. Weischenfeldt, I. Buchhalter, K. Kleinheinz, V.A. Rudneva, P.D. Johann, G.P. Balasubramanian, 
M. Segura-Wang, S. Brabetz, S. Bender, B. Hutter, D. Sturm, E. Pfaff, D. Hübschmann, G. Zipprich, M. Heinold, J. Eils, C. 
Lawerenz, S. Erkek, S. Lambo, S. Waszak, C. Blattmann, A. Borkhardt, M. Kuhlen, A. Eggert, S. Fulda, M. Gessler, J. Wegert, R. 
Kappler, D. Baumhoer, S. Burdach, R. Kirschner-Schwabe, U. Kontny, A.E. Kulozik, D. Lohmann, S. Hettmer, C. Eckert, S. 
Bielack, M. Nathrath, C. Niemeyer, G.H. Richter, J. Schulte, R. Siebert, F. Westermann, J.J. Molenaar, G. Vassal, H. Witt, I.P.-
S. Project, P. Lichter, U. Weber, R. Eils, A. Korshunov, O. Witt, S. Pfister, G. Reifenberger, J. Felsberg, C. von Kalle, M. Schmidt, 
C. Bartholomä, M. Taylor, S. Pfister, D. Jones, P. Lichter, N. Jäger, I. Buchhalter, J. Korbel, A. Stütz, T. Rausch, B. Radlwimmer, 
M.-L. Yaspo, H. Lehrach, H.-J. Warnatz, P. Landgraf, A. Borkhardt, B. Brors, M. Zapatka, R. Eils, R. Eils, J. Eils, C. Lawerenz, I.M.-
S. Project, R. Siebert, S. Wagner, A. Haake, J. Richter, G. Richter, R. Eils, C. Lawerenz, J. Eils, J. Kerssemakers, C. Jaeger-Schmidt, 
I. Scholz, A.K. Bergmann, C. Borst, B. Burkhardt, A. Claviez, M. Dreyling, S. Eberth, H. Einsele, N. Frickhofen, S. Haas, M.-L. 
Hansmann, D. Karsch, M. Kneba, J. Lisfeld, L. Mantovani-Löffler, M. Rohde, G. Ott, C. Stadler, P. Staib, S. Stilgenbauer, L. 
Trümper, T. Zenz, M.-L. Hansmann, D. Kube, R. Küppers, M. Weniger, M. Hummel, W. Klapper, U. Kostezka, D. Lenze, P. 
Möller, A. Rosenwald, G. Ott, M. Szczepanowski, O. Ammerpohl, S.M. Aukema, V. Binder, A. Borkhardt, A. Haake, J.I. Hoell, 
E. Leich, P. Lichter, C. López, I. Nagel, J. Pischimariov, B. Radlwimmer, J. Richter, P. Rosenstiel, A. Rosenwald, M. Schilhabel, 
S. Schreiber, I. Vater, R. Wagener, R. Siebert, S.H. Bernhart, H. Binder, B. Brors, G. Doose, R. Eils, S. Hoffmann, L. Hopp, D. 
Hübschmann, K. Kleinheinz, H. Kretzmer, M. Kreuz, J. Korbel, D. Langenberger, M. Loeffler, M. Rosolowski, M. Schlesner, P.F. 
Stadler, S. Sungalee, B. Burkhardt, C.P. Kratz, O. Witt, C.M. van Tilburg, C.M. Kramm, G. Fleischhack, U. Dirksen, S. Rutkowski, 
M. Frühwald, K. von Hoff, S. Wolf, T. Klingebiel, E. Koscielniak, P. Landgraf, J. Koster, A.C. Resnick, J. Zhang, Y. Liu, X. Zhou, 
A.J. Waanders, D.A. Zwijnenburg, P. Raman, B. Brors, U.D. Weber, P.A. Northcott, K.W. Pajtler, M. Kool, R.M. Piro, J.O. Korbel, 
M. Schlesner, R. Eils, D.T.W. Jones, P. Lichter, L. Chavez, M. Zapatka, S.M. Pfister, The landscape of genomic alterations across 
childhood cancers, Nature, 555 (2018) 321. 
[10] T.J. Pugh, O. Morozova, E.F. Attiyeh, S. Asgharzadeh, J.S. Wei, D. Auclair, S.L. Carter, K. Cibulskis, M. Hanna, A. Kiezun, J. 
Kim, M.S. Lawrence, L. Lichenstein, A. McKenna, C.S. Pedamallu, A.H. Ramos, E. Shefler, A. Sivachenko, C. Sougnez, C. Stewart, 
A. Ally, I. Birol, R. Chiu, R.D. Corbett, M. Hirst, S.D. Jackman, B. Kamoh, A.H. Khodabakshi, M. Krzywinski, A. Lo, R.A. Moore, 
K.L. Mungall, J. Qian, A. Tam, N. Thiessen, Y. Zhao, K.A. Cole, M. Diamond, S.J. Diskin, Y.P. Mosse, A.C. Wood, L. Ji, R. Sposto, 
T. Badgett, W.B. London, Y. Moyer, J.M. Gastier-Foster, M.A. Smith, J.M. Guidry Auvil, D.S. Gerhard, M.D. Hogarty, S.J. Jones, 
E.S. Lander, S.B. Gabriel, G. Getz, R.C. Seeger, J. Khan, M.A. Marra, M. Meyerson, J.M. Maris, The genetic landscape of high-
risk neuroblastoma, Nat Genet, 45 (2013) 279-284. 
[11] J.J. Molenaar, J. Koster, D.A. Zwijnenburg, P. van Sluis, L.J. Valentijn, I. van der Ploeg, M. Hamdi, J. van Nes, B.A. 
Westerman, J. van Arkel, M.E. Ebus, F. Haneveld, A. Lakeman, L. Schild, P. Molenaar, P. Stroeken, M.M. van Noesel, I. Ora, 
E.E. Santo, H.N. Caron, E.M. Westerhout, R. Versteeg, Sequencing of neuroblastoma identifies chromothripsis and defects in 
neuritogenesis genes, Nature, 483 (2012) 589-593. 
[12] G.M. Brodeur, R.C. Seeger, M. Schwab, H.E. Varmus, J.M. Bishop, Amplification of N-myc in untreated human 
neuroblastomas correlates with advanced disease stage, Science, 224 (1984) 1121-1124. 
[13] R.C. Seeger, G.M. Brodeur, H. Sather, A. Dalton, S.E. Siegel, K.Y. Wong, D. Hammond, Association of multiple copies of 
the N-myc oncogene with rapid progression of neuroblastomas, The New England journal of medicine, 313 (1985) 1111-
1116. 
[14] Scott C. Bresler, Daniel A. Weiser, Peter J. Huwe, Jin H. Park, K. Krytska, H. Ryles, M. Laudenslager, Eric F. Rappaport, 
Andrew C. Wood, Patrick W. McGrady, Michael D. Hogarty, Wendy B. London, R. Radhakrishnan, Mark A. Lemmon, Yaël P. 
Mossé, ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma, 
Cancer Cell, 26 (2014) 682-694. 
[15] Y. Chen, J. Takita, Y.L. Choi, M. Kato, M. Ohira, M. Sanada, L. Wang, M. Soda, A. Kikuchi, T. Igarashi, A. Nakagawara, Y. 
Hayashi, H. Mano, S. Ogawa, Oncogenic mutations of ALK kinase in neuroblastoma, Nature, 455 (2008) 971-974. 
[16] R.E. George, T. Sanda, M. Hanna, S. Frohling, W. Luther, 2nd, J. Zhang, Y. Ahn, W. Zhou, W.B. London, P. McGrady, L. 
Xue, S. Zozulya, V.E. Gregor, T.R. Webb, N.S. Gray, D.G. Gilliland, L. Diller, H. Greulich, S.W. Morris, M. Meyerson, A.T. Look, 




[17] M. Sausen, R.J. Leary, S. Jones, J. Wu, C.P. Reynolds, X. Liu, A. Blackford, G. Parmigiani, L.A. Diaz Jr, N. Papadopoulos, B. 
Vogelstein, K.W. Kinzler, V.E. Velculescu, M.D. Hogarty, Integrated genomic analyses identify ARID1A and ARID1B alterations 
in the childhood cancer neuroblastoma, Nature Genetics, 45 (2012) 12. 
[18] N. Bown, S. Cotterill, M. Lastowska, S. O'Neill, A.D. Pearson, D. Plantaz, M. Meddeb, G. Danglot, C. Brinkschmidt, H. 
Christiansen, G. Laureys, F. Speleman, J. Nicholson, A. Bernheim, D.R. Betts, J. Vandesompele, N. Van Roy, Gain of 
chromosome arm 17q and adverse outcome in patients with neuroblastoma, The New England journal of medicine, 340 
(1999) 1954-1961. 
[19] N. Bown, M. Łastowska, S. Cotterill, S. O'Neill, C. Ellershaw, P. Roberts, I. Lewis, 17q gain in neuroblastoma predicts 
adverse clinical outcome, Medical and Pediatric Oncology, 36 (2001) 14-19. 
[20] E.F. Attiyeh, W.B. London, Y.P. Mossé, Q. Wang, C. Winter, D. Khazi, P.W. McGrady, R.C. Seeger, A.T. Look, H. Shimada, 
G.M. Brodeur, S.L. Cohn, K.K. Matthay, J.M. Maris, Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma, New 
England Journal of Medicine, 353 (2005) 2243-2253. 
[21] J.M. Maris, M.J. Weiss, C. Guo, R.B. Gerbing, D.O. Stram, P.S. White, M.D. Hogarty, E.P. Sulman, P.M. Thompson, J.N. 
Lukens, K.K. Matthay, R.C. Seeger, G.M. Brodeur, Loss of Heterozygosity at 1p36 Independently Predicts for Disease 
Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group Study, 
Journal of Clinical Oncology, 18 (2000) 1888-1899. 
[22] H. Caron, P. van Sluis, M. van Hoeve, J. de Kraker, J. Bras, R. Slater, M. Mannens, P.A. Voûte, A. Westerveld, R. Versteeg, 
Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N–myc amplification, 
Nature Genetics, 4 (1993) 187. 
[23] P.S. White, P.M. Thompson, B.A. Seifried, E.P. Sulman, S.J. Jensen, C. Guo, J.M. Maris, M.D. Hogarty, C. Allen, J.A. Biegel, 
T.C. Matise, S.G. Gregory, C.P. Reynolds, G.M. Brodeur, Detailed molecular analysis of 1p36 in neuroblastoma, Med Pediatr 
Oncol, 36 (2001) 37-41. 
[24] A. Bagchi, A.A. Mills, The quest for the 1p36 tumor suppressor, Cancer Res, 68 (2008) 2551-2556. 
[25] T. Fujita, J. Igarashi, E.R. Okawa, T. Gotoh, J. Manne, V. Kolla, J. Kim, H. Zhao, B.R. Pawel, W.B. London, J.M. Maris, P.S. 
White, G.M. Brodeur, CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas, J Natl Cancer Inst, 100 (2008) 
940-949. 
[26] K.A. Cole, E.F. Attiyeh, Y.P. Mosse, M.J. Laquaglia, S.J. Diskin, G.M. Brodeur, J.M. Maris, A functional screen identifies 
miR-34a as a candidate neuroblastoma tumor suppressor gene, Mol Cancer Res, 6 (2008) 735-742. 
[27] C. Welch, Y. Chen, R.L. Stallings, MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in 
neuroblastoma cells, Oncogene, 26 (2007) 5017. 
[28] E.R. Okawa, T. Gotoh, J. Manne, J. Igarashi, T. Fujita, K.A. Silverman, H. Xhao, Y.P. Mosse, P.S. White, G.M. Brodeur, 
Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas, 
Oncogene, 27 (2007) 803. 
[29] M. Ohira, H. Kageyama, M. Mihara, S. Furuta, T. Machida, T. Shishikura, H. Takayasu, A. Islam, Y. Nakamura, M. 
Takahashi, N. Tomioka, S. Sakiyama, Y. Kaneko, A. Toyoda, M. Hattori, Y. Sakaki, M. Ohki, A. Horii, E. Soeda, J. Inazawa, N. 
Seki, H. Kuma, I. Nozawa, A. Nakagawara, Identification and characterization of a 500-kb homozygously deleted region at 
1p36.2-p36.3 in a neuroblastoma cell line, Oncogene, 19 (2000) 4302. 
[30] K. Ejeskar, R.M. Sjoberg, F. Abel, P. Kogner, P.F. Ambros, T. Martinsson, Fine mapping of a tumour suppressor candidate 
gene region in 1p36.2-3, commonly deleted in neuroblastomas and germ cell tumours, Med Pediatr Oncol, 36 (2001) 61-66. 
[31] M. Jiang, J. Stanke, J.M. Lahti, Chapter 4 - The Connections Between Neural Crest Development and Neuroblastoma, in: 
M.A. Dyer (Ed.) Current Topics in Developmental Biology, Academic Press, Place Published, 2011, pp. 77-127. 
[32] G.M. Marshall, D.R. Carter, B.B. Cheung, T. Liu, M.K. Mateos, J.G. Meyerowitz, W.A. Weiss, The prenatal origins of cancer, 
Nature Reviews Cancer, 14 (2014) 277. 
[33] C.-J. Bae, J.-P. Saint-Jeannet, Chapter 2 - Induction and Specification of Neural Crest Cells: Extracellular Signals and 
Transcriptional Switches, in: P.A. Trainor (Ed.) Neural Crest Cells, Academic Press, Place Published, 2014, pp. 27-49. 
[34] M. Simoes-Costa, M.E. Bronner, Establishing neural crest identity: a gene regulatory recipe, Development, 142 (2015) 
242-257. 
[35] M.L. Martik, M.E. Bronner, Regulatory Logic Underlying Diversification of the Neural Crest, Trends in Genetics, 33 (2017) 
715-727. 
[36] E. Dupin, L. Sommer, Neural crest progenitors and stem cells: From early development to adulthood, Developmental 
Biology, 366 (2012) 83-95. 
[37] K.L. Gallik, R.W. Treffy, L.M. Nacke, K. Ahsan, M. Rocha, A. Green-Saxena, A. Saxena, Neural crest and cancer: Divergent 
travelers on similar paths, Mech Dev, 148 (2017) 89-99. 
[38] E. Theveneau, R. Mayor, Neural crest delamination and migration: From epithelium-to-mesenchyme transition to 
collective cell migration, Developmental Biology, 366 (2012) 34-54. 
[39] N. Gouignard, C. Andrieu, E. Theveneau, Neural crest delamination and migration: Looking forward to the next 150 years, 
genesis, 56 (2018) e23107. 
[40] J.P. Thiery, H. Acloque, R.Y.J. Huang, M.A. Nieto, Epithelial-Mesenchymal Transitions in Development and Disease, Cell, 
139 (2009) 871-890. 
[41] S.A. Mani, W. Guo, M.-J. Liao, E.N. Eaton, A. Ayyanan, A.Y. Zhou, M. Brooks, F. Reinhard, C.C. Zhang, M. Shipitsin, L.L. 
Campbell, K. Polyak, C. Brisken, J. Yang, R.A. Weinberg, The Epithelial-Mesenchymal Transition Generates Cells with 
Properties of Stem Cells, Cell, 133 (2008) 704-715. 
Chapter 1
28
[42] K. Polyak, R.A. Weinberg, Transitions between epithelial and mesenchymal states: acquisition of malignant and stem 
cell traits, Nature Reviews Cancer, 9 (2009) 265. 
[43] A. Dongre, R.A. Weinberg, New insights into the mechanisms of epithelial–mesenchymal transition and implications for 
cancer, Nature Reviews Molecular Cell Biology, (2018). 
[44] J.H. Tsai, J. Yang, Epithelial-mesenchymal plasticity in carcinoma metastasis, Genes Dev, 27 (2013) 2192-2206. 
[45] X. Ye, R.A. Weinberg, Epithelial–Mesenchymal Plasticity: A Central Regulator of Cancer Progression, Trends in Cell 
Biology, 25 (2015) 675-686. 
[46] M.A. Nieto, R.Y. Huang, R.A. Jackson, J.P. Thiery, Emt: 2016, Cell, 166 (2016) 21-45. 
[47] V. Mittal, Epithelial Mesenchymal Transition in Tumor Metastasis, Annual Review of Pathology: Mechanisms of Disease, 
13 (2018) 395-412. 
[48] T. Shibue, R.A. Weinberg, EMT, CSCs, and drug resistance: the mechanistic link and clinical implications, Nature Reviews 
Clinical Oncology, 14 (2017) 611. 
[49] B.N. Smith, N.A. Bhowmick, Role of EMT in Metastasis and Therapy Resistance, J Clin Med, 5 (2016). 
[50] J. Pasquier, N. Abu-Kaoud, H. Al Thani, A. Rafii, Epithelial to Mesenchymal Transition in a Clinical Perspective, Journal of 
Oncology, 2015 (2015) 10. 
[51] M. Yu, A. Bardia, B.S. Wittner, S.L. Stott, M.E. Smas, D.T. Ting, S.J. Isakoff, J.C. Ciciliano, M.N. Wells, A.M. Shah, K.F. 
Concannon, M.C. Donaldson, L.V. Sequist, E. Brachtel, D. Sgroi, J. Baselga, S. Ramaswamy, M. Toner, D.A. Haber, S. 
Maheswaran, Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition, Science, 
339 (2013) 580. 
[52] K.R. Fischer, A. Durrans, S. Lee, J. Sheng, F. Li, S.T.C. Wong, H. Choi, T. El Rayes, S. Ryu, J. Troeger, R.F. Schwabe, L.T. 
Vahdat, N.K. Altorki, V. Mittal, D. Gao, Epithelial-to-mesenchymal transition is not required for lung metastasis but 
contributes to chemoresistance, Nature, 527 (2015) 472. 
[53] X. Zheng, J.L. Carstens, J. Kim, M. Scheible, J. Kaye, H. Sugimoto, C.-C. Wu, V.S. LeBleu, R. Kalluri, Epithelial-to-
mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer, Nature, 527 (2015) 
525. 
[54] O. Piskareva, H. Harvey, J. Nolan, R. Conlon, L. Alcock, P. Buckley, P. Dowling, M. Henry, F. O'Sullivan, I. Bray, R.L. Stallings, 
The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro, 
Cancer Letters, 364 (2015) 142-155. 
[55] A. Schramm, J. Köster, Y. Assenov, K. Althoff, M. Peifer, E. Mahlow, A. Odersky, D. Beisser, C. Ernst, A.G. Henssen, H. 
Stephan, C. Schröder, L. Heukamp, A. Engesser, Y. Kahlert, J. Theissen, B. Hero, F. Roels, J. Altmüller, P. Nürnberg, K. 
Astrahantseff, C. Gloeckner, K. De Preter, C. Plass, S. Lee, H.N. Lode, K.-O. Henrich, M. Gartlgruber, F. Speleman, P. Schmezer, 
F. Westermann, S. Rahmann, M. Fischer, A. Eggert, J.H. Schulte, Mutational dynamics between primary and relapse 
neuroblastomas, Nature Genetics, 47 (2015) 872. 
[56] J.A. Tomolonis, S. Agarwal, J.M. Shohet, Neuroblastoma pathogenesis: deregulation of embryonic neural crest 
development, Cell Tissue Res, 372 (2018) 245-262. 
[57] A. Puisieux, T. Brabletz, J. Caramel, Oncogenic roles of EMT-inducing transcription factors, Nature Cell Biology, 16 (2014) 
488. 
[58] S. Goossens, N. Vandamme, P. Van Vlierberghe, G. Berx, EMT transcription factors in cancer development re-evaluated: 
Beyond EMT and MET, Biochim Biophys Acta Rev Cancer, 1868 (2017) 584-591. 
[59] D. Li, H. Mei, M. Qi, D. Yang, X. Zhao, X. Xiang, J. Pu, K. Huang, L. Zheng, Q. Tong, FOXD3 is a novel tumor suppressor that 
affects growth, invasion, metastasis and angiogenesis of neuroblastoma, Oncotarget, 4 (2013) 2021-2044. 
[60] R. Vitali, C. Mancini, V. Cesi, B. Tanno, M. Mancuso, G. Bossi, Y. Zhang, R.V. Martinez, B. Calabretta, C. Dominici, G. 
Raschellà, Slug (SNAI2) Down-Regulation by RNA Interference Facilitates Apoptosis and Inhibits Invasive Growth in 
Neuroblastoma Preclinical Models, Clinical Cancer Research, 14 (2008) 4622. 
[61] L.A. Taneyhill, R. Padmanabhan, Chapter 3 - The Cell Biology of Neural Crest Cell Delamination and EMT, in: P.A. Trainor 
(Ed.) Neural Crest Cells, Academic Press, Place Published, 2014, pp. 51-72. 
[62] K. Campbell, J. Casanova, A common framework for EMT and collective cell migration, Development, 143 (2016) 4291. 
[63] S. Lamouille, J. Xu, R. Derynck, Molecular mechanisms of epithelial–mesenchymal transition, Nature Reviews Molecular 
Cell Biology, 15 (2014) 178. 
[64] P. Friedl, R. Mayor, Tuning Collective Cell Migration by Cell–Cell Junction Regulation, Cold Spring Harbor Perspectives in 
Biology, 9 (2017). 
[65] D.R. Pattabiraman, R.A. Weinberg, Targeting the Epithelial-to-Mesenchymal Transition: The Case for Differentiation-
Based Therapy, Cold Spring Harb Symp Quant Biol, 81 (2016) 11-19. 
[66] A. Dongre, R.A. Weinberg, New insights into the mechanisms of epithelial–mesenchymal transition and implications for 
cancer, Nature Reviews Molecular Cell Biology, 20 (2019) 69-84. 
[67] M. Yilmaz, G. Christofori, EMT, the cytoskeleton, and cancer cell invasion, Cancer Metastasis Rev, 28 (2009) 15-33. 
[68] M. Yilmaz, G. Christofori, Mechanisms of motility in metastasizing cells, Mol Cancer Res, 8 (2010) 629-642. 
[69] M.-F. Carlier, S. Shekhar, Global treadmilling coordinates actin turnover and controls the size of actin networks, Nature 
Reviews Molecular Cell Biology, 18 (2017) 389. 
[70] L.B. Case, C.M. Waterman, Integration of actin dynamics and cell adhesion by a three-dimensional, mechanosensitive 
molecular clutch, Nature Cell Biology, 17 (2015) 955. 
[71] J.T. Parsons, A.R. Horwitz, M.A. Schwartz, Cell adhesion: integrating cytoskeletal dynamics and cellular tension, Nature 




[72] M. Vicente-Manzanares, X. Ma, R.S. Adelstein, A.R. Horwitz, Non-muscle myosin II takes centre stage in cell adhesion 
and migration, Nature Reviews Molecular Cell Biology, 10 (2009) 778. 
[73] U.S. Schwarz, M.L. Gardel, United we stand – integrating the actin cytoskeleton and cell–matrix adhesions in cellular 
mechanotransduction, Journal of Cell Science, 125 (2012) 3051. 
[74] M.L. Gardel, I.C. Schneider, Y. Aratyn-Schaus, C.M. Waterman, Mechanical Integration of Actin and Adhesion Dynamics 
in Cell Migration, Annual Review of Cell and Developmental Biology, 26 (2010) 315-333. 
[75] C.M. Fife, J.A. McCarroll, M. Kavallaris, Movers and shakers: cell cytoskeleton in cancer metastasis, British Journal of 
Pharmacology, 171 (2014) 5507-5523. 
[76] F.M. Vega, A.J. Ridley, Rho GTPases in cancer cell biology, FEBS Letters, 582 (2008) 2093-2101. 
[77] A.J. Ridley, Rho GTPase signalling in cell migration, Current Opinion in Cell Biology, 36 (2015) 103-112. 
[78] E.-E. Govek, S.E. Newey, L. Van Aelst, The role of the Rho GTPases in neuronal development, Genes & Development, 19 
(2005) 1-49. 
[79] A.P. Porter, A. Papaioannou, A. Malliri, Deregulation of Rho GTPases in cancer, Small GTPases, 7 (2016) 123-138. 
[80] R.G. Hodge, A.J. Ridley, Regulating Rho GTPases and their regulators, Nature Reviews Molecular Cell Biology, 17 (2016) 
496. 
[81] C. Dyberg, S. Fransson, T. Andonova, B. Sveinbjörnsson, J. Lännerholm-Palm, T.K. Olsen, D. Forsberg, E. Herlenius, T. 
Martinsson, B. Brodin, P. Kogner, J.I. Johnsen, M. Wickström, Rho-associated kinase is a therapeutic target in neuroblastoma, 
Proceedings of the National Academy of Sciences, 114 (2017) E6603. 
[82] J. Middelbeek, K. Vrenken, D. Visser, E. Lasonder, J. Koster, K. Jalink, K. Clark, F.N. van Leeuwen, The TRPM7 interactome 
defines a cytoskeletal complex linked to neuroblastoma progression, European Journal of Cell Biology, 95 (2016) 465-474. 
[83] T. Svitkina, The Actin Cytoskeleton and Actin-Based Motility, Cold Spring Harb Perspect Biol, 10 (2018). 
[84] K. Rottner, J. Faix, S. Bogdan, S. Linder, E. Kerkhoff, Actin assembly mechanisms at a glance, Journal of Cell Science, 130 
(2017) 3427. 
[85] Tristan P. Driscoll, Brian D. Cosgrove, S.-J. Heo, Zach E. Shurden, Robert L. Mauck, Cytoskeletal to Nuclear Strain Transfer 
Regulates YAP Signaling in Mesenchymal Stem Cells, Biophysical Journal, 108 (2015) 2783-2793. 
[86] E.K. Rajakyla, M.K. Vartiainen, Rho, nuclear actin, and actin-binding proteins in the regulation of transcription and gene 
expression, Small GTPases, 5 (2014) e27539. 
[87] T.D. Pollard, Actin and Actin-Binding Proteins, Cold Spring Harbor Perspectives in Biology, 8 (2016). 
[88] L. Christian, H. Bahudhanapati, S. Wei, Extracellular metalloproteinases in neural crest development and craniofacial 
morphogenesis, Critical Reviews in Biochemistry and Molecular Biology, 48 (2013) 544-560. 
[89] L. Roth, R. Kalev-Altman, E. Monsonego-Ornan, D. Sela-Donenfeld, A new role of the membrane-type matrix 
metalloproteinase 16 (MMP16/MT3-MMP) in neural crest cell migration, Int J Dev Biol, 61 (2017) 245-256. 
[90] D. Alfandari, L.A. Taneyhill, Cut loose and run: The complex role of ADAM proteases during neural crest cell development, 
genesis, 56 (2018) e23095. 
[91] P. Lu, K. Takai, V.M. Weaver, Z. Werb, Extracellular matrix degradation and remodeling in development and disease, 
Cold Spring Harb Perspect Biol, 3 (2011). 
[92] D. Dreymueller, K. Theodorou, M. Donners, A. Ludwig, Fine Tuning Cell Migration by a Disintegrin and 
Metalloproteinases, Mediators of Inflammation, 2017 (2017) 22. 
[93] E.I. Deryugina, J.P. Quigley, Matrix metalloproteinases and tumor metastasis, Cancer and Metastasis Reviews, 25 (2006) 
9-34. 
[94] A. Jacob, R. Prekeris, The regulation of MMP targeting to invadopodia during cancer metastasis, Frontiers in Cell and 
Developmental Biology, 3 (2015) 4. 
[95] H. Zhang, M. Qi, S. Li, T. Qi, H. Mei, K. Huang, L. Zheng, Q. Tong, microRNA-9 Targets Matrix Metalloproteinase 14 to 
Inhibit Invasion, Metastasis, and Angiogenesis of Neuroblastoma Cells, Molecular Cancer Therapeutics, 11 (2012) 1454. 
[96] S. Jodele, C.F. Chantrain, L. Blavier, C. Lutzko, G.M. Crooks, H. Shimada, L.M. Coussens, Y.A. DeClerck, The Contribution 
of Bone Marrow–Derived Cells to the Tumor Vasculature in Neuroblastoma Is Matrix Metalloproteinase-9 Dependent, Cancer 
Research, 65 (2005) 3200. 
[97] C.F. Chantrain, H. Shimada, S. Jodele, S. Groshen, W. Ye, D.R. Shalinsky, Z. Werb, L.M. Coussens, Y.A. DeClerck, Stromal 
Matrix Metalloproteinase-9 Regulates the Vascular Architecture in Neuroblastoma by Promoting Pericyte Recruitment, 
Cancer Research, 64 (2004) 1675. 
[98] Y. Sugiura, H. Shimada, R.C. Seeger, W.E. Laug, Y.A. DeClerck, Matrix Metalloproteinases-2 and -9 Are Expressed in 
Human Neuroblastoma: Contribution of Stromal Cells to Their Production and Correlation with Metastasis, Cancer Research, 
58 (1998) 2209. 
[99] J.L. Duband, G.C. Tucker, T.J. Poole, M. Vincent, H. Aoyama, J.P. Thiery, How do the migratory and adhesive properties 
of the neural crest govern ganglia formation in the avian peripheral nervous system?, Journal of Cellular Biochemistry, 27 
(1985) 189-203. 
[100] J.C. Kasemeier-Kulesa, R. Bradley, E.B. Pasquale, F. Lefcort, P.M. Kulesa, Eph/ephrins and N-cadherin coordinate to 
control the pattern of sympathetic ganglia, Development, 133 (2006) 4839-4847. 
[101] T.E. Lallier, M. Bronner-Fraser, A spatial and temporal analysis of dorsal root and sympathetic ganglion formation in 
the avian embryo, Dev Biol, 127 (1988) 99-112. 
[102] J.A. Tomolonis, S. Agarwal, J.M. Shohet, Neuroblastoma pathogenesis: deregulation of embryonic neural crest 
development, Cell and Tissue Research, 372 (2018) 245-262. 
Chapter 1
30
[103] J.I. Johnsen, C. Dyberg, M. Wickström, Neuroblastoma—A Neural Crest Derived Embryonal Malignancy, Frontiers in 
Molecular Neuroscience, 12 (2019). 
[104] E. Matas-Rico, M. van Veen, D. Leyton-Puig, J. van den Berg, J. Koster, Katarzyna M. Kedziora, B. Molenaar, 
Marjolein J.A. Weerts, I. de Rink, René H. Medema, Ben N.G. Giepmans, A. Perrakis, K. Jalink, R. Versteeg, Wouter H. 
Moolenaar, Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a 
Marker of Clinical Outcome, Cancer Cell, 30 (2016) 548-562. 
[105] S. Huang, J. Laoukili, M.T. Epping, J. Koster, M. Hölzel, B.A. Westerman, W. Nijkamp, A. Hata, S. Asgharzadeh, R.C. 
Seeger, R. Versteeg, R.L. Beijersbergen, R. Bernards, ZNF423 Is Critically Required for Retinoic Acid-Induced Differentiation 
and Is a Marker of Neuroblastoma Outcome, Cancer Cell, 15 (2009) 328-340. 
[106] N. Sidell, A. Altman, M.R. Haussler, R.C. Seeger, Effects of retinoic acid (RA) on the growth and phenotypic expression 
of several human neuroblastoma cell lines, Experimental Cell Research, 148 (1983) 21-30. 
[107] K.K. Matthay, J.G. Villablanca, R.C. Seeger, D.O. Stram, R.E. Harris, N.K. Ramsay, P. Swift, H. Shimada, C.T. Black, G.M. 
Brodeur, R.B. Gerbing, C.P. Reynolds, Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, 
autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group, The New England journal of 
medicine, 341 (1999) 1165-1173. 
[108] C.P. Reynolds, K.K. Matthay, J.G. Villablanca, B.J. Maurer, Retinoid therapy of high-risk neuroblastoma, Cancer Lett, 
197 (2003) 185-192. 
[109] K.K. Matthay, C.P. Reynolds, R.C. Seeger, H. Shimada, E.S. Adkins, D. Haas-Kogan, R.B. Gerbing, W.B. London, J.G. 
Villablanca, Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative 
therapy followed by 13-cis-retinoic acid: a children's oncology group study, J Clin Oncol, 27 (2009) 1007-1013. 
[110] A. Szabó, R. Mayor, Mechanisms of Neural Crest Migration, Annual Review of Genetics, 52 (2018) 43-63. 
[111] L. Dyson, A. Holmes, A. Li, P.M. Kulesa, A chemotactic model of trunk neural crest cell migration, genesis, 56 (2018) 
e23239. 
[112] M. Minoux, F.M. Rijli, Molecular mechanisms of cranial neural crest cell migration and patterning in craniofacial 
development, Development, 137 (2010) 2605. 
[113] E. Theveneau, R. Mayor, Neural crest migration: interplay between chemorepellents, chemoattractants, contact 
inhibition, epithelial–mesenchymal transition, and collective cell migration, Wiley Interdisciplinary Reviews: Developmental 
Biology, 1 (2012) 435-445. 
[114] E. Scarpa, A. Szabó, A. Bibonne, E. Theveneau, M. Parsons, R. Mayor, Cadherin Switch during EMT in Neural Crest Cells 
Leads to Contact Inhibition of Locomotion via Repolarization of Forces, Developmental Cell, 34 (2015) 421-434. 
[115] R. Perris, D. Perissinotto, Role of the extracellular matrix during neural crest cell migration, Mechanisms of 
Development, 95 (2000) 3-21. 
[116] T. Rozario, D.W. DeSimone, The extracellular matrix in development and morphogenesis: A dynamic view, 
Developmental Biology, 341 (2010) 126-140. 
[117] E.H. Barriga, K. Franze, G. Charras, R. Mayor, Tissue stiffening coordinates morphogenesis by triggering collective cell 
migration in vivo, Nature, 554 (2018) 523. 
[118] N.R. Chevalier, E. Gazquez, L. Bidault, T. Guilbert, C. Vias, E. Vian, Y. Watanabe, L. Muller, S. Germain, N. Bondurand, S. 
Dufour, V. Fleury, How Tissue Mechanical Properties Affect Enteric Neural Crest Cell Migration, Scientific Reports, 6 (2016) 
20927. 
[119] S. Maman, I.P. Witz, A history of exploring cancer in context, Nature Reviews Cancer, 18 (2018) 359-376. 
[120] M. Gees, B. Colsoul, B. Nilius, The Role of Transient Receptor Potential Cation Channels in Ca2+ Signaling, Cold Spring 
Harbor Perspectives in Biology, 2 (2010). 
[121] D.E. Clapham, TRP channels as cellular sensors, Nature, 426 (2003) 517. 
[122] D.J. Cosens, A. Manning, Abnormal Electroretinogram from a Drosophila Mutant, Nature, 224 (1969) 285. 
[123] C. Montell, G.M. Rubin, Molecular characterization of the Drosophila trp locus: a putative integral membrane protein 
required for phototransduction, Neuron, 2 (1989) 1313-1323. 
[124] N. Damann, T. Voets, B. Nilius, TRPs in Our Senses, Current Biology, 18 (2008) R880-R889. 
[125] N. Eijkelkamp, K. Quick, J.N. Wood, Transient Receptor Potential Channels and Mechanosensation, Annual Review of 
Neuroscience, 36 (2013) 519-546. 
[126] A.P. Christensen, D.P. Corey, TRP channels in mechanosensation: direct or indirect activation?, Nature Reviews 
Neuroscience, 8 (2007) 510. 
[127] C. Liu, C. Montell, Forcing open TRP channels: Mechanical gating as a unifying activation mechanism, Biochemical and 
Biophysical Research Communications, 460 (2015) 22-25. 
[128] K.S. Vrenken, K. Jalink, F.N. van Leeuwen, J. Middelbeek, Beyond ion-conduction: Channel-dependent and -
independent roles of TRP channels during development and tissue homeostasis, Biochimica et Biophysica Acta (BBA) - 
Molecular Cell Research, 1863 (2016) 1436-1446. 
[129] K. Clark, J. Middelbeek, F.N. van Leeuwen, Interplay between TRP channels and the cytoskeleton in health and disease, 
European Journal of Cell Biology, 87 (2008) 631-640. 
[130] T. Smani, N. Dionisio, J.J. López, A. Berna-Erro, J.A. Rosado, Cytoskeletal and scaffolding proteins as structural and 
functional determinants of TRP channels, Biochimica et Biophysica Acta (BBA) - Biomembranes, 1838 (2014) 658-664. 
[131] K. Venkatachalam, C. Montell, TRP Channels, Annual Review of Biochemistry, 76 (2007) 387-417. 
[132] A.J. Kuipers, J. Middelbeek, F.N. van Leeuwen, Mechanoregulation of cytoskeletal dynamics by TRP channels, European 




[133] G. Thiel, A. Lesch, S. Rubil, T.M. Backes, O.G. Rössler, Chapter Five - Regulation of Gene Transcription Following 
Stimulation of Transient Receptor Potential (TRP) Channels, in: F. Loos (Ed.) International Review of Cell and Molecular 
Biology, Academic Press, Place Published, 2018, pp. 167-189. 
[134] H. Ishise, B. Larson, Y. Hirata, T. Fujiwara, S. Nishimoto, T. Kubo, K. Matsuda, S. Kanazawa, Y. Sotsuka, K. Fujita, M. 
Kakibuchi, K. Kawai, Hypertrophic scar contracture is mediated by the TRPC3 mechanical force transducer via NFkB 
activation, Scientific Reports, 5 (2015) 11620. 
[135] P.B. Thippegowda, V. Singh, P.C. Sundivakkam, J. Xue, A.B. Malik, C. Tiruppathi, Ca2+ influx via TRPC channels induces 
NF-κB-dependent A20 expression to prevent thrombin-induced apoptosis in endothelial cells, American Journal of 
Physiology-Cell Physiology, 298 (2009) C656-C664. 
[136] B.C. Paria, A.M. Bair, J. Xue, Y. Yu, A.B. Malik, C. Tiruppathi, Ca2+ Influx Induced by Protease-activated Receptor-1 
Activates a Feed-forward Mechanism of TRPC1 Expression via Nuclear Factor-κB Activation in Endothelial Cells, Journal of 
Biological Chemistry, 281 (2006) 20715-20727. 
[137] H. Soni, A. Adebiyi, TRPC6 channel activation promotes neonatal glomerular mesangial cell apoptosis via 
calcineurin/NFAT and FasL/Fas signaling pathways, Scientific Reports, 6 (2016) 29041. 
[138] T. Nijenhuis, A.J. Sloan, J.G.J. Hoenderop, J. Flesche, H. van Goor, A.D. Kistler, M. Bakker, R.J.M. Bindels, R.A. de Boer, 
C.C. Möller, I. Hamming, G. Navis, J.F.M. Wetzels, J.H.M. Berden, J. Reiser, C. Faul, J. van der Vlag, Angiotensin II Contributes 
to Podocyte Injury by Increasing TRPC6 Expression via an NFAT-Mediated Positive Feedback Signaling Pathway, The American 
Journal of Pathology, 179 (2011) 1719-1732. 
[139] V. Lehen'Kyi, M. Flourakis, R. Skryma, N. Prevarskaya, TRPV6 channel controls prostate cancer cell proliferation via 
Ca2+/NFAT-dependent pathways, Oncogene, 26 (2007) 7380. 
[140] H. Nakayama, B.J. Wilkin, I. Bodi, J.D. Molkentin, Calcineurin-dependent cardiomyopathy is activated by TRPC in the 
adult mouse heart, The FASEB Journal, 20 (2006) 1660-1670. 
[141] A.J. Kuipers, J. Middelbeek, K. Vrenken, C. Pérez-González, G. Poelmans, J. Klarenbeek, K. Jalink, X. Trepat, F.N. van 
Leeuwen, TRPM7 controls mesenchymal features of breast cancer cells by tensional regulation of SOX4, Biochimica et 
Biophysica Acta (BBA) - Molecular Basis of Disease, 1864 (2018) 2409-2419. 
[142] Y. Komiya, L.W. Runnels, TRPM channels and magnesium in early embryonic development, Int J Dev Biol, 59 (2015) 
281-288. 
[143] M.R. Hutson, A.L. Keyte, M. Hernández-Morales, E. Gibbs, Z.A. Kupchinsky, I. Argyridis, K.N. Erwin, K. Pegram, M. 
Kneifel, P.B. Rosenberg, P. Matak, L. Xie, J. Grandl, E.E. Davis, N. Katsanis, C. Liu, E.J. Benner, Temperature-activated ion 
channels in neural crest cells confer maternal fever–associated birth defects, Science Signaling, 10 (2017). 
[144] T. Smani, G. Shapovalov, R. Skryma, N. Prevarskaya, J.A. Rosado, Functional and physiopathological implications of TRP 
channels, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1853 (2015) 1772-1782. 
[145] B. Fels, E. Bulk, Z. Petho, A. Schwab, The Role of TRP Channels in the Metastatic Cascade, Pharmaceuticals (Basel), 11 
(2018). 
[146] G.R. Monteith, N. Prevarskaya, S.J. Roberts-Thomson, The calcium–cancer signalling nexus, Nature Reviews Cancer, 17 
(2017) 367. 
[147] E. Fonfria, P.R. Murdock, F.S. Cusdin, C.D. Benham, R.E. Kelsell, S. McNulty, Tissue distribution profiles of the human 
TRPM cation channel family, J Recept Signal Transduct Res, 26 (2006) 159-178. 
[148] V. Chubanov, S. Waldegger, M. Mederos y Schnitzler, H. Vitzthum, M.C. Sassen, H.W. Seyberth, M. Konrad, T. 
Gudermann, Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia 
with secondary hypocalcemia, Proc Natl Acad Sci U S A, 101 (2004) 2894-2899. 
[149] M. Li, J. Jiang, L. Yue, Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7, J Gen 
Physiol, 127 (2006) 525-537. 
[150] C. Schmitz, M.V. Dorovkov, X. Zhao, B.J. Davenport, A.G. Ryazanov, A.L. Perraud, The channel kinases TRPM6 and 
TRPM7 are functionally nonredundant, J Biol Chem, 280 (2005) 37763-37771. 
[151] P.R. Tsuruda, D. Julius, D.L. Minor, Jr., Coiled coils direct assembly of a cold-activated TRP channel, Neuron, 51 (2006) 
201-212. 
[152] Y. Fujiwara, D.L. Minor, Jr., X-ray crystal structure of a TRPM assembly domain reveals an antiparallel four-stranded 
coiled-coil, J Mol Biol, 383 (2008) 854-870. 
[153] J. Duan, Z. Li, J. Li, R.E. Hulse, A. Santa-Cruz, W.C. Valinsky, S.A. Abiria, G. Krapivinsky, J. Zhang, D.E. Clapham, Structure 
of the mammalian TRPM7, a magnesium channel required during embryonic development, Proceedings of the National 
Academy of Sciences, 115 (2018) E8201. 
[154] A. Fleig, V. Chubanov, TRPM7, in: B. Nilius, V. Flockerzi (Eds.) Mammalian Transient Receptor Potential (TRP) Cation 
Channels: Volume I, Springer Berlin Heidelberg, Place Published, 2014, pp. 521-546. 
[155] R. Chokshi, M. Matsushita, J.A. Kozak, Detailed examination of Mg2+ and pH sensitivity of human TRPM7 channels, 
American Journal of Physiology-Cell Physiology, 302 (2012) C1004-C1011. 
[156] T. Numata, T. Shimizu, Y. Okada, Direct Mechano-Stress Sensitivity of TRPM7 Channel, Cellular Physiology and 
Biochemistry, 19 (2007) 1-8. 
[157] T. Numata, T. Shimizu, Y. Okada, TRPM7 is a stretch- and swelling-activated cation channel involved in volume 
regulation in human epithelial cells, American Journal of Physiology-Cell Physiology, 292 (2007) C460-C467. 




[159] E. Xiao, H.Q. Yang, Y.-H. Gan, D.-H. Duan, L.-H. He, Y. Guo, S.Q. Wang, Y. Zhang, Brief Reports: TRPM7 Senses Mechanical 
Stimulation Inducing Osteogenesis in Human Bone Marrow Mesenchymal Stem Cells, STEM CELLS, 33 (2014) 615-621. 
[160] Y.-S. Liu, Y.-A. Liu, C.-J. Huang, M.-H. Yen, C.-T. Tseng, S. Chien, O.K. Lee, Mechanosensitive TRPM7 mediates shear 
stress and modulates osteogenic differentiation of mesenchymal stromal cells through Osterix pathway, Scientific Reports, 
5 (2015) 16522. 
[161] S. Song, A. Yamamura, H. Yamamura, R.J. Ayon, K.A. Smith, H. Tang, A. Makino, J.X.-J. Yuan, Flow shear stress enhances 
intracellular Ca2+ signaling in pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension, 
American Journal of Physiology-Cell Physiology, 307 (2014) C373-C383. 
[162] J. Won, H. Vang, J.H. Kim, P.R. Lee, Y. Kang, S.B. Oh, TRPM7 Mediates Mechanosensitivity in Adult Rat Odontoblasts, 
Journal of Dental Research, 97 (2018) 1039-1046. 
[163] J. Middelbeek, K. Clark, H. Venselaar, M.A. Huynen, F.N. van Leeuwen, The alpha-kinase family: an exceptional branch 
on the protein kinase tree, Cell Mol Life Sci, 67 (2010) 875-890. 
[164] L.W. Runnels, TRPM6 and TRPM7: A Mul-TRP-PLIK-cation of channel functions, Curr Pharm Biotechnol, 12 (2011) 42-
53. 
[165] M.J.S. Nadler, M.C. Hermosura, K. Inabe, A.-L. Perraud, Q. Zhu, A.J. Stokes, T. Kurosaki, J.-P. Kinet, R. Penner, A.M. 
Scharenberg, A. Fleig, LTRPC7 is a Mg·ATP-regulated divalent cation channel required for cell viability, Nature, 411 (2001) 
590. 
[166] L.W. Runnels, L. Yue, D.E. Clapham, TRP-PLIK, a bifunctional protein with kinase and ion channel activities, Science, 291 
(2001) 1043-1047. 
[167] A.L. Perraud, X. Zhao, A.G. Ryazanov, C. Schmitz, The channel-kinase TRPM7 regulates phosphorylation of the 
translational factor eEF2 via eEF2-k, Cell Signal, 23 (2011) 586-593. 
[168] M.V. Dorovkov, S.N. Beznosov, S. Shah, L. Kotlianskaia, A.S. Kostiukova, [Effect of mutations imitating the 
phosphorylation by TRPM7 kinase on the function of the N-terminal domain of tropomodulin], Biofizika, 53 (2008) 943-949. 
[169] M.V. Dorovkov, A.G. Ryazanov, Phosphorylation of Annexin I by TRPM7 Channel-Kinase, Journal of Biological Chemistry, 
279 (2004) 50643-50646. 
[170] K. Clark, M. Langeslag, B. van Leeuwen, L. Ran, A.G. Ryazanov, C.G. Figdor, W.H. Moolenaar, K. Jalink, F.N. van Leeuwen, 
TRPM7, a novel regulator of actomyosin contractility and cell adhesion, EMBO J, 25 (2006) 290-301. 
[171] K. Clark, J. Middelbeek, E. Lasonder, N.G. Dulyaninova, N.A. Morrice, A.G. Ryazanov, A.R. Bresnick, C.G. Figdor, F.N. van 
Leeuwen, TRPM7 regulates myosin IIA filament stability and protein localization by heavy chain phosphorylation, J Mol Biol, 
378 (2008) 790-803. 
[172] F. Deason-Towne, A.L. Perraud, C. Schmitz, Identification of Ser/Thr phosphorylation sites in the C2-domain of 
phospholipase C gamma2 (PLCgamma2) using TRPM7-kinase, Cell Signal, 24 (2012) 2070-2075. 
[173] K. Clark, J. Middelbeek, M.V. Dorovkov, C.G. Figdor, A.G. Ryazanov, E. Lasonder, F.N. van Leeuwen, The alpha-kinases 
TRPM6 and TRPM7, but not eEF-2 kinase, phosphorylate the assembly domain of myosin IIA, IIB and IIC, FEBS Lett, 582 (2008) 
2993-2997. 
[174] K. Clark, J. Middelbeek, N.A. Morrice, C.G. Figdor, E. Lasonder, F.N. van Leeuwen, Massive autophosphorylation of the 
Ser/Thr-rich domain controls protein kinase activity of TRPM6 and TRPM7, PLoS One, 3 (2008) e1876. 
[175] M. Matsushita, J.A. Kozak, Y. Shimizu, D.T. McLachlin, H. Yamaguchi, F.-Y. Wei, K. Tomizawa, H. Matsui, B.T. Chait, M.D. 
Cahalan, A.C. Nairn, Channel Function Is Dissociated from the Intrinsic Kinase Activity and Autophosphorylation of 
TRPM7/ChaK1, Journal of Biological Chemistry, 280 (2005) 20793-20803. 
[176] N. Cai, Z. Bai, V. Nanda, L.W. Runnels, Mass Spectrometric Analysis of TRPM6 and TRPM7 Phosphorylation Reveals 
Regulatory Mechanisms of the Channel-Kinases, Scientific Reports, 7 (2017) 42739. 
[177] L.V. Ryazanova, M.V. Dorovkov, A. Ansari, A.G. Ryazanov, Characterization of the Protein Kinase Activity of 
TRPM7/ChaK1, a Protein Kinase Fused to the Transient Receptor Potential Ion Channel, Journal of Biological Chemistry, 279 
(2004) 3708-3716. 
[178] Bimal N. Desai, G. Krapivinsky, B. Navarro, L. Krapivinsky, Brett C. Carter, S. Febvay, M. Delling, A. Penumaka, I.S. 
Ramsey, Y. Manasian, David E. Clapham, Cleavage of TRPM7 Releases the Kinase Domain from the Ion Channel and Regulates 
Its Participation in Fas-Induced Apoptosis, Developmental Cell, 22 (2012) 1149-1162. 
[179] G. Krapivinsky, L. Krapivinsky, Y. Manasian, David E. Clapham, The TRPM7 Chanzyme Is Cleaved to Release a Chromatin-
Modifying Kinase, Cell, 157 (2014) 1061-1072. 
[180] J. Jin, B.N. Desai, B. Navarro, A. Donovan, N.C. Andrews, D.E. Clapham, Deletion of Trpm7 Disrupts Embryonic 
Development and Thymopoiesis Without Altering Mg2+ Homeostasis, Science, 322 (2008) 756. 
[181] J. Jin, L.-J. Wu, J. Jun, X. Cheng, H. Xu, N.C. Andrews, D.E. Clapham, The channel kinase, TRPM7, is required for early 
embryonic development, Proceedings of the National Academy of Sciences, 109 (2012) E225-E233. 
[182] R. Sah, P. Mesirca, X. Mason, W. Gibson, C. Bates-Withers, M. Van den Boogert, D. Chaudhuri, W.T. Pu, M.E. Mangoni, 
D.E. Clapham, Timing of myocardial trpm7 deletion during cardiogenesis variably disrupts adult ventricular function, 
conduction, and repolarization, Circulation, 128 (2013) 101-114. 
[183] B.L. Arduini, P.D. Henion, Melanophore sublineage-specific requirement for zebrafish touchtone during neural crest 
development, Mech Dev, 121 (2004) 1353-1364. 
[184] R.A. Cornell, E. Yemm, G. Bonde, W. Li, C. d'Alencon, L. Wegman, J. Eisen, A. Zahs, Touchtone promotes survival of 




[185] S.E. Low, K. Amburgey, E. Horstick, J. Linsley, S.M. Sprague, W.W. Cui, W. Zhou, H. Hirata, L. Saint-Amant, R.I. Hume, 
J.Y. Kuwada, TRPM7 Is Required within Zebrafish Sensory Neurons for the Activation of Touch-Evoked Escape Behaviors, The 
Journal of Neuroscience, 31 (2011) 11633. 
[186] M. Ratnam, J. Chan, N. Lesani, E. Sidorova-Darmos, J.H. Eubanks, M.M. Aarts, mRNA expression of transient receptor 
potential melastatin (TRPM) channels 2 and 7 in perinatal brain development, International Journal of Developmental 
Neuroscience, 69 (2018) 23-31. 
[187] E. Turlova, C.Y.J. Bae, M. Deurloo, W. Chen, A. Barszczyk, F.D. Horgen, A. Fleig, Z.P. Feng, H.S. Sun, TRPM7 Regulates 
Axonal Outgrowth and Maturation of Primary Hippocampal Neurons, Mol Neurobiol, 53 (2016) 595-610. 
[188] Y. Liu, C. Chen, Y. Liu, W. Li, Z. Wang, Q. Sun, H. Zhou, X. Chen, Y. Yu, Y. Wang, N. Abumaria, TRPM7 Is Required for 
Normal Synapse Density, Learning, and Memory at Different Developmental Stages, Cell Reports, 23 (2018) 3480-3491. 
[189] V.A. Blomen, P. Majek, L.T. Jae, J.W. Bigenzahn, J. Nieuwenhuis, J. Staring, R. Sacco, F.R. van Diemen, N. Olk, A. Stukalov, 
C. Marceau, H. Janssen, J.E. Carette, K.L. Bennett, J. Colinge, G. Superti-Furga, T.R. Brummelkamp, Gene essentiality and 
synthetic lethality in haploid human cells, Science, 350 (2015) 1092-1096. 
[190] C. Schmitz, A.L. Perraud, C.O. Johnson, K. Inabe, M.K. Smith, R. Penner, T. Kurosaki, A. Fleig, A.M. Scharenberg, 
Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7, Cell, 114 (2003) 191-200. 
[191] D. Visser, J. Middelbeek, F.N. van Leeuwen, K. Jalink, Function and regulation of the channel-kinase TRPM7 in health 
and disease, Eur J Cell Biol, 93 (2014) 455-465. 
[192] S.N. Yee, A.A. Kazi, K.R. Yee, Cellular and Developmental Biology of TRPM7 Channel-Kinase: Implicated Roles in Cancer, 
Cells, 3 (2014). 
[193] P. Rybarczyk, M. Gautier, F. Hague, I. Dhennin-Duthille, D. Chatelain, J. Kerr-Conte, F. Pattou, J.-M. Regimbeau, H. 
Sevestre, H. Ouadid-Ahidouch, Transient receptor potential melastatin-related 7 channel is overexpressed in human 
pancreatic ductal adenocarcinomas and regulates human pancreatic cancer cell migration, International Journal of Cancer, 
131 (2012) E851-E861. 
[194] S.N. Yee, Role of TRPM7 in Cancer: Potential as Molecular Biomarker and Therapeutic Target, Pharmaceuticals, 10 
(2017). 
[195] N.S. Yee, W. Zhou, I.C. Liang, Transient receptor potential ion channel Trpm7 regulates exocrine pancreatic epithelial 
proliferation by Mg2+-sensitive Socs3a signaling in development and cancer, Disease Models &amp;amp; Mechanisms, 4 
(2011) 240. 
[196] J. Middelbeek, A.J. Kuipers, L. Henneman, D. Visser, I. Eidhof, R. van Horssen, B. Wieringa, S.V. Canisius, W. Zwart, L.F. 
Wessels, F.C.G.J. Sweep, P. Bult, P.N. Span, F.N. van Leeuwen, K. Jalink, TRPM7 Is Required for Breast Tumor Cell Metastasis, 
Cancer Research, 72 (2012) 4250. 
[197] J. Middelbeek, D. Visser, L. Henneman, A. Kamermans, A.J. Kuipers, P.M. Hoogerbrugge, K. Jalink, F.N. van Leeuwen, 
TRPM7 maintains progenitor-like features of neuroblastoma cells: implications for metastasis formation, Oncotarget, 6 
(2015) 8760-8776. 
[198] A. Guilbert, M. Gautier, I. Dhennin-Duthille, P. Rybarczyk, J. Sahni, H. Sevestre, A.M. Scharenberg, H. Ouadid-Ahidouch, 
Transient receptor potential melastatin 7 is involved in oestrogen receptor-negative metastatic breast cancer cells migration 
through its kinase domain, European Journal of Cancer, 49 (2013) 3694-3707. 
[199] K. Inoue, Z.G. Xiong, Silencing TRPM7 promotes growth/proliferation and nitric oxide production of vascular endothelial 
cells via the ERK pathway, Cardiovasc Res, 83 (2009) 547-557. 
[200] M. Aarts, K. Iihara, W.L. Wei, Z.G. Xiong, M. Arundine, W. Cerwinski, J.F. MacDonald, M. Tymianski, A key role for TRPM7 
channels in anoxic neuronal death, Cell, 115 (2003) 863-877. 
[201] H.S. Sun, M.F. Jackson, L.J. Martin, K. Jansen, L. Teves, H. Cui, S. Kiyonaka, Y. Mori, M. Jones, J.P. Forder, T.E. Golde, 
B.A. Orser, J.F. Macdonald, M. Tymianski, Suppression of hippocampal TRPM7 protein prevents delayed neuronal death in 
brain ischemia, Nat Neurosci, 12 (2009) 1300-1307. 
[202] W. Chen, B. Xu, A. Xiao, L. Liu, X. Fang, R. Liu, E. Turlova, A. Barszczyk, X. Zhong, C.L.F. Sun, L.R.G. Britto, Z.-P. Feng, H.-
S. Sun, TRPM7 inhibitor carvacrol protects brain from neonatal hypoxic-ischemic injury, Molecular Brain, 8 (2015) 11. 
[203] N.S. Yee, A.A. Kazi, Q. Li, Z. Yang, A. Berg, R.K. Yee, Aberrant over-expression of TRPM7 ion channels in pancreatic 
cancer: required for cancer cell invasion and implicated in tumor growth and metastasis, Biology Open, 4 (2015) 507. 
[204] J.-P. Chen, J. Wang, Y. Luan, C.-X. Wang, W.-H. Li, J.-B. Zhang, D. Sha, R. Shen, Y.-G. Cui, Z. Zhang, L.-M. Zhang, W.-B. 
Wang, TRPM7 promotes the metastatic process in human nasopharyngeal carcinoma, Cancer Letters, 356 (2015) 483-490. 
[205] F.M. Davis, I. Azimi, R.A. Faville, A.A. Peters, K. Jalink, J.W. Putney Jr, G.J. Goodhill, E.W. Thompson, S.J. Roberts-
Thomson, G.R. Monteith, Induction of epithelial–mesenchymal transition (EMT) in breast cancer cells is calcium signal 
dependent, Oncogene, 33 (2013) 2307. 
[206] L. Chen, R. Cao, G. Wang, L. Yuan, G. Qian, Z. Guo, C.L. Wu, X. Wang, Y. Xiao, Downregulation of TRPM7 suppressed 
migration and invasion by regulating epithelial-mesenchymal transition in prostate cancer cells, Med Oncol, 34 (2017) 127. 
[207] R. Cao, Z. Meng, T. Liu, G. Wang, G. Qian, T. Cao, X. Guan, H. Dan, Y. Xiao, X. Wang, Decreased TRPM7 inhibits activities 
and induces apoptosis of bladder cancer cells via ERK1/2 pathway, Oncotarget, 7 (2016) 72941-72960. 
[208] Y. Sun, A. Schaar, P. Sukumaran, A. Dhasarathy, B.B. Singh, TGFβ-induced epithelial-to-mesenchymal transition in 
prostate cancer cells is mediated via TRPM7 expression, Molecular Carcinogenesis, 57 (2018) 752-761. 
[209] K. Liu, S.-H. Xu, Z. Chen, Q.-X. Zeng, Z.-J. Li, Z.-M. Chen, TRPM7 overexpression enhances the cancer stem cell-like and 




[210] Z. Zhang, M. Faouzi, J. Huang, D. Geerts, H. Yu, A. Fleig, R. Penner, N-Myc-induced up-regulation of TRPM6/TRPM7 
channels promotes neuroblastoma cell proliferation, Oncotarget, 5 (2014) 7625-7634. 
[211] I. Lange, D.-L.T. Koomoa, MycN promotes TRPM7 expression and cell migration in neuroblastoma through a process 







Kirsten S. Vrenken, Kees Jalink, Frank N. van Leeuwen, Jeroen Middelbeek
Adapted from: 
Biochemica et Biophysica Acta 1863, 1436-1446, (2016).
Chapter 2
Beyond ion-conduction: 
Channel-dependent and -independent 
roles of TRP channels during 
development and tissue homeostasis
Abstract 
Transient receptor potential (TRP) channels comprise a family of cation channels implicated 
in a variety of cellular processes, including proliferation, cell migration and cell survival.  As a 
consequence, members of this ion family play prominent roles during embryonic 
development, tissue maintenance and cancer progression. Although most TRP channels are 
non-selective, many cellular responses, mediated by TRP channels, appear to be calcium-
dependent. In addition, there is mounting evidence for channel-independent roles for TRP 
channels. In this review, we will discuss how both these channel-dependent and -independent 
mechanisms affect cellular programs essential during embryonic development, and how 






Communication between cells and their tissue microenvironment plays a prominent role 
during embryonic development as well as in the maintenance of tissue homeostasis. As cell-
cell or cell-matrix interactions control key cellular processes such as proliferation, apoptosis 
and cell migration, perturbations of these interactions contribute to a large variety of 
developmental defects and diseases, including cancer [1-7].  Apart from adhesion molecules 
and cell surface receptors that perceive and respond to extracellular cues, plasma membrane 
(PM) ion channels play an essential role in cellular communication.  This review focuses on 
members of the transient receptor potential (TRP) family, which affect a variety of cellular 
processes owing to their roles as sensors and integrators of extracellular cues [8-11]. 
Extensive research on TRP family members has uncovered a large diversity in biological 
functions, activation mechanisms and ion selectivity (see box 1) [8-10]. Moreover, the 
importance of these channels during embryonic development and tumor progression is now 
widely recognized [12-18].  
While most TRP channels are permeable to both monovalent and divalent cations, a 
significant number of TRP channels control calcium homeostasis and/or mediate 
spatiotemporally confined calcium signaling. Accordingly, many TRP channels are able to 
control cell behavior by permeation of this important second messenger. In addition, TRP 
channels affect cell behavior through additional, channel-independent mechanisms [19-22]. 
For instance, it was demonstrated that TRP channels organize into large macromolecular 
complexes linked to the cytoskeleton, acting as signaling hubs [23]. Apart from functioning as 
cytoskeletal scaffolds, necessary for the proper architecture of the complex itself, TRP 
channels regulate cytoskeletal dynamics and cell contractility through these complexes [19]. 
In addition, enzymatic domains present in some of the TRP family-members may directly 
affect cell behavior [22, 24]. Finally, TRP channels control cellular differentiation by regulation 
of gene expression, both in channel-dependent and -independent manners [20, 25-27]. In this 
review we will outline how both these channel-dependent and -independent functions of TRP 
channels guide embryonic development and describe how perturbations in expression or 
function of channel complexes can contribute to tumor progression, tissue fibrosis or other 
pathologies. 
 
TRP channels as regulators of tissue homeostasis through calcium gating 
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The control of calcium signaling events in space and time is indispensable for normal 
embryonic development, cellular differentiation and the maintenance of tissue homeostasis 
[46]. Calcium entry through plasmamembrane (PM) ion channels results in a spatiotemporally 
confined calcium signal. The information encoded by these local, transient calcium signals is 
decoded by calcium-binding proteins that trigger adequate biochemical and cellular 
Box 1. TRP channels and their activation mechanisms  
The TRP channel super-family comprises 28 mammalian members divided into six subfamilies based 
upon sequence homology, namely canonical (TRPC), vaniloid (TRPV), melastatin (TRPM), ankyrin 
(TRPA), polycystic (TRPP) and mucolipin (TRPML) TRP channels [28]. Whereas all TRP proteins have 
cytoplasmic NH2- and COOH-termini, a large variety of additional functional domains, including 
domains mediating protein-protein interactions and enzymatic domains, are present among the 
different members [9]. TRP proteins usually consist of 6 transmembrane domains, of which domains 
5 and 6 contribute to the channel pore. Functional TRP channels organize into homo- or 
heterotetrameric complexes, where the composition of the tetramers determines the specific 
characteristics of the channel [9]. While most heterotetrameric complexes are formed within the 
same subfamily, subunit interactions can occur between members of different subfamilies, for 
example between TRPP2 and TRPV4 [29-31]. 
TRP channels are controlled by a broad range of intra- and extracellular cues. Moreover, individual 
TRP channels can be activated by multiple signals, functioning as multimodal sensors [10, 32]. While 
TRP channel gating was always considered to be voltage-independent, for several TRP channels, 
including TRPV1, and TRPM8, voltage-dependent gating mechanisms have been reported recently 
[32-34]. In addition, a variety of TRP channels respond to specific temperature and pH ranges. For 
instance, pore opening of TRPV1 [35] and TRPV3 [36, 37] are induced by temperatures exceeding 
43 and 31 degrees, respectively. TRP channels can also act as ligand-gated calcium channels, being 
directly activated by a variety of chemical signals, including capsaicin and menthol, as well as 
calmodulin (CaM) and even calcium itself. In addition, TRP channels can be activated by receptor-
activated second messenger pathways [32, 33]. For example, TRPM7 activity can be triggered by 
the hydrolytic activity of phospholipase C (PLC), a downstream target of Gq-protein coupled 
receptors (GPCRs) [38]. In addition, by interacting with STIM1, an ER-located calcium sensor, TRPC 
channels are involved in store-operated calcium entry (SOCE). Upon calcium store depletion, STIM1 
translocates to ER-plasma membrane junctions to trigger calcium influx across the plasma 
membrane through Orai and TRPC channels [39] [40].   
TRP channels can also be activated by mechanical stimuli, but in most cases it remains unclear 
whether channel opening is directly regulated by mechanical stress, for example by stretch-induced 
membrane tension [41], or is the result of mechanically activated signaling cascades [42].  Channel 
opening in response to mechanical forces frequently involves close interactions between TRP 
channels and the actomyosin cytoskeleton, with actomyosin contractility facilitating pore opening 
[19]. In addition, TRP channels can be part of macromolecular complexes where mechanosensitive 
proteins that interact with adhesion sites and the cytoskeleton, activate channel gating [19]. 
Interestingly, apart from affecting gating by physically interacting with either TRP channels or their 
macromolecular complexes, the cytoskeleton also modulates gating activity by controlling 
localization and clustering of TRP channels in distinct plasma membrane domains [43-45]. 
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responses. In healthy tissues, calcium influx through ion channels affects important cellular 
processes, including cell proliferation, cell survival and cell migration [10, 18, 47]. In a 
pathological setting, dysregulated calcium signaling contributes to tumor progression [17, 18, 
48]. Accordingly, a number of TRP channels play an important role during embryogenesis, 
tissue maintenance and cancer development (Table 1). For instance, deletion of a variety of 
TRP channels, including TRPM7, TRPM6 or TRPP2 results in early embryonic lethality [15, 49, 
50]. Moreover, TRPP2 plays an essential role in early pronephric development in Xenopus [51] 
and the determination of left-right asymmetry in mice [52]. In addition, embryos of TRPM6 
null mice display defects in neural tube closure [49], while the use of TRPM7 conditional 
knockout mice revealed that TRPM7 is essential at various stages of organogenesis, such as 
the development of the kidney, dorsal root ganglion neurons and the brain [15, 53]. In the 
adult organism, ectopic activation or expression of TRP channels can contribute to cancer 
progression [17, 18, 54]. Consistently, expression levels of TRP channels were found to be 
associated with patient outcome in a variety of cancer types [55-57]. Manipulating expression 
of these channels in tumor cell models often affects malignant cell behavior in vitro or in vivo  
[17, 58]. In the next part, we will discuss how calcium-dependent signaling mechanisms, 
activated by TRP channel-mediated calcium influx, affect cellular processes such as 
proliferation, apoptosis and migration. 
 
TRP channels control proliferation and apoptosis by calcium-dependent activation of ERK and 
Akt pathways 
Calcium entry through TRP channels can lead to activation of several calcium-dependent 
signaling cascades of which the MAPK/ERK pathway and the PI3K/Akt pathway have been 
described in most detail (Fig. 1). The MAPK/ERK pathway plays a prominent role in the 
regulation of proliferation, apoptosis and differentiation. Calcium entering through PM 
channels can activate calmodulin (CaM), initiating a cascade of events that leads to the 
activation of extracellular signal-regulated kinases (ERK) [59, 60]. ERK subsequently activates 
a number of regulatory targets in the cytoplasm, including the MAPK-activated protein 
kinases RSK, MNK and MSK as well as the protease calpain [60-63]. These downstream 
proteins play important regulatory roles during cell cycle progression, cell survival and nuclear 
signaling [60]. Additionally, activated ERK can translocate to the nucleus where it can 
influence transcription and translation by phosphorylating transcription factors, including  
2
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STAT3 and NFAT [60, 63].  
While activation of ERK is mainly associated with enhanced proliferation and increased cell 
survival,  the effects of ERK activation are highly context dependent; in particular cell lineages 
a pro-apoptotic role for the ERK-pathway has been documented [64, 65]. As a consequence, 
calcium influx through TRP channels can either positively or negatively regulate apoptosis 
through activation of the ERK pathway. For instance, specific activation of TRPA1 in TRPA1-
positive H146 small cell lung cancer cells and HEK293 cells that were made to express TRPA1, 
results in calcium- and Src-dependent activation of ERK1/2 and prevents serum starvation-
induced apoptosis [66]. In addition, TRPC channels play an important role in preventing 
apoptosis induced by the HIV-1 envelope protein Tat in primary neurons. This 
neuroprotection is mediated through PDGF signaling, and requires the presence of TRPC5 and 
TRPC6 to mediate intracellular calcium elevations that activate the ERK pathway and 
downstream effectors [67]. On the other hand, overexpression of TRPV2 was shown to 
enhance apoptosis in glioma cells by activating the ERK-pathway [68], while in human small 
cell lung cancer (SCLC) cells, TRPV6 is required for capsaicin-induced apoptosis [69]. Although 
the involvement of the ERK-pathway was not directly investigated, treatment of SCLC cells 
with capsaicin enhanced activation of calpain [69], a known mediator of apoptosis [61] and a 
downstream target of ERK, suggesting that capsaicin induces apoptosis via TRPV6 in an ERK-
dependent manner [69].  
Next to affecting apoptosis signaling, TRP channels also regulate proliferation by activation of 
the ERK-cascade. For instance, proliferation of MCF-7 breast cancer cells is enhanced under 
high extracellular calcium levels. In response to high extracellular calcium levels, MCF-7 breast 
cancer cells upregulate TRPC1 expression, resulting in TRPC1-dependent increased calcium 
entry, phosphorylation of ERK1/2 and cell proliferation [70]. Similarly, in glioma cells, 
proliferation depends on the activation of the ERK-pathway by TRPV2 [68]. Finally, TRPM7 
was shown to positively regulate cell proliferation in astrocytes in an ERK-dependent manner 
[71].  
Apart from the ERK-pathway, TRP channels affect PI3K/Akt signaling. Activation of the 
PI3K/Akt pathway generally requires ligand-induced activation of specific cell surface 
receptors leading to the activation of phosphatidylinositide 3-kinase (PI3K) by the assembly 




Figure 1. Channel-dependent mechanisms by which TRP channels regulate different aspects of cell behavior. Calcium 
entry through TRP channels leads to CAM-dependent activation of NFAT or NF-κB, while CAM-mediated activation of ERK 
and Akt leads to phosphorylation-induced activation of other downstream transcription factors. Besides transcription, 
ERK1/2 and Akt control many other cellular processes by phosphorylation of downstream targets. Calcium influx through 
TRP channels also regulates focal adhesion turnover and influences actin cytoskeletal dynamics, leading to changes in cell 
adhesion and migration. 
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manner [74]. At the plasma membrane, PI3K converts phosphatidylinositol(4,5)-phosphate 
(PI(4,5)P2) into phosphatidylinositol(3,4,5)-phosphate (PI(3,4,5)P3), thereby recruiting Akt to 
the plasma membrane, where it is activated by phosphatidylinositol-dependent kinase-1 
(PDK1). By the subsequent phosphorylation of downstream targets, such as mTOR, CREB and 
FOXO, Akt stimulates cell cycle progression and proliferation, while promoting cell survival 
[72, 75].   
Recently, TRPV4 was implicated in liver fibrosis by negatively regulating hepatic stellate cell 
(HSC) apoptosis in an Akt-dependent manner [76]. Activation of HSCs, which eventually leads 
to the differentiation of HSC into myofibroblast-like cells, is a significant event in the 
development of liver fibrosis [77, 78]. Consequently, enhancing apoptosis of activated HSCs 
may act to reverse liver fibrosis [79]. Treatment of HSC-T6 cells with TFG-β1, one of the main 
profibrotic mediators in liver, was shown to enhance HSC proliferation and reduce the 
expression of pro-apoptotic factors caspase-3 and Bax. To the contrary, silencing of TRPV4 in 
these TGF-β1 treated cells significantly enhanced the expression of caspase-3 and Bax and 
promoted apoptosis while reducing Akt phosphorylation, indicating that TRPV4 confers 
apoptosis resistance through the activation of the Akt pathway [76]. In contrast to TRPV4, 
TRPV6 plays a role in controlling cell proliferation by regulation of PI3K/Akt signaling. 
Abnormal proliferation of the intestinal epithelial, as a result of dietary calcium deficiency, 
can lead to the formation of colon cancer. Under these low extracellular calcium conditions 
and in response to IGF-signaling, TRPV6 was shown to activate the PI3K/Akt-pathway and 
enhance human colon cancer cell proliferation [80]. Interestingly,  EGF-stimulation of 
proliferation in non-small cell lung cancer cells requires TRPC1-mediated calcium entry to 
activate both Akt and ERK cascades [81].  
Apart from proliferation and apoptosis, angiogenesis is another essential process during 
embryonic development and cancer progression. TRPV1 was found to play a vital role during 
simvastatin-elicited angiogenesis which appears to involve activation of Akt [82]. In human 
microvascular endothelial cells, TRPV1 is essential for the simvastatin-induced activation of a 
signaling cascade involving the phosphorylation of CaM-dependent kinase II (CaMKII) and the 
formation of a complex containing TRPV1, Akt and CaMKII, amongst other proteins. 
Moreover, in vivo simvastin-induced angiogenesis was significantly reduced in TRPV1-/- mice, 




Calcium-dependent regulation of the cytoskeleton by TRP channels; consequences for cell 
adhesion and migration  
Cell migration is of fundamental importance to embryonic development. For instance, during 
formation of neural crest-derived tissues, neural crest (NC) cells undergo a process known as 
epithelial- mesenchymal transition (EMT). As part of this process, NC cells lose their apical to 
basal polarity and delaminate from the neuroepithelium, after which these cells migrate away 
from the neural tube to specific sites in the embryo where they give rise to a number of 
different tissues [83-86]. Defects in cell migration affecting neural crest-derived or other cell 
types can result in severe malformations of the embryo while impacting important cellular 
processes in the adult, such as immunity and wound healing [87-89]. In contrast, cancer cells 
frequently reactivate pro-migratory gene expression programs in order to invade the 
surrounding tissue and/or spread through the body to form distant metastases [90-92].  
Cell migration is a multistep process involving the formation of adhesions in the front of the 
cell, the generation of traction force and subsequent disassembly of cell adhesion sites at the 
cell rear [93]. As a consequence, spatiotemporal regulation of adhesion dynamics determines 
the efficiency of cell migration [94, 95]. Local calcium signals play a prominent role in 
controlling focal adhesion (FA) turnover to allow optimal migration. For instance, disassembly 
of focal adhesions requires the cleavage of focal adhesion proteins, such as talin, vinculin, 
focal adhesion kinase (FAK) and integrins, by the calcium-dependent protease calpain [96]. At 
the same time, discrete local increases in calcium concentration prolong the association of 
FAK with focal adhesions, thereby enhancing the local activation of FAK effectors and the 
disassembly of FA [97]. Moreover, activation of calcium/CaM-dependent-myosin light chain 
(MLC) kinases leads to increased MLC phosphorylation, resulting in enhanced actomyosin-
based contraction [96]. Recently, TRPM7 mediated local calcium signaling events at the 
leading edge of the cell, known as calcium flickers, were shown to regulate cell polarization 
to direct cell migration, possibly by facilitating local adhesion turnover and cytoskeletal 
remodeling at the cell front [98] (Fig. 1).  
A role for TRP channels in controlling cell migration is now well recognized. For instance, we 
have shown that TRPM7 controls cell migration in both breast cancer as well as 
neuroblastoma cells [99, 100]. Similarly, activation of several other TRP channels including, 
but not limited to, TRPC1 [101, 102], TRPV2 [103, 104], TRPV4 [105, 106] and TRPM8 [107, 
108] enhances cell migration in a large variety of cell types. Of potential relevance to the clinic, 
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tumor biopsies of invasive breast cancer areas displayed significantly higher abundance of 
TRPV6 in comparison with non-invasive areas, suggesting that TRPV6 expression might be 
involved in breast cancer invasion [109].  
The mechanisms by which TRP channels influence cell migration are not completely 
understood and may differ between cell type and channel subtypes. For instance, TRPV2 [103] 
and TRPC1 [110] affect cell migration of prostate and thyroid cancer cells, respectively, by 
regulating the expression and secretion of MMP2 and MMP9, two matrix metalloproteases 
known to facilitate cell migration by extracellular matrix degradation. Likewise, 
pharmacological inhibition of TRPM8 reduced MMP9 secretion, migration and invasion of oral 
squamous cell carcinoma cells [107]. A different mechanism was put forward for TRPP1, also 
known as PKD1. This channel facilitates cell migration by affecting both actin cytoskeletal 
dynamics as well as microtubule stabilization [111, 112]. In addition, PKD1 promotes FA-
dynamics, as phosphorylation of FAK is enhanced upon overexpression of PKD1 [111, 113]. 
Interestingly, enhanced FAK phosphorylation only requires the COOH-terminal end of PKD1, 
suggesting that PKD1 is able to regulate cell migration in a channel-independent manner (see 
below) [113]. Recently, TRPM4 mediated local calcium influx was shown to affect cell 
migration by regulating focal adhesion disassembly and cell contractility, involving activation 
of FAK in focal adhesions [114]. TRPM7 mediated calcium flickers that localize to adhesion 
sites at the leading edge of migrating cells [98] may steer cell migration by activating m-
calpain in the close vicinity of focal adhesions, leading to subsequent cleavage of focal 
adhesion components, including FAK [115]. TRPM7 mediated calcium flickers are triggered by 
shear stress and the chemoattractant platelet-derived growth factor (PDGF). Hence, by 
elevating local calcium concentrations, TRPM7 may enhance FA turnover and regulate 
movement towards a chemoattractant or the direction from which shear stress was induced 
[98]. Similarly, TRPC1 was shown to locally elevate intracellular calcium concentrations in the 
cell front of renal epithelial cells [101] and glioma cells [102] and regulate directional 
migration either unstimulated or in response to chemotactic gradients, indicating that TRPC1 
could regulate directional migration in a fashion similar to TRPM7.  
 
TRP channels regulate calcium-dependent transcription  
Apart from directly influencing cellular processes through calcium-dependent signaling 
cascades, calcium permeated by TRP channels can produce more sustained effects by 
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regulation of gene expression (Fig. 1). Nuclear factor of activated T cells (NFAT) is one of the 
best characterized calcium sensitive transcription factors [116-118]. Under basal conditions, 
NFAT remains inactive in the cytoplasm. In response to specific calcium signals, however, CaM 
will bind to and activate the phosphatase calcineurin, which in turn dephosphorylates specific 
residues within the NFAT protein. This will mask a nuclear export sequence and reveal a 
nuclear localization sequence, resulting in the nuclear translocation of NFAT [116-118]. In the 
nucleus, NFAT either binds DNA directly or through interactions with complexes of other 
nucleoproteins [117]. Depending on the composition of these complexes, NFAT-DNA 
interactions can lead to either activation or repression of target genes [119]. By regulating 
transcription, NFAT plays important roles during embryonic development as well as tumor 
cell transformation, having a profound impact on proliferative capacity, (anchorage-
independent) cell growth, cell migration and invasion [116, 118-120]. Several TRP channels 
were shown to affect gene expression through activation of NFAT. For instance, activation of 
TRPC6 enhances the proliferation speed of both U-373MG glioblastoma cells as well as 
primary human prostate cancer epithelial cells via the calcineurin-NFAT pathway [121, 122]. 
Similarly, TRPV6 activation enhances proliferation of LNCaP prostate cancer cells through 
NFAT signaling [123]. In transgenic mice, cardiac-specific overexpression of either TRPC6 or 
TRPC3 was observed to significantly enhance NFAT transcriptional activity, which coincided 
with increased pathological hypertrophy [124, 125].   
A second important gene regulatory pathway activated by TRP channels involves the 
transcription factor NF-κB. While NF-κB can also be active in the absence of calcium, calcium 
signaling triggers NF-κB activity [119, 126]. Under resting conditions, NF-κB is retained in the 
cytosol in an inactive conformation by the binding to NF-κB regulatory protein IκB [127, 128]. 
Upon calcium signaling, IκB kinases, IKKα and IKKβ, are activated by calmodulin-dependent 
kinase II (CaMKII) or calcium-dependent protein kinase C (PKC) activity [119, 129]. 
Phosphorylation of IκB by an IKK-complex will lead to the degradation of IκB and the release 
of NF-kB [127, 128]. Free NF-κB will enter the nucleus and activate transcription of genes 
involved in cell adhesion, cell growth and apoptosis resistance [127, 128, 130]. Moreover, NF-
κB-mediated transcription plays a dominant role during  inflammatory responses [131], which 
is however, beyond the scope of this review. 
Recently, TRPC3 was shown to stimulate fibrosis in a NF-κB-dependent manner. Expression of 
the channel was enhanced in stretched human scar tissue compared to normal skin [132]. 
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When modeled in vitro by repetitive stretching of TRPC3 overexpressing fibroblasts, calcium 
influx was induced, coinciding with nuclear localization and enhanced activity of NF-κB. In 
addition, fibronectin production increased compared to control cells undergoing the same 
stretching regimen, indicating that TRPC3 regulates transcription of fibronectin through NF-
κB activation [132]. As fibronectin is an essential component of the extracellular matrix (ECM) 
and induces cell migration, cell differentiation and coagulation leading to wound contraction 
[133-136], secretion of fibronectin in response to mechanical stress is important during 
wound healing. As a consequence, over-deposition of fibronectin in response to repetitive 
mechanical stretching drives scar tissue formation [137], directly linking induced expression 
of TRPC3 in mechanically stretched tissue to the induction of fibrosis. In human umbilical vein 
endothelial cells (HUVEC) TRPC1 was shown to protect against thrombin-induced apoptosis 
by activating NF-κB signaling [27, 138]. Calcium influx through TRPC1 resulted in a positive 
feedforward loop where TRPC1 activation induced its own expression through NF-κB signaling 
[138]. In addition, TRPC1 activation enhanced NF-κB-dependent expression of the anti-
apoptotic zinc finger protein A20, while silencing of TRPC1 promoted expression of pro-
apoptotic proteins Bax and caspase-3 in thrombin-treated HUVEC [27].  
Next to activation of NFAT or NF-κB transcription factors, other transcription factors have 
been implicated in TRP channels regulated gene expression. For instance, EGF-stimulated 
activation of TRPM7 in a breast cancer model was shown to regulate calcium-dependent 
activation of signal-transducer and activator of transcription 3 (STAT3), leading to increased 
expression of the EMT marker vimentin [25]. Moreover, in Xenopus embryos, TRPP2- 
dependent calcium signaling regulates the expression of pax8, a transcription factor critical 
during early kidney development. In breast cancer cell lines, TRPM8 controls gene expression 
through the transcriptional repressor and promoter of EMT, SNAI1 [139]. Overexpression of 
TRPM8 enhanced phosphorylation of Akt and its downstream target GSK-3β [139], thereby 
inhibiting GSK-3β-induced cytoplasmic translocation and degradation of SNAI1 [140], 
consequently enhancing SNAI1 levels and facilitating SNAI1 target gene repression [139]. 
Similarly, we have recently shown that TRPM7 controls a progenitor-like gene expression 
program in human neuroblastoma cell lines, which involves transcriptional regulation of the 
EMT transcription factor SNAI2 [100]. 
Finally, expression of the full-length TRPM2 isoform (TRPM2-L) in neuroblastoma cells was 
linked to higher expression of the hypoxia-inducible transcription factor (HIF)-1/2α compared 
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to neuroblastoma cells expressing the dominant negative short isoform (TRPM2-S). 
Consistently, expression of HIF-1/2α target genes was significantly higher in 
TRPM2-L-expressing cells, as was cell viability in these cells [141]. While the role of calcium in 
regulating HIF-1/2α expression was not a point of investigation, intracellular calcium levels of 
neuroblastoma cells expressing TRPM2-L were elevated compared to TRPM2-S expressing 
cells and HIF1α activity was previously shown to be regulated via the calcium/CaM/ERK 
cascade [142, 143], suggesting involvement of ERK signaling in TRPM2 mediated transcription. 
Altogether these results demonstrate that TRP channels, in addition to producing immediate 
effects on cell adhesion turnover and migration, bring about more sustained effects on cell 
behavior by regulating a variety of transcription factor pathways. Inappropriate activation of 
these gene regulatory networks may lead to developmental defects seen in the embryo 
and/or contribute to cancer formation/progression in the adult organism.  
 
Channel-independent roles of TRP channels in tissue homeostasis 
TRP channels as molecular scaffolds 
Although most of the effects of TRP channels on cell behavior are dictated by the ions that 
they permeate, there are also channel-independent roles for TRP channels. For long it has 
been known that the Drosophila TRP channels (TRP and TRPL) assemble into a large 
macromolecular complex known as the signalplex [144]. Within this complex, the scaffolding 
protein INAD (inactivation no afterpotential D) mediates direct interactions between several 
proteins including TRP, TRPL, protein kinase C, phospholipase C and myosin III. The assembly 
of these signaling proteins into one complex is thought to be essential for proper and rapid 
signal transduction [23]. Interestingly, the localization of INAD and interacting proteins 
appears to be dependent on the availability of TRP, indicating that TRP also functions as an 
anchoring protein [145, 146]. In addition, through the interaction with Dmoesin and myosin 
III, TRP and TRPL are physically linked to the actomyosin cytoskeleton. This direct interaction 
with the cytoskeleton can control both gating of the channels as well as their localization. 
Reciprocally, TRP channels may influence cytoskeletal dynamics through these interactions 
[19]. Similar to Drosophila TRP channels, several mammalian TRP channels assemble into 
macromolecular complexes [82, 147, 148], suggesting that mammalian TRP channels also 
function as scaffolding proteins and regulate cytoskeletal dynamics from within these 
signaling hubs (Fig. 2A). 
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Figure 2. Channel-independent mechanisms by which TRP channels regulate cell behavior. (A) TRP channels function as 
scaffolding proteins for the assembly of large cytoskeletal complexes that facilitate rapid signal transduction as well as 
changes in cytoskeletal organization in response to channel activation. (B) By interacting with tubulin through its COOH- 
and NH2-terminal tails, TRPV1 regulates microtubule dynamics. (C) The COOH-terminus of TRPP1 induces phosphorylation 
of focal adhesion components FAK and Paxilin (PAX), thereby increasing focal adhesion dynamics. (D) TRPM7 
phosphorylates the myosin heavy chain with its COOH-terminal kinase domain, thereby inducing cytoskeletal relaxation. 
(E) The cleaved COOH-terminal tail of TRPP1 can enter the nucleus to control gene expression, and can bind β-Catenin to 
inhibit Wnt-signaling. (F) The cleaved COOH-terminal kinase domain of TRPM7 modulates gene expression by entering the 
nucleus and affecting chromosome organization.  
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Channel-independent regulation of cytoskeletal dynamics by TRP channels 
Cytoskeletal dynamics and focal adhesion turnover are key processes during cell migration 
and several TRP channels have been implicated in the regulation of cytoskeletal remodeling, 
independent of their ion conducting properties. For instance, it was shown that TRPV1 is 
involved in the initiation and regulation of neurite-like extensions and filopodia in neuronal 
as well as non-neuronal cells [149] [21]. Filopodia are thin, actin-rich plasma membrane 
protrusions that probe the cellular microenvironment and play an important role in the 
formation of cellular contacts and migration [150]. Ectopic expression of TRPV1, both in F11 
neuronal cells and in non-neuronal HEK and HeLa cells was shown to increase filopodia 
formation [149]. While microtubules are normally not present within these structures, a 
number of filopodia displayed microtubules extending from the base to the TRPV1-enriched 
tip of the protrusion. The initiation and subsequent protrusion extension was independent of 
TRPV1 channel-activity and required the NH2-terminal domain of TRPV1, while the COOH-
terminal intracellular domain regulated the stabilization of microtubules [149] (Fig. 2B). The 
mechanism by which the COOH-terminal domain stabilizes microtubules is not completely 
understood, however, it was recently shown that this domain interacts with tubulin-dimers. 
This interaction is lost by estrogen-triggered phosphorylation of the S800 position located in 
the TRPV1-COOH-terminus, resulting in microtubule destabilization. Microtubule 
destabilization was independent of TRPV1 ion-conductivity, as estrogen-triggered 
microtubule disassembly was still observed in the presence of a channel-inactive TRPV1 
mutant (TRPV1-ΔN) or the general cation-channel blocker ruthenium red [21]. Taken 
together, TRPV1 regulates microtubule dynamics independent of its ion conductivity with the 
NH2- and COOH-terminal domains exerting different functions in regulating microtubule 
stabilization. While TRPV1 mediated protrusion formation was not directly linked to a 
biological process, protrusion formation often precedes migration [150], suggesting that 
TRPV1 affects cell migration by regulation of the microtubule cytoskeleton. 
The COOH-terminal domain of TRPP1, also known as PKD1, displays a clear channel-
independent role in the regulation of focal adhesion turnover [113] (Fig. 2C). Joly et al. 
showed that the COOH-terminal cytoplasmic domain of PKD-1 fused to a heterologous 
integral membrane protein (PKD1-CT) localizes to cell-extracellular matrix contacts. In 
addition, PKD1-CT was able to interact with focal adhesion proteins FAK and paxilin. 
Overexpression of PKD1-CT enhanced ERK-mediated FAK and paxillin phosphorylation, 
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enabling FAK-paxillin association and the formation of small focal complexes. Interestingly, 
localization of the COOH-terminus to the plasma membrane turned out to be essential for 
FAK and paxillin phosphorylation and association. In addition, interactions with other 
proteins, possibly including TRPP2, are required for PKD1-function, as disruption of a coiled-
coil domain, responsible for these protein interactions, inhibits PKD1-mediated regulation of 
focal adhesions [113].  
 
TRP ‘chanzymes’ 
Within the TRP superfamily, three members (TRPM2, TRPM6 and TRPM7) contain carboxy 
terminal domains with enzymatic activity by which they may directly influence cell behavior 
[8, 19, 28]. Whereas the COOH-terminal domain of TRPM2 possesses ADP-ribose hydrolase 
activity, both TRPM6 and TRPM7 channels are fused to a COOH-terminal kinase domain [8, 
28]. We have previously provided evidence that TRPM7 regulates cytoskeletal relaxation via 
its kinase domain. By phosphorylation of the myosin II heavy chain, TRPM7 interferes with 
myosin II filament formation, thereby enhancing cytoskeletal relaxation and cell spreading 
[22, 24] (Fig. 2D). Consequently, silencing of TRPM7 enhances cell contractility and cell-cell 
adhesion, while impairing cell migration [99]. Interestingly, effects of TRPM7 silencing on cell 
migration can be rescued by pharmacological inhibition of cellular tension [99]. In addition, a 
TRPM7 kinase-dead mutant loses its ability to interact with the actomyosin cytoskeleton, fails 
to induce actomyosin relaxation [22] and reduces serum gradient-induced migration [151], 
suggesting that TRPM7 kinase activity is, at least in part, responsible for actomyosin relaxation 
and cell migration. However, as the interaction of the kinase with its substrates is 
calcium-dependent, it remains unclear whether TRPM7 can regulate cell migration 
completely independent of its channel function [22].  
 
TRP channels as global regulators of gene expression and DNA damage 
Apart from controlling cellular processes through calcium-dependent transcription, TRP 
channels also regulate gene expression independent of their ion conducting properties (Fig. 
2E and F). For instance, the COOH-terminal tail of PKD1 was shown to regulate two distinct 
processes depending on whether the tail is located to the plasma membrane or whether it is 
released intracellularly by proteolytic cleavage. Upon release of the COOH-terminus (PKD1-
CT) by proteolytic cleavage, the COOH-terminal tail can enter the nucleus to initiate signaling 
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processes [26, 152]. Free PKD1-CT was later shown to associate with β-catenin and facilitate 
its accumulation in the nucleus. This interaction between PKD1-CT and β-catenin reduces the 
affinity of β-catenin for its nuclear interaction partner T cell factor (TCF) [153] (Fig. 2E). TCF is 
a DNA-bound transcriptional repressor involved in β-catenin/Wnt-signaling, a conserved 
signaling pathway essential during embryonic development and tissue homeostasis [154]. 
Complex formation between TCF and β-catenin releases the repressing activity of TCF, 
resulting in Wnt target gene expression [155]. Hence, through the interaction with β-catenin, 
PKD1-CT inhibits canonical Wnt-dependent transcription [153] and could play an important 
role during development and tissue maintenance. Comparable to PKD-1, the kinase moiety of 
TRPM7 can be proteolytically cleaved from the channel [20]. The released kinase fragments 
(M7CKs) subsequently translocate to the nucleus to interact with multiple components of 
chromatin-remodeling complexes, including Polycomb group proteins. In addition, M7CKs can 
phosphorylate specific residues of histone 3 at promoters of TRPM7-dependent genes, 
thereby regulating the transcription of these genes [20] (Fig. 2F). Interestingly, as these 
promotor regions were found to belong to genes important for cell differentiation and 
embryonic development [20], TRPM7 cleavage products might directly affect developmental 
processes by epigenetic remodeling. 
Next to influencing gene expression by the release and nuclear translocation of the 
COOH-termini, TRP channels can translocate to the nucleus as intact proteins, as was 
previously shown for TRPM2. While TRPM2 resides on the plasma membrane in non-cancer 
cells, a nuclear localization was observed for TRPM2 in both breast cancer cell lines and 
prostate cancer cell lines [156, 157]. Interestingly, pharmacological inhibition or silencing of 
TRPM2 enhanced DNA damage levels by 4 fold in breast cancer cell lines, while no differences 
in DNA damage were observed in non-cancer cells. This indicates that TRPM2 may play an 
important role in preventing apoptosis by protecting the integrity of genomic DNA in breast 
cancer cells. As TRPM2 possesses ADP-ribose pyrophosphatase activity, Hopkins et al. suggest 
that TRPM2 may activate a pro-survival nucleotide signaling pathway by hydrolyzing ADP-
ribose [157]. Indeed, in prostate cancer cells nuclear TRPM2 inhibited nuclear ADP-
ribosylation [156], a post-translational modification involved in cellular processes such as DNA 
repair and apoptosis [158, 159]. Hence, apart from regulating calcium signaling at the plasma 
membrane, TRPM2 translocation to the nucleus can enhance cell survival of tumor cells. 
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Concluding remarks 
By integrating a large variety of intra- and extracellular signals, TRP channels regulate key 
cellular processes during embryonic development and tissue homeostasis. Consequently, 
perturbed TRP channel function contributes to a variety of pathologies, including cancer 
progression. Therefore, TRP channels are considered interesting drug targets for a number of 
different diseases. A primary mechanism by which TRP channels influence cell behavior is by 
regulating calcium homeostasis. In addition, local calcium entry through TRP channels can 
activate calcium-dependent signaling cascades, either through the ERK and Akt pathways or 
by calcium-dependent remodeling of the cytoskeleton, resulting in effects on cell 
proliferation, -survival and -migration. Moreover, TRP channels affect gene expression, for 
example by activation of calcium-dependent transcription factors, leading to more sustained 
effects on cell behavior.  
In addition to these well-established ion-dependent mechanisms, TRP channels affect cell 
behavior in other ways, for instance by acting as molecular scaffolds that organize into 
macromolecular complexes linked to the cytoskeleton, by cleavage and/or nuclear 
translocation of cytosolic domains, or by the presence of enzymatic activities present in the 
COOH-domains of some TRP channels. Similarly, other channels appear to control cell 
behavior through channel-independent mechanisms. For instance, regulation of transcription 
by cleaved cytosolic fragments also occurs in the family of L-type voltage-gated calcium 
channels where both C-terminal fragments of Cav1.2 and Cav1.3 can translocate to the 
nucleus and regulate gene expression [160-162]. In addition, the ability of Na+-H+ exchanger 
NHE1 to regulate actomyosin cytoskeleton organization, formation of FAs and cell polarity by 
facilitating the recruitment of proteins into large macromolecular complexes is independent 
of its ion-transport functions [163, 164]. Hence, while the described channel-independent 
mechanisms have only been observed for a limited number of TRP channels so far, the 
similarities within the TRP channel family and the occurrence of similar channel-independent 
functions in other channel families suggests that the same principles may apply to other 
members of the TRP family. Therefore, a more complete understanding of the complex 
contributions of channel-independent functions of TRP channels to pathologies is needed 
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Chapter 3
The TRPM7 interactome defines a 




Neuroblastoma is the second-most common solid tumor in children and originates from 
poorly differentiated neural crest-derived progenitors. Although most advanced stage 
metastatic neuroblastoma patients initially respond to treatment, a therapy resistant pool of 
poorly differentiated cells frequently arises, leading to refractory disease. A lack of insight into 
the molecular mechanisms that underlie neuroblastoma progression hampers the 
development of effective new therapies for these patients. 
Normal neural crest development and maturation is guided by physical interactions between 
the cell and its surroundings, in addition to soluble factors such as growth factors. This 
mechanical crosstalk is mediated by actin-based adhesion structures and cell protrusions that 
probe the cellular environment to modulate migration, proliferation, survival and 
differentiation. Whereas such signals preserve cellular quiescence in non-malignant cells, 
perturbed adhesion signaling promotes de-differentiation, uncontrolled cell proliferation, 
tissue invasion and therapy resistance. We previously reported that high expression levels of 
the channel-kinase TRPM7, a protein that maintains the progenitor state of embryonic neural 
crest cells, are closely associated with progenitor-like features of tumor cells, accompanied 
by extensive cytoskeletal reorganization and adhesion remodeling. To define mechanisms by 
which TRPM7 may contribute to neuroblastoma progression, we applied a proteomics 
approach to identify TRPM7 interacting proteins. We show that TRPM7 is part of a large 
complex of proteins, many of which function in cytoskeletal organization, cell protrusion 
formation and adhesion dynamics. Expression of a subset of these TRPM7 interacting proteins 
strongly correlates with neuroblastoma progression in independent neuroblastoma patient 
datasets. Thus, TRPM7 is part of a large cytoskeletal complex that may affect the malignant 







Neuroblastoma is one of the most common malignancies in childhood and responsible for 
12% of cancer associated deaths in children [1, 2]. A lack of insight into the molecular 
mechanisms that contribute to neuroblastoma progression hampers the development of 
effective new therapies [1-3]. Neuroblastoma is an embryonic tumor derived from 
pluripotent cells of the neural crest. The neural crest is a heterogeneous cell population that 
arises at the borders of the neuro-ectoderm during early embryogenesis. Neural crest cells 
exhibit adaptive plasticity, i.e. the ability of phenotypic switching to allow cell-fate changes 
when necessary [4-6]. These cell fate decisions are largely controlled by cues from the tissue 
microenvironment. In addition to growth factors and other soluble cues, cellular processes 
such as proliferation, migration and differentiation are directed by the mechanical crosstalk 
between cells and their microenvironment [7-10]. The physical cross-talk between a cell and 
the surrounding tissue is mediated by cell adhesion sites and cellular protrusions such as 
lamellipodia and filopodia. These structures constantly probe the cellular microenvironment 
for chemical and mechanical cues, and signal to control cytoskeletal dynamics and gene 
expression. Whereas such signals preserve cellular quiescence in non-malignant cells, 
perturbed adhesion signaling promotes de-differentiation, uncontrolled cell proliferation, 
tissue invasion and therapy resistance [9, 11-16]. Indeed, several studies indicate that altered 
cell-matrix interactions significantly contribute to neuroblastoma pathogenesis [17-22].  
Members of the mammalian TRP channel family play a central role in mechano-signaling [23-
28]. Localized within mechano-sensory structures such as cell adhesions, channel opening is 
induced by membrane stretch and/or cytoskeletal tension. The resulting changes in local ion 
concentrations trigger cytoskeletal responses and regulate gene expression. The importance 
of these channels during embryonic development, tissue homeostasis and tumor progression 
is now widely recognized (reviewed in [23, 29-31]). For instance, TRPM7, a calcium permeable 
TRP-channel with a functional C-terminal kinase domain that localizes to cell adhesion sites, 
is required during the development of embryonic organ systems in mice, zebrafish and 
Xenopus, and maintains stemcell-like features of neural crest progenitor cells [32-34]. 
Consistently, we identified TRPM7 as a regulator of cell mechanics that drives the malignant 
behavior of neuroblastoma cells by activating developmental programs in vitro and in vivo 
[35]. Recent reports have confirmed the association between high TRPM7 expression and 
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cancer progression in other tumor types, including pancreatic, nasopharyngeal, breast and 
prostate cancer [36-39]. Although little is known about the molecular mechanism by which 
TRPM7 promotes tumor progression, we previously established that TRPM7 regulates cellular 
tension through Ca2+- and kinase-dependent interactions with the actomyosin cytoskeleton 
[40-42]. Based on the presence of TRPM7 in adhesion structures and because TRPM7 can be 
activated by mechanical stress, this cation channel may act to control cytoskeletal dynamics 
and downstream signaling pathways in response to mechanical cues, to promote the 
progenitor-like features of neuroblastoma cells [26-28, 40, 43]. 
By performing mass-spectrometry on TRPM7 immune complexes, obtained from N1E-115 
neuroblastoma cells expressing HA-tagged TRPM7, we set out to identify the TRPM7 
interactome in neuroblastoma cells. We show that TRPM7 is part of a large cytoskeletal 
protein complex which mostly contains proteins involved in cell protrusion dynamics and 
adhesion formation. By combining a comprehensive literature study with microarray-based 
gene expression analysis, we demonstrate that ~55% of the TRPM7 interactors are associated 
with cancer progression and metastasis formation. Moreover, a number of these components 
accurately predicts neuroblastoma disease outcome in three independent neuroblastoma 
patient cohorts. Together, our results provide further insight into the close interactions 
between TRPM7 and the actomyosin cytoskeleton, and suggest a regulatory role for the 
TRPM7 interactome in cancer progression. 
 
Results & Discussion 
TRPM7 associates with a protein complex that controls cytoskeletal organization  
To define the mechanism by which TRPM7 contributes to neuroblastoma progression, we 
identified proteins in complex with TRPM7 using a proteomic approach (Fig. 1A). The TRPM7 
complex was purified by immunoprecipitation from mouse N1E-115 neuroblastoma cells 
made to express TRPM7-HA [40]. Associated proteins were resolved by SDS-PAGE. Silver 
staining of the gels revealed several proteins that were strongly enriched in the TRPM7 
fraction (Fig. 1B). Proteins present in the control and TRPM7 immunoprecipitations were 
identified by nano liquid chromatography tandem mass spectrometry (LC-MS/MS) and 
proteins were considered to specifically interact with TRPM7 when corresponding peptides 
were exclusively detected in the TRPM7 fraction (TRPM7 IP exclusive), or when peptides were 




control fraction greater than 10 (enriched). This analysis led to the identification of 251 
proteins of which 64 appear to be in a complex with TRPM7 (Table 1 & S1). Proteins were 
classified according to Gene Ontology (GO) annotation for molecular function, cell component 
and biological process. A distribution of GO terms between the control and TRPM7 fractions 
showed that the TRPM7 protein complex is specifically enriched for proteins involved in the 
organization and biogenesis of the actomyosin cytoskeleton (Fig. 1C). This set of proteins 
 
Figure 1. TRPM7 associates with components of the actomyosin cytoskeleton A) Flow chart for proteomic analysis of the 
TRPM7 complex. B) Detection of TRPM7 associated proteins by silver staining of SDS-PAGE gels. HA-tagged TRPM7 was 
isolated by immunoprecipitation using anti-HA monoclonal antibodies (12CA5) from N1E-115 control and TRPM7-
transduced cells. Proteins were separated by SDS-PAGE on 6% (top) and 12% (bottom) gels and subjected to silver staining. 
Proteins which co-immunoprecipitating with TRPM7, are indicated. C. TRPM7-HA immunoprecipitates (IP) are enriched for 
cytoskeletal proteins. Gene ontology (GO) analysis was performed on the set of proteins exclusively present or enriched 
(iBAQ > 10) in TRPM7 IP and proteins identified in control IP. GO enrichment, relative to the mouse whole genome, was 
determined for both IPs. GO terms in categories 'biological process', 'molecular function' and 'cell component', that were 
most significantly enriched in the TRPM7 IPs, are indicated. The fraction of proteins within the IPs, annotated to these 
terms, are presented in a bar chart. Statistical significance between control and TRPM7 IP content was determined by a 
fisher exact test (*** = p < 0.0001). 
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includes conventional myosin II and several non-conventional myosins (myosins I, V and VI) 
as well as proteins regulating actin dynamics such as components of the Arp2/3 complex, 
F-actin capping proteins, drebrin, tropomyosins, tropomodulin, gelsolin and cofilin. 
Moreover, a group of structural proteins involved in cross-linking and scaffolding the 
cytoskeleton, including α-actinin4 and plectin, was also present (Table 1).  
We were able to confirm a substantial number of interactions between TRPM7 and its 
cytoskeletal interactors by immunoprecipitation and Western blotting (Fig. 2). The 
interactions between TRPM7 and the actomyosin cytoskeleton appear to be highly specific. 
First of all, none of the interactors were found in significant quantities in control 
immunoprecipitations (Table S1). Moreover, actin-binding proteins such as α-actinin1, 
cortactin, talin and vinculin, which are abundantly expressed in these cells and thus likely 
contaminants in immunoprecipitations, were not detected either by mass spectrometry or 
Western blotting (Table S1, Fig. 2). Finally, the detection of myosin IIA, IIB and IIC heavy chain, 
known substrates of the TRPM7 kinase domain [40-42], further validates our proteomics 
approach. Note that the interaction between TRPM7 and the cytoskeleton is not restricted to 
ectopically expressed TRPM7-HA, as we previously showed that endogenous TRPM7 also 
interacts with the actomyosin cytoskeleton [40].  
 
The TRPM7 interactome is a macromolecular complex involved in cell adhesion and 
protrusion formation 
We previously showed that TRPM7 is enriched in invadosome-type adhesions where it may 
aid in the assembly of such structures [40]. Invadosomes are highly dynamic, matrix degrading 
adhesion structures that act as mechanosensory devices by detecting rigidity and topography 
of the substratum [44-46]. Consistent with a role for TRPM7 in mechanical regulation of 
cytoskeletal dynamics, a significant number of TRPM7 interactors are known constituents of 
either the invadosome core, such as F-actin, F-actin capping proteins, Arp2/3, gelsolin, cofilin, 
or the ring, such as nonmuscle myosin IIA and tropomyosin [44, 45, 47] (Table 1). Moreover, 
the 'TRPM7 interactome' comprises previously unknown invadosome components, including 
drebrin, myosin IIB and IIC, myosin Va, α-actinin4 and SIPA1-L1/SPAR1 (Fig. 3). The 
observation that many TRPM7 interactors localize to these defined cellular structures 




Consistent with the fact that invadosomes are actin-based protrusive structures, many of the 
TRPM7 interactors are known to regulate the dynamic formation of cellular protrusions such 
as filopodia, neuronal growth cones, dendritic spines and podocytes [30, 48, 49]. For instance, 
the ‘TRPM7 interactome’ component calmodulin is a calcium sensor that can activate the 
serine/threonine phosphatase calcineurin [50]. Calcineurin regulates cytoskeletal 
organization and neurite extension by activation of the phosphatase slingshot (SSH2) and its 
substrate cofillin (CFL1), both of which are present in the TRPM7 interactome [51, 52]. The 
vesicle carrier myosin Va links long distance microtubule-based cargo transport to short 
distance actin-based transport and is crucial for filopodia and neurite extension [53-55]. 
Tropomodulin 2, in turn, is an actin-regulatory protein with capping activity that regulates 
actin polymerization and neurite extension [56]. Many other TRPM7 interacting proteins, 
such as myosin VI [57], drebrin [58-60], TAX1BP1 [61], and SIPA1-L1/SPAR1 [62], have been 
similarly implicated in the regulation of adhesion dynamics and cell protrusion formation. 
Together, these findings suggest that, as a functional complex located at sites of cell adhesion 
or in cellular protrusions, the TRPM7 interactome may control cytoskeletal organization in 
response to mechanical cues from the tissue microenvironment. 
 
Figure 2. TRPM7 specifically interacts with a 
cytoskeletal complex. The interactions between TRPM7 
and the actomyosin cytoskeleton are specific. Protein 
complexes were immunoprecipitated from N1E-115 
control and TRPM7 overexpressing cells, using anti-HA 
antibodies (12CA5). Proteins present in 
immunoprecipitations (IP, left) and total lysates (TL, 
right) were detected by Western blot.  
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The functional implications of the interactions between TRPM7 and its cytoskeletal binding 
partners remain incompletely understood. We have shown in the past that inhibition of 
TRPM7 results in the disassembly of invadosomes [63], which suggests that activity of TRPM7 
is involved in maintaining the integrity of the ‘TRPM7 interactome’. This is consistent with the 
general notion that TRP channels act as cytoskeletal scaffolding proteins [23, 30]. 
Furthermore, our earlier work revealed that TRPM7 regulates the activity non-muscle myosin 
II isoforms through kinase-dependent interactions with the myosin II heavy chain, promoting 
the assembly of invadosomes. If and how TRPM7 may affect the localization and function of 
other interactome components will be addressed in future studies. 
 
Components of the ‘TRPM7 interactome’ correlate with human neuroblastoma metastasis 
A recent study by Molenaar et al. shows that defects in genes encoding regulators of 
cytoskeletal dynamics strongly associate with high-risk neuroblastomas with an aggressive  
 
Figure 3. TRPM7 cytoskeletal interactors localize to invadosomes. By using confocal microscopy, known (myosin IIA) and 
novel invadosome components were identified in N1E-115 cells that stably overexpress TRPM7. If available, antibody 
staining was performed (myosin IIA, IIB and IIC, drebrin, p116Rip, Tropomodulin2 and α-actinin4). Alternatively, protein 
localization was evaluated by expression of GPP- or myc-tagged proteins (myosin V and SIPA1-L1). Actin was visualized by 
Alexa-568 Phalloidin labeling, to indicate invadosome cores (Red). All the tested TRPM7 interactors (green) localized to 




clinical course [21]. An extensive literature survey demonstrated that expression of TRPM7 
and many TRPM7 interactors (~55%) have been associated with disease outcome in various 
cancers, although only a minority of these have thus far been implicated in neuroblastoma 
progression (~5%) (Table 1).  
We therefore tested to what extent components of the TRPM7 interactome associate with 
outcome in human neuroblastoma, using microarray-based neuroblastoma gene expression 
 
 
Figure 4. Expression levels of TRPM7 interactome components correlate with disease outcome in a neuroblastoma 
patient cohorts. A) Overview of TRPM7 interactome components that correlate with overall survival (OS) and recurrence 
free survival (RFS) in at least two out of three patient datasets (Kocak-649, Versteeg-88 and Oberthuer-251). P-values are 
corrected for multiple testing (Bonferroni and false discovery rate). n.s. = not significant; - = gene not present on array; KM-
arm ‘low’ means that low expression correlates with poor outcome, ‘high’ means that high expression predicts poor 
outcome in the Kaplan-Meier analysis. P < 0.05 was considered significant. B) Kaplan-Meier analysis of overall survival 
according to mRNA expression levels of TRPM7 cytoskeletal interactors. Low expression of JUP, MYL6, MYO5A in the Kocak-
649 patient dataset, and TMOD2 in the Versteeg-88 patient dataset, strongly correlate with poor disease outcome. P-values 
are based on log-rank test and corrected for multiple testing (Bonferroni). 
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datasets. The discovery dataset (Kocak - 649) contained expression profiles of 649 primary 
tumor biopsies, along with clinical information on overall and relapse-free survival [64]. 
Probes for all validated components of the TRPM7 interactome were present on this 
microarray. We previously reported that TRPM7 itself associates with disease outcome in this 
dataset [35]. Additionally, mRNA expression of a substantial number of TRPM7 interactors 
correlate significantly with overall (33 out of 64) and relapse free survival (30 out of 64) after 
correction for multiple testing. We performed similar analyses using two independent 
validation cohorts of 88 (Versteeg-88) and 251 (Oberthuer-251) neuroblastoma patients [65, 
66]. In the Versteeg-88 and Oberthuer-251 cohorts, respectively 14 out of 60 and 25 out of 
35 TRPM7 interactors present on the array correlate significantly with disease outcome (Table 
S2). Across the three datasets, we observed striking similarities in the co-regulation of genes 
that associate with neuroblastoma disease progression. Expression of 18 interactors were 
similarly associated with disease progression in at least 2 out of 3 datasets (Fig. 4A). 
Regulators of adhesion dynamics and cytoskeletal organization junctional plakoglobin (JUP), 
myosin light chain 6 (MYL6), myosin 5A (MYO5A), tropomodulin 2 (TMOD2) are amongst the 
interactors that correlated most significantly with disease outcome (Fig. 4B).  
The TRPM7 interactome comprises proteins that either positively or negatively associate with 
tumor progression. This may seem to be at odds with the notion that high TRPM7 expression 
is generally associated with poor disease outcome. However, TRPM7 may either positively OR 
negatively regulate the activity of its interactors. Similarly, the different interactors of TRPM7 
may oppositely affect the aggressive features of neuroblastoma cells. Overall, these 
observations suggest that TRPM7 is part of a cytoskeletal complex that controls the dynamic 
formation and function of mechanosensory structures such as cell adhesions and cellular 
protrusions. This complex may function to control neural crest development in response to 




There is growing evidence that mammalian TRP channels form large macromolecular 
complexes linked to the actomyosin cytoskeleton [23, 30]. Organization of TRP channels into 




pathways and/or enhance the rate of signal transmission. By similarity to TRP channels in 
Drosophila photoreceptors [67], TRPM7 may function to anchor and maintain the integrity of 
the complex. Additionally, TRPM7 kinase activity and ion conductance potentially modulate 
the activity of cytoskeletal components within the complex. A more detailed understanding 
of the function of the TRPM7 interactome in neuroblastoma may offer new strategies for 
inducing neuroblastoma differentiation and to overcome therapy resistance in the patient. 
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Material and Methods 
Constructs and cell lines 
Full length TRPM7 cDNA, cloned into LZRS-neo, was previously described [40]. The recombinant protein contains 
an HA-tag at the C-terminus. Mouse N1E-115 neuroblastoma cells were cultured in DMEM supplemented with 
10% FCS and 1% penicillin-streptomycin. N1E-115 cells stably expressing TRPM7-HA and empty vector control 
were generated using retroviral transduction. Transduced cells were selected by the addition of 0.8 mg/ml G418.  
 
Immunoprecipitation 
N1E-115 control and TRPM7-transduced cells were washed twice in ice-cold PBS and subsequently, lysed on ice 
for 30 min in a buffer containing 50 mM Tris pH 7.5, 300 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 
1% Triton X-100 and protease inhibitors. The lysate was cleared by centrifugation for 30 min at 16000 g. HA-
tagged proteins were immunoprecipitated by incubating the supernatant with proteinG-sepharose beads that 
were blocked with 0.5 %w/v BSA and precoupled with 12CA5 monoclonal anti-HA antibodies (Sigma Aldrich). 
The samples were incubated on an end-over-end rotor for 3 h at 4 °C. Subsequently, the immunocomplexes 
were washed in MyoII lysis buffer and solubilized in Laemmli buffer.  
 
Mass Spectrometry 
1. Nano LC-MS/MS measurements  
Proteins were separated by SDS-PAGE on 6% and 12% polyacrylamide gels and subsequently, detected by silver 
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staining. Gels were sliced into pieces and digested with trypsin overnight at 37 °C. Peptide mass spectrometric 
experiments were performed using a nano-HPLC Agilent 1100 system connected to a 7-Tesla linear quadruple 
ion trap-Ion Cyclotron Resonance Fourier transform (LTQFT) mass spectrometer (Thermo Fisher). Peptides were 
separated on 15 cm 100 µm ID PicoTip (New Objective) columns packed with 3 µm Reprosil C18 beads (Dr. 
Maisch GmbH) using a 45 min gradient from 10% buffer B to 35% buffer B (80% acetonitrile in 0.5% acetic acid). 
Peptides eluting from the column tip were electrosprayed directly into the mass spectrometer with a spray 
voltage of 2.1 kV. Peptide selection and fragmentation was set by the Xcalibur 1.4 data acquisition software 
(Thermo Electron). The mass spectrometer was operated in the data-dependent mode to sequence the four 
most intense ions per duty cycle. Briefly, full-scan MS spectra of intact peptides (m/z 350–1500) with an 
automated gain control accumulation target value of 106 ions were acquired in the Fourier transform ion 
cyclotron resonance (FT ICR) cell with a resolution of 50000. The four most abundant ions were sequentially 
isolated and fragmented in the linear ion trap by applying collisionally induced dissociation using an 
accumulation target value of 20000 (capillary temperature, 150°C; normalized collision energy, 30%). A dynamic 
exclusion of ions previously sequenced within 180 s was applied. All unassigned charge states were excluded 
from sequencing. A minimum of 500 counts was required for MS2 selection.  
 
2. Proteome data analysis 
Mass spectrometry data were analyzed with the protein identification and quantification algorithms embedded 
in the MaxQuant /Andromeda software [68]. Raw spectrum files were converted into peak lists for the top 6 
peaks per 100 Da window. Peptides and proteins were identified by searching the peak lists against the mouse 
IPI database (version 3.88) supplemented with frequently observed contaminants and concatenated with 
reversed copies of all entries. Andromeda [69] search parameters for protein identification specified a mass 
tolerance of 6 ppm for the parental peptide and 0.5 Da fragmentation spectra and a trypsin specificity allowing 
up to 3 miscleaved sites. Carboxyamidomethylation of cysteines was specified as a fixed modification, and 
oxidation of methionine were set as variable modifications. The required minimal peptide length was set at 6 
amino acids. We accepted peptides and proteins with a false discovery rate (FDR) better than 0.01. Label-free 
quantification was performed by MaxQuant with iBAQ values reflecting protein abundance [70]. 
 
3. Functional annotation of identified proteins  
Validated peptides of all samples combined were remapped to mouse IPI database version 3.88 to remove 
protein redundancy between different samples using an in-house Perl script. Priority of redundant IPI entries 
was given to Swiss prot, TREMBL, and REFSEQ entries respectively for maximising Gene Ontology (GO) 
annotation of identified proteins. External contaminating proteins (keratins, trypsin) were excluded for further 
analysis. Entrez gene identifiers were obtained using the Gene Conversion ID tool of DAVID 
(http://david.abcc.ncifcrf.gov/). Proteins in TRPM7 and control immuniprecipitations were quantified by 
intensity-based absolute quantification (iBAQ) [70], and normalized with median expression values. Proteins 
were considered enriched in the TRPM7 immunoprecipitate when the ratio between normalized iBAQ score in 




using the DAVID functional annotation tool. First, GO-term enrichment in both TRPM7 and control 
immunoprecipitates, relative to the mouse whole genome, was determined. Next, the number of proteins in 
TRPM7 and control immunoprecipitates, functionally annotated to the most significantly enriched terms in the 
categories 'molecular function', 'biological process' and 'cellular function', were compared. Statistical 
significance was calculated using the fisher exact test and corrected for multiple testing (FDR). 
 
Western blotting 
Proteins were separated by SDS-PAGE and transferred to nitrocellulose. Subsequently, proteins were detected 
by immunoblotting using anti-α-actinin1 (1:1000; Sigma), anti-cortactin (1:500; [71]), anti-talin (1:500; Sigma), 
anti-vinculin (1:2000; Sigma), anti-myosin IIA (1:1000; Sigma), anti-myosin IIB (1:1000; Sigma), anti-myosin IIC 
(1:1000; [72]), anti-drebrin (1:1000, Progene), anti-p116Rip (1:2000, [73]), anti-α-actinin4 (1:500, K. Cho), and 
anti-tropomodulin2 (1:1000, Abcam) followed by HRP-conjugated secondary antibodies (1:5000; Dako). 




N1E-115/TRPM7 cells were seeded on glass coverslips and serum starved (0.1% FCS) overnight prior to 
stimulation with 200nM bradykinin for 15 min. Cells were fixed with 4% paraformaldehyde in PBS for 10 minutes 
at room temperature and subsequently permeabilized with 0.1% triton X-100 in PBS for 3 minutes. Antibodies 
were used to reveal the presence of anti-myosin IIA (1:100; BTI), anti-myosin IIB (1:100, Sigma), anti-myosin IIC 
(1:100, [72]), anti-drebrin (1:100, Progene), anti-p116Rip (1:200, [73]), anti-α-actinin4 (1:200, K. Cho), anti-
tropomodulin2 (1:100, Abcam) and alexa488-conjugated secondary antibodies (1:1000; Molecular Probes). As 
no antibodies were available against myosin V and SIPA1-L1, GFP- and Myc-tagged proteins, respectively, were 
introduced into N1E-115/TRPM7 cells. Transfections were carried out using Fugene HD Transfection Reagent 
(Roche Applied Science) according to manufacturer’s protocol. F-actin was detected using Aleaxa-568 phalloidin 
(1:100; Molecular Probes). Cells were viewed using a Leica TCS SP5 confocal microscope. 
 
Microarray-based patient dataset analysis 
Both the discovery cohort (Kocak-649) and validation cohorts (Versteeg-88 and Oberthuer-251) have been 
previously described and microarray based expression data are publically available). Statistical analyses were 
performed using R2 genomics analysis and visualization platform, developed at the department of 
Oncogenomics, Academic Medical Center in the University of Amsterdam (http://r2.amc.nl). For each gene that 
was analyzed, discovery and validation cohorts were dichotomized based on an optimal cut-off value 
(Kaplanscan). In short, the optimal threshold was determined as follows: (1) patient samples were sorted, based 
on normalized expression of the gene of interest; (2) for all possible thresholds, significance of the correlation 
with disease outcome (overall survival, recurrence free survival or bone/bonemarrow metastasis free survival) 
was calculated using the log-rank test; (3) the best performing threshold is used as cut-off value to dichotomize 
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the cohort. To correct for multiple testing, p-values were Bonferroni corrected. Survival curves were visualized 
by Kaplan-Meier plots, using overall survival as endpoints, and compared using log-rank tests.  
 
Literature survey 
Association of TRPM7 interactome components with cancer progression was evaluated by an online Pubmed 
search, using Gene ID and cancer, tumor or metastasis as search terms, followed by hand screening of titles, 
abstracts and full text articles. Genes were considered cancer-associated when shown to correlate with patient 
outcome in microarray-based gene expression profiles or when differential expression in tumor cell models 
affects tumorigenesis in vitro or in vivo. 
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Table S1. Proteins identified in control and TRPM7 immunoprecipitations by LC-MS/MS. 
Overview of peptide annotations in control and TRPM7 immunoprecipitations (IP). Indicated are IPI accession number, protein name, gene 
symbol, number of peptides and the normalized IBAQ score in either the control or TRPM7 IPs, and IBAQ ratio. Note that tropomodulin 3 
gamma isoform 1, tropomyosin 1 alpha, myosin 11 and DEAD box polypeptide 5, were detected by only 1 peptide in the control sample and 
IBAQ scores could therefore not be determined. However, based on their abundance in the TRPM7 IP and absence in the control IP, these 
proteins were considered enriched in the TRPM7 fraction.  
 
Protein name Gene symbol 
Peptides  iBAQ   
Control TRPM7 Control TRPM7 Ratio 
tropomyosin 3, gamma isoform 1 TPM3 1 21 0 231900 nd 
tropomyosin 1, alpha TPM1 1 15 0 116350 nd 
myosin, heavy polypeptide 11, smooth muscle MYH11 1 22 0 10740 nd 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 DDX5 1 5 0 9929 nd 
lamin A LMNA 0 2 0 0 TRPM7 
actin related protein 2/3 complex, subunit 5-like ARPC5L 0 2 0 80199 TRPM7 
capping protein (actin filament) muscle Z-line, 
alpha 2 CAPZA2 0 8 0 584280 
TRPM7 
gelsolin GSN 0 2 0 1240 TRPM7 
stratifin SFN 0 2 0 6472 TRPM7 
actinin alpha 4 ACTN4 0 12 0 18076 TRPM7 
tropomodulin 3 TMOD3 0 6 0 38515 TRPM7 
voltage-dependent anion channel 1 VDAC1 0 2 0 3936 TRPM7 
actin related protein 2/3 complex, subunit 3 ARPC3 0 4 0 274150 TRPM7 
actin related protein 2/3 complex, subunit 1B ARPC1B 0 4 0 48984 TRPM7 
actin related protein 2/3 complex, subunit 1A ARPC1A 0 4 0 55220 TRPM7 
importin 9 IPO9 0 10 0 30143 TRPM7 
myosin, light polypeptide 3 MYL3 0 2 0 709080 TRPM7 
drebrin 1 DBN1 0 17 0 262900 TRPM7 
actin related protein 2/3 complex, subunit 4 ARPC4 0 5 0 423610 TRPM7 
ubiquitin specific peptidase 15 USP15 0 2 0 628 TRPM7 
ARP2 actin-related protein 2 homolog (yeast) ACTR2 0 8 0 207850 TRPM7 
junction plakoglobin JUP 0 4 0 5492 TRPM7 
transient receptor potential cation channel, 
subfamily M, member 7 TRPM7 0 9 0 4968 
TRPM7 
tripartite motif-containing 28 TRIM28 0 2 0 2197 TRPM7 
Tax1 (human T-cell leukemia virus type I) binding 
protein 1 TAX1BP1 0 2 0 956 
TRPM7 
myosin IE MYO1E 0 15 0 17124 TRPM7 
importin 7 IPO7 0 2 0 1586 TRPM7 
ATPase, Ca++ transporting, cardiac muscle, slow 
twitch 2 ATP2a2 0 4 0 3093 
TRPM7 
actin related protein 2/3 complex, subunit 5  ARPC5 0 2 0 40802 TRPM7 
tropomodulin 2 TMOD2 0 2 0 10069 TRPM7 
myosin phosphatase Rho interacting protein MPRIP 0 8 0 2900 TRPM7 
protein phosphatase 1, regulatory subunit 9B PPP1R9B 0 5 0 8071 TRPM7 
tropomyosin 4 TPM4 0 9 0 191370 TRPM7 
signal-induced proliferation-associated 1 like 1 SIPA1L1 0 4 0 685 TRPM7 
myosin VI MYO6 0 8 0 5218 TRPM7 
SEC16 homolog B (S. cerevisiae) SEC16B 0 2 0 651 TRPM7 
calmodulin 1 CALM1 0 2 0 21928 TRPM7 
annexin A2  ANXA2 0 2 0 2835 TRPM7 
myosin IC MYO1C 0 37 0 274780 TRPM7 
plectin 1 PLEC 0 11 0 526 TRPM7 
slingshot homolog 2 (Drosophila) SSH2 0 7 0 3779 TRPM7 
elongation factor Tu GTP binding domain 
containing 2 EFTUD2 0 2 0 1102 
TRPM7 
capping protein (actin filament) muscle Z-line, 
alpha 1 CAPZA1 0 7 0 341240 
TRPM7 
actin related protein 2/3 complex, subunit 2 ARPC2 0 10 0 305890 TRPM7 
LIM domain and actin binding 1 LIMA1 0 8 0 21672 TRPM7 
pericentriolar material 1 PCM1 0 2 0 128 TRPM7 
aldolase A, fructose-bisphosphate ALDOA 0 2 0 1795 TRPM7 
LIM and calponin homology domains 1 LIMCH1 0 13 0 24971 TRPM7 
myosin, heavy polypeptide 14 MYH14 0 71 0 134470 TRPM7 
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AT rich interactive domain 1A (SWI-like) ARID1A 0 2 0 861 TRPM7 
cofilin 1, non-muscle CFL1 0 3 0 21929 TRPM7 
myosin, light polypeptide 6 MYL6 1 9 2724 6376800 2340.56 
tropomyosin 3, gamma isoform 2 TPM3 1 21 757 1575800 2082.85 
myosin, heavy polypeptide 9, non-muscle MYH9 3 131 4971 6689900 1345.68 
myosin, heavy polypeptide 10, non-muscle MYH10 1 107 1259 1407800 1118.00 
myosin, light chain 12A, regulatory, non-
sarcomeric MYL12a 2 9 15613 6227500 398.87 
capping protein (actin filament) muscle Z-line, 
beta CAPZB 1 12 777 301410 387.91 
myosin IB MYO1B 1 45 1615 285350 176.63 
myosin VA MYO5A 1 86 2663 450660 169.24 
actin, gamma, cytoplasmic 1 ACTG1 10 21 39237 4320100 110.10 
actin, beta ACTB 13 25 254900 20963000 82.24 
ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 3 (Hu antigen C) ELAVL3 5 2 44637 931190 20.86 
desmoplakin DSP 3 15 151 2677 17.77 
histone cluster 1, H3e HIST1H3E 2 4 28719 319860 11.14 
kinase D-interacting substrate 220 KIDINS220 2 7 140 1459 10.41 
ubiquitin C UBC 1 4 2745 22582 8.23 
histone cluster 1, H1b HIST1H1B 1 2 4006 20073 5.01 
cullin 2 CUL2 3 11 4637 21759 4.69 
histone cluster 1, H4k HIST1H4K 5 8 696209 3251600 4.67 
heterogeneous nuclear ribonucleoprotein U-like 
1 HNRNPUL1 21 33 224939 985770 4.38 
damage specific DNA binding protein 1 DDB1 13 21 11419 45034 3.94 
heterogeneous nuclear ribonucleoprotein U-like 
2 HNRNPUL2 3 10 5090 19707 3.87 
interleukin enhancer binding factor 3 ILF3 4 8 3342 12278 3.67 
heat shock protein 90, beta (Grp94), member 1 HSP90B1 1 2 1208 3974 3.29 
UPF1 regulator of nonsense transcripts homolog 
(yeast) UPF1 2 4 444 1389 3.13 
RNA binding motif protein 14 RBM14 14 19 183701 547350 2.98 
SEC16 homolog A (S. cerevisiae) SEC16A 41 72 100492 298870 2.97 
histone cluster 1, H2bp HIST1H2BP 4 5 377946 1122200 2.97 
Histone cluster 3, H2a HIST3H2A 4 4 469604 1335500 2.84 
mab-21-like 2 (C. elegans) MAB21L2 6 1 40544 113330 2.80 
ribosomal protein L22 RPL22 3 3 47005 126580 2.69 
heterogeneous nuclear ribonucleoprotein U HNRNPU 23 26 321915 850970 2.64 
transformed mouse 3T3 cell double minute 1 MDM1 1 2 866 2260 2.61 
lysozyme 1 Lyz1 2 2 16104 40373 2.51 
ribosomal protein S14 RPS14 1 2 11714 27069 2.31 
NHP2 non-histone chromosome protein 2-like 1 
(S. cerevisiae) NHP2L1 2 2 13006 28757 2.21 
heat shock protein 8  HSPA8 24 29 514047 1136400 2.21 
ribosomal protein S5 RPS5 2 3 32525 69986 2.15 
heat shock protein 90, alpha (cytosolic), class A 
member 1 HSP90AA1 2 3 5205 10897 2.09 
ribosomal protein L9 RPL9 2 3 20538 42162 2.05 
heat shock protein 9     HSPA9 32 40 3354449 6640000 1.98 
Sec24 related gene family, member C (S. 
cerevisiae)      SEC24C 1 3 1020 1950 1.91 
eukaryotic translation initiation factor 2C, 3   EIF2C3 13 13 6549 12368 1.89 
ribosomal protein S7 rps7 1 2 33989 63091 1.86 
ribosomal protein L24 rpl24 3 3 13966 24772 1.77 
A kinase (PRKA) anchor protein 8         AKAP8 16 19 462648 811980 1.76 
clathrin, heavy polypeptide (Hc)         CLTC 2 2 381 657 1.72 
proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 2  PSMD2 7 13 31671 53361 1.68 
proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 1       PSMD1 17 23 63900 107040 1.68 
ribosomal protein L12 rpl12 4 4 48240 80103 1.66 
ribosomal protein L18      RPL18 2 1 10488 17294 1.65 
ribosomal protein L27 Rpl27 2 2 23992 38291 1.60 
Ewing sarcoma breakpoint region 1   EWSR1 7 7 337523 531430 1.57 
ribosomal protein S6; RPS6 3 3 22594 35320 1.56 




heat shock protein 5     HSPA5 16 18 114589 171850 1.50 
poly(A) binding protein, cytoplasmic 1   PABPC1 12 17 83539 124960 1.50 
trypsin 10       Try10 2 2 2057889 3054700 1.48 
trinucleotide repeat containing 6b       TNRC6B 41 38 89422 129720 1.45 
PRP39 pre-mRNA processing factor 39 homolog 
(yeast) prpf39 8 12 108977 156160 1.43 
transcription elongation factor B (SIII) Tceb2 4 6 81191 113920 1.40 
fusion, derived from t(12;16) malignant 
liposarcoma (human)      fus 11 12 4649543 6321400 1.36 
phospholipase C, beta 3  plcb3 7 8 12316 16685 1.35 
ribosomal protein L11 rpl11 2 2 65765 88563 1.35 
ribosomal protein S16        rps16 3 4 83571 105880 1.27 
ribosomal protein S19 rps19 6 7 44200 55656 1.26 
GrpE-like 1, mitochondrial       GRPEL1 2 2 7391 9261 1.25 
ribosomal protein S26 RPS26 1 2 63983 79394 1.24 
ribosomal protein S24 RPS24 2 2 39040 47789 1.22 
RIKEN cDNA 0610009D07 gene       0610009D07Rik 2 2 17968 21727 1.21 
ribosomal protein S13 rps13 4 3 29920 35307 1.18 
ribosomal protein L23 rpl23 3 3 79792 93794 1.18 
trinucleotide repeat containing 6a       TNRC6A 19 16 21640 25272 1.17 
KH-type splicing regulatory protein      khsrp 1 3 3930 4561 1.16 
heterogeneous nuclear ribonucleoprotein A/B      Hnrnpab 14 13 5388355 5951200 1.10 
keratin 77       KRT77 7 8 643693 710870 1.10 
DEAH (Asp-Glu-Ala-His) box polypeptide 9         dhx9 37 38 339198 373080 1.10 
ribosomal protein L31 rpl31 1 2 40588 44574 1.10 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 1         DDX1 3 5 6194 6774 1.09 
eukaryotic translation initiation factor 2C, 2   EIF2C2 28 33 379942 415190 1.09 
nucleolin        ncl 1 3 655 700 1.07 
eukaryotic translation initiation factor 2C, 1   EIF2C1 13 12 5931 6287 1.06 
TAF15 RNA polymerase II, TATA box binding 
protein (TBP)-associated factor        taf15 5 8 171123 180380 1.05 
ribosomal protein S12 rps12 3 3 103338 108490 1.05 
fructosamine 3 kinase related protein    FN3KRP 2 2 7666 7601 0.99 
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 
3, X-linked         DDX3X 18 21 261719 259510 0.99 
ribosomal protein L6   rpl6 6 4 61130 59700 0.98 
ATP synthase, H+ transporting, mitochondrial F1 
complex, gamma polypeptide 1     Atp5c1 1 1 2299 2228 0.97 
transcription elongation factor B (SIII) TCEB1 4 4 110478 106320 0.96 
leucine zipper-EF-hand containing 
transmembrane protein 1        LETM1 27 32 1834168 1760300 0.96 
ribosomal protein L18A   RpL18A 3 2 9524 8952 0.94 
similar to Immunogloblin heavy chain LOC630320 5 4 3128713 2886300 0.92 
ubiquitination factor E4A, UFD2 homolog (S. 
cerevisiae)  ube4a 6 6 7157 6538 0.91 
kelch domain containing 10       KLHDC10 9 5 141410 128930 0.91 
NHP2 ribonucleoprotein homolog (yeast)   NHP2 3 3 860952 777490 0.90 
ribosomal protein L30 RpL30 3 2 151085 131880 0.87 
small nuclear ribonucleoprotein D3       snrpd3 2 2 62940 54441 0.86 
ribosomal protein, large, P0         rplP0 8 5 163827 140220 0.86 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily c, 
member 1 SMARCC1 5 3 4012 3392 0.85 
ribosomal protein S9 rps9 4 3 24414 19905 0.82 
immunoglobulin light chain variable region       Gm10883 6 6 708988 571590 0.81 
heterogeneous nuclear ribonucleoprotein C        Hnrnpc 8 4 175279 140370 0.80 
immunoglobulin heavy chain 3 (serum IgG2b) Igh-3 11 10 1671778 1323500 0.79 
ribosomal protein S10 rps10 3 2 44611 34171 0.77 
poly(A) binding protein, cytoplasmic 4 PABPC4 6 5 2529 1932 0.76 
ribosomal protein SA;   rpsA 6 4 153072 114700 0.75 
ribosomal protein L7 RPL7 9 6 73446 53889 0.73 
programmed cell death 6  pdcd6 7 6 133491 97116 0.73 
ribosomal protein, large P2 Rplp2 4 4 344104 247270 0.72 
guanine nucleotide binding protein (G protein), 
beta polypeptide 2 like 1        GNB2L1 12 9 116923 83800 0.72 
Ribosomal protein L7a Rpl7a 6 5 69504 48136 0.69 
peroxiredoxin 2  PRDX2 2 1 4623 3177 0.69 
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SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, 
member 4        SMARCA4 17 13 14103 9443 0.67 
ribosomal protein S25 RPS25 3 2 88709 57869 0.65 
ribosomal protein S3     rps3 16 12 219556 142780 0.65 
heterogeneous nuclear ribonucleoprotein D        HNRNPD 16 13 4284943 2716000 0.63 
ribosomal protein S17 rps17 2 2 54573 33807 0.62 
proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 6       PSMD6 11 9 94322 55368 0.59 
peroxiredoxin 1; predicted gene 7204     PRDX1 3 1 5000 2839 0.57 
ribosomal protein L14 rpl14 2 1 9477 5380 0.57 
c-myc binding protein    MYCBP 2 2 54128 30666 0.57 
ribosomal protein S3A rps3a 7 6 53948 30022 0.56 
proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 14      PSMD14 3 2 84612 45749 0.54 
RNA binding motif protein, X chromosome 
retrogene        Rbmxrt 7 4 230816 122970 0.53 
heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 13 11 1327316 706940 0.53 
heterogeneous nuclear ribonucleoprotein A3 Hnrnpa3 16 15 3399028 1781300 0.52 
ribosomal protein L26 RPL26 2 2 17284 8958 0.52 
immunoglobulin kappa chain variable 8 (V8)-19    Igk-V8-19 2 2 612588 312200 0.51 
heterogeneous nuclear ribonucleoprotein D-like   HNRPDL 14 10 522185 264850 0.51 
coiled-coil domain containing 106        CCDC106 13 8 204443 102890 0.50 
trinucleotide repeat containing 6C       TNRC6C 19 12 20579 10237 0.50 
splicing factor, arginine/serine-rich 7  sfrs7 4 2 24819 12152 0.49 
eukaryotic translation elongation factor 1 alpha 
1      EEF1A1 5 3 30645 14976 0.49 
proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 7       psmd7 5 3 80296 37787 0.47 
proteasome (prosome, macropain) 26S subunit, 
ATPase, 6   Psmc6 14 10 333431 156730 0.47 
proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 11        Psmd11 17 11 162930 76508 0.47 
SEC13 homolog (S. cerevisiae)    sec13 7 4 801791 372040 0.46 
immunoglobulin kappa chain variable V19 - 17    Igk-V19-17 4 3 1853849 859510 0.46 
protease (prosome, macropain) 26S subunit, 
ATPase 5      PSMC5 17 13 525755 240680 0.46 
eukaryotic translation initiation factor 3, subunit 
J EIF3J 23 22 20682333 9047500 0.44 
heterogeneous nuclear ribonucleoprotein A2/B1     HNRNPA2B1 20 18 13826058 6006900 0.43 
La ribonucleoprotein domain family, member 1     LARP1 2 1 594 255 0.43 
adhesion regulating molecule 1 Adrm1 2 1 23221 9933 0.43 
ribosomal protein S18 rps18 4 2 25261 10246 0.41 
TAR DNA binding protein    TARDBP 7 5 260722 104990 0.40 
proteasome (prosome, macropain) 26S subunit, 
ATPase 2    PSMC2 21 10 231704 88876 0.38 
ribosomal protein L27a RPL27A 2 1 18198 6145 0.34 
protein phosphatase 4, catalytic subunit         PPP4C 2 1 5761 1944 0.34 
succinate dehydrogenase complex, subunit A, 
flavoprotein (Fp)    SDHA 1 2 3078 1012 0.33 
ribosomal protein S2  rps2 6 2 49903 16134 0.32 
Tia1 cytotoxic granule-associated RNA binding 
protein-like 1     Tial1 14 9 2755875 869660 0.32 
PCI domain containing 2  PCID2 2 1 9149 2853 0.31 
cytotoxic granule-associated RNA binding 
protein 1       Tia1 10 7 341450 106410 0.31 
lactate dehydrogenase A LdhA 8 4 17407 5412 0.31 
proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 8       PSMD8 6 3 102862 31273 0.30 
heterogeneous nuclear ribonucleoprotein H3       Hnrnph3 8 7 846352 251190 0.30 
heterogeneous nuclear ribonucleoprotein A0       HNRNPA0 8 5 2116383 626160 0.30 
WD repeat domain 51A     poc1a 17 8 527338 151290 0.29 
hnRNP-associated with lethal yellow  RALY 5 2 49676 13381 0.27 
heterogeneous nuclear ribonucleoprotein F   HNRNPF 7 3 143671 34959 0.24 
mitochondrial ribosomal protein S23 MRPS23 3 1 10151 2100 0.21 
microtubule-associated protein 1B        Mtap1b 4 1 1680 344 0.20 
ribosomal protein L3; predicted gene 5851 RPL3 3 1 22678 4266 0.19 




Sjogren syndrome antigen B       ssb 6 1 55799 9472 0.17 
interleukin enhancer binding factor 2    ilf2 8 4 166793 28030 0.17 
ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 4 (Hu antigen D)       ELAVL4 10 4 160257 26165 0.16 
ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 1 (Hu antigen R)       ELAVL1 5 3 35316 5734 0.16 
small nuclear ribonucleoprotein polypeptide A snrpa 6 1 64448 9087 0.14 
Era (G-protein)-like 1 (E. coli)         ERAL1 8 1 31512 4242 0.13 
Trk-fused gene   TFG 10 5 1248227 167940 0.13 
proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 13      PSMD13 10 3 163461 10304 0.06 
DAZ associated protein 1         DAZAP1 4 1 93022 5491 0.06 
tRNA selenocysteine 1 associated protein 1       Trnau1ap 6 3 165356 9486 0.06 
proteasome (prosome, macropain) 26S subunit, 
ATPase 3    psmc3 9 1 52991 2241 0.04 
ribosomal protein S4, X-linked    rps4x 11 1 64270 2472 0.04 
proteasome (prosome, macropain) 26S subunit, 
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Table S2. TRPM7 interactome components correlate with poor prognosis in three 
independent neuroblastoma patient cohorts.  
Overview of all TRPM7 interactome components that correlate with overall survival (OS) or recurrence free survival (RFS) in 
the Kocak-649, Versteeg-88 and Oberthuer-251 cohorts. P-values are corrected for multiple testing (Bonferroni and false 
discovery rate). P < 0.05 was considered significant.  
 
Cohort Kocak-649   -   64/64 reporters available  Cohort Versteeg-88   -   60/64 reporters available 
Gene symbol OS RFS KM-arm  Gene symbol OS RFS KM-arm 
MYL6 7.50E-29 4.50E-14 low  MYO5A 1.60E-10 4.10E-06 low 
IPO7 1.10E-17 7.60E-16 high  TMOD2 6.90E-10 2.40E-05 low 
JUP 3.90E-17 2.50E-16 low  EFTUD2 8.50E-07 6.90E-04 high 
TAX1BP1 1.00E-16 6.50E-16 low  TRIM28 1.70E-05 2.40E-03 high 
ANXA2 1.10E-15 4.70E-09 low  ACTR2 1.90E-04 8.60E-04 low 
TRIM28 2.70E-13 3.00E-09 high  KIDINS220 2.00E-04 0.022 low 
IPO9 5.30E-13 4.00E-05 high  DDX5 2.20E-04 8.10E-04 low 
MYO5A 2.40E-11 2.20E-11 low  IPO7 2.90E-04 4.00E-04 high 
ARPC2 1.50E-10 3.70E-05 low  TAX1BP1 1.70E-03 0.011 low 
TPM4 4.40E-10 5.60E-11 high  TPM3 3.10E-03 n.s. high 
MYO1C 1.60E-08 2.80E-05 low  ALDOA 0.014 n.s. high 
ARID1A 3.70E-08 5.00E-04 low  CFL1 0.039 n.s. high 
KIDINS220 7.90E-08 1.20E-05 low  TPM4 0.049 n.s. high 
ATP2A2 1.20E-07 6.20E-04 low  ANXA2 n.s. 0.021 low 
GSN 1.30E-07 1.10E-05 low  TPM4  n.s. 0.026 high 
ACTB 2.80E-07 0.013 low      
EFTUD2 7.00E-07 1.30E-03 high  Oberthuer-251   -   35/64 reporters available 
ELAVL3 7.90E-07 5.10E-05 low  Gene symbol OS RFS KM-arm 
CALM1 6.70E-06 5.00E-04 low  TRIM28 7.30E-20 9.70E-12 high 
TRPM7 8.90E-06 2.40E-08 high  GSN 2.60E-17 6.70E-09 low 
USP15 9.50E-06 0.049 low  TAX1BP1 9.70E-14 1.50E-06 low 
CFL1 5.80E-05 3.40E-05 high  JUP 5.10E-09 4.50E-09 low 
VDAC1 7.20E-05 0.047 high  MYO5A 6.00E-07 1.40E-08 low 
TPM1 1.20E-04 n.s. low  ELAVL3 7.00E-07 5.90E-06 low 
PLEC 1.20E-04 1.50E-04 low  ARPC5 2.80E-06 n.s. low 
CAPZB 1.90E-04 n.s. low  MYL6 6.20E-05 8.20E-05 low 
ARPC1B 7.40E-04 n.s. low  TMOD2 1.50E-04 1.20E-04 low 
MYH9 8.70E-04 0.048 low  PCM1 3.00E-04 1.60E-03 high 
ACTR2 1.10E-03 n.s. low  CAPZB 1.00E-03 n.s. low 
MYO1E 1.20E-03 0.048 low  MYO6 3.20E-03 0.011 low 
DDX5 2.90E-03 0.047 low  ALDOA 8.30E-03 0.012 high 
ARPC5L 5.70E-03 8.60E-05 high  DDX5 0.013 n.s. high 
MYO6 0.013 n.s. low  ACTG1 0.021 n.s. high 
ARPC3 n.s. 3.20E-03 high  LMNA 0.026 n.s. low 
TPM3 n.s. 3.70E-03 high  SIPA1L1 0.041 2.70E-03 low 
     CAPZA1 n.s. 1.50E-03 high 
     PPP1R9B n.s. 3.60E-03 low 
     IPO7 n.s. 0.012 high 
     MYH9 n.s. 0.013 low 
     SFN n.s. 0.013 low 
     TPM1 n.s. 0.036 high 
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Chapter 4
TMOD2 suppresses neuroblastoma 
disease progression by controlling actin 
dynamics, cell migration and invasion
Abstract  
Similar to other solid tumors, neuroblastoma progression is strongly influenced by the cellular 
microenvironment. The physical cross-talk between tumor cells and the extracellular matrix 
is mediated by cell adhesion sites and cell protrusions. As the formation of these structures 
depends on the spatiotemporal regulation of the actomyosin cytoskeleton, the proteins and 
signaling pathways involved are considered potential therapeutic targets.  
We have previously shown that TRPM7, a Ca2+-permeable cation channel that regulates 
cytoskeletal dynamics and controls neuroblastoma metastasis formation, is part of a large 
cytoskeletal protein complex of which many components are associated with neuroblastoma 
progression in patients.  Low mRNA expression of one of these TRMP7-interactors, the 
neuronal-specific actin-regulatory protein TMOD2, correlates exceptionally well with a poor 
overall survival probability. Here, we have further evaluated the correlation between TMOD2 
expression, event free survival probability, and clinical and molecular characteristics in two 
independent neuroblastoma patient cohorts. In addition, we show that loss of TMOD2 
expression by shRNA mediated knockdown increases the invasive properties of 
neuroblastoma cells in vitro, affecting cell adhesion dynamics, protrusion elongation and 
collective migration from tumor spheres. In contrast, no effects of TMOD2 loss on 
proliferation or cell viability were seen. Together, our findings suggest that reduced TMOD2 
expression may contribute to poor outcome in neuroblastoma patients by enhancing 






Neuroblastoma is the second-most common solid tumor in children and accounts for 10% of 
cancer related deaths in children [1, 2]. Despite major improvements in treatment, there are 
currently no curative therapies for relapsed metastatic disease [3]. As  recurrent somatic 
mutations that can serve as potential targets for treatment are relatively rare [3-6], a detailed 
understanding of the molecular mechanisms contributing to neuroblastoma progression is 
required to develop novel treatment strategies that can improve outcome.  
Neuroblastoma is an embryonic tumor that originates from poorly differentiated neural crest 
cells [7, 8]. During normal neural crest development, cells delaminate from the neural plate 
borders and migrate throughout the embryo to eventually differentiate into a variety of 
different cell types [8]. In addition to chemical cues, the mechanical cross talk between neural 
crest cells and their micro-environment guides neural crest migration and maturation [9-11]. 
Integration of these signals requires physical interactions between cells and their 
environment, and is mediated by cell adhesion sites and cell protrusions [12-16]. The dynamic 
formation and turnover of cell adhesions and protrusions allows the cell to explore the cellular 
microenvironment, and control cytoskeletal dynamics and gene expression in response to 
environmental cues [12-16]. Given the importance of these signals during development and 
homeostasis, perturbed adhesion signaling has been linked to uncontrolled proliferation, 
de-differentiation, tissue invasion and even therapy resistance [15, 17-21]. Indeed, several 
studies have shown that defects in genes that regulate cell protrusion formation or cell-matrix 
interactions contribute to neuroblastoma pathogenesis [6, 21-26].  
Members of the mammalian Transient Receptor Potential (TRP) channel family are 
considered key integrators of mechanical and chemical signals, and play important roles 
during embryonic development, tissue homeostasis and tumor progression [27-30]. Channel 
opening can be induced in response to a variety of stimuli, resulting in local changes of ion 
concentrations that can trigger cytoskeletal responses and even affect gene expression [30-
32]. Consistently, we and others showed that TRPM7, a mechanosensitive TRP channel with 
kinase activity, drives the malignant behavior of a number of malignancies, including 
neuroblastoma and breast cancer [33-37]. Additionally, we demonstrated that TRPM7 is part 
of a large cytoskeletal protein complex involved in cell protrusion dynamics and adhesion 
formation. Expression of many of these TRPM7 interactors accurately predict neuroblastoma 
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patient survival, suggesting a role for this complex in regulating neuroblastoma progression 
[38]. An exceptionally strong correlation was seen with the TRPM7 interactor tropomodulin 
2 [38]. Therefore, we set out to determine how tropomodulin 2 expression affects 
neuroblastoma progression.  
Tropomodulins (TMODs) are a conserved family of actin-capping proteins that regulate actin 
dynamics by stabilizing the pointed ends of actin filaments, thereby preventing actin filament 
polymerization and disassembly [39, 40]. Of the four TMODs identified, TMOD1 and 3 are 
ubiquitously expressed, whereas expression of TMOD2 and TMOD4 is restricted to neuronal 
and skeletal muscle tissue, respectively [39]. Apart from controlling organelle- and cell shape, 
TMODs have been implicated in regulating protrusion formation and cell migration [39, 41-
46]. Additionally, low expression levels of TMOD1 and TMOD2 have been linked to tumor 
progression [38, 47, 48]. Here, we show that high TMOD2 expression is positively correlated 
with neuroblastoma event free survival and favorable clinical characteristics. Using a variety 
of microscopical and migratory assays, we examined the effects of TMOD2 loss on  
neuroblastoma cell adhesion, migration and differentiation.  
 
Results and Discussion 
High TMOD2 mRNA expression levels in primary neuroblastoma tumors correlate with a 
high event free survival probability   
We previously showed that TMOD2 is part of a cytoskeletal protein complex linked to TRPM7. 
Together with several other regulators of adhesion dynamics and cytoskeletal organization, 
TMOD2 was amongst the interactors that correlated most significantly with overall survival 
of neuroblastoma patients [38]. We further extended these initial analysis by evaluating the 
prognostic value of TMOD2 mRNA levels in neuroblastoma event free survival and in relation 
to known neuroblastoma risk factors. After dichotomization of micro-array based expression 
data from primary neuroblastoma tumors of untreated patients (discovery cohort: Versteeg; 
n= 88) based on the expression level of TMOD2, the TMOD2-high group (n= 53) showed a 
significantly longer event free survival compared to the TMOD2-low group (n = 35, pdiscovery = 
6.2e-07) (Fig 1A) [49]. A similar correlation of TMOD2 expression with event free survival was 
found in an independent cohort of 498 primary neuroblastoma samples (validation cohort: 
SEQC; n=498, pvalidatio = 8.0e-05) (Fig 1A) [50]. Moreover, while the effects of TMOD2 mRNA 
expression levels on outcome lacked statistical significance in patients with MYCN  
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amplification (data not shown), the predictive value of TMOD2 mRNA expression was highly 
significant in the subset of patients with no MYCN amplification in both the discovery and 
validation cohort (pdiscovery = 2.0e-06, pvalidation = 7.2e-05; Fig 1B), indicating that TMOD2 
expression can be used to further stratify patients that do not carry a MYCN amplification.    
 
Figure 1. TMOD2 is a strong independent prognostic marker for neuroblastoma progression and correlates with clinical 
and molecular characteristics. (A) Kaplan-Meier analysis of Event Free Survival according to TMOD2 mRNA expression 
obtained from micro-analysis of a discovery cohort (Versteeg - 88 neuroblastoma patients) and a validation cohort (SEQC - 
498 neuroblastoma patients). High expression and low expression curves were determined based on the most significant 
expression cut-off for survival analyses as tested by log-rank test and corrected for multiple testing by Bonferroni correction. 
(B) Kaplan-Meier analysis of Event Free Survival according to TMOD2 mRNA expression in non-MCYN amplified 
neuroblastoma tumors obtained from micro-analysis of a discovery cohort (Versteeg – 72 non-MYCN amplified 
neuroblastoma samples) and a validation cohort (SEQC - 401 non-MYCN amplified neuroblastoma samples). High expression 
and low expression curves were determined based on the most significant expression cut-off for survival analyses as tested 
by log-rank test and corrected for multiple testing by Bonferroni correction.  (C-E) Box and whiskers plots of TMOD2 
expression in the populations defined by (C) INSS stage, (D) Age at diagnosis, and (E) MYCN amplification status in the 
discovery (Versteeg) and validation (SEQC) cohorts. Significance of the differences between the means were assessed by 
unpaired t-test. 
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We next examined the relationship between TMOD2 expression and standard clinical 
parameters. In support of the correlation of TMOD2 expression with disease progression, 
expression of TMOD2 was significantly lower in high risk patients (stage IV) compared to lower 
grade tumors (stages I, II, III, and IVs) (pdiscovery = 1.2e-08, pvalidation = 3.6e-20; Fig 1C). 
Accordingly, higher TMOD2 expression was observed in patients that were younger than 18 
months of age at time of diagnosis (pdiscovery = 4.0e-06, pvalidation = 1.8e-12; Fig 1D) and in 
primary tumors without MYCN amplification (pdiscovery = 8.8e-04, pvalidation = 3.6e-20; Fig 1E). 
Together these results indicate that high TMOD2 expression positively correlates with 
favorable clinical characteristics and patient outcome.   
 
TMOD2 knockdown does not interfere with the viability or proliferative ability of SH-SY5Y 
neuroblastoma cells 
To establish a causal relation between low TMOD2 expression levels and neuroblastoma 
progression, shRNA-mediated knockdown of TMOD2 was established using invasive human 
SH-SY5Y neuroblastoma cells. To rule out off-target effects, two independent TMOD2 oligo’s 
were used to establish two knockdown cell lines (SH-SY5Y shTMOD2#1 and shTMOD2#2). 
Knockdown efficiency at the mRNA level reached about 40% and 70% for shTMOD2#1 and 
shTMOD2#2, respectively (Fig 2A). Accordingly, protein expression was reduced to ~30% in 
shTMOD2#1 cells, whereas TMOD2 protein level decreased to ~20% in shTMOD2#2 cells 
when compared to SH-SY5Y cells expressing control shRNA (Fig 2B&C).  
While no data is currently available on how TMOD2 expression levels affect cell proliferation, 
it was recently shown that TMOD1 knock-in reduces neuroblastoma cell proliferation by 
trapping cells in the G0/G1 phase [47]. Hence, given that TMODs are highly conserved [51] 
and low TMOD2 expression correlates with poor overall survival [38, 47] and event free 
survival of neuroblastoma patients, loss of TMOD2 might enhance the viability and 
proliferative ability of neuroblastoma cells. However, TMOD2 silencing did not affect the 
viability of SH-SY5Y control and shTMOD2 cells, nor their proliferative capacity as assessed by 
MTS-assays (Fig 2D & E). We conclude from these results that it is unlikely that the tumor 
promoting effects of reduced TMOD2 expression are a result of  increased cell proliferation 




TMOD2 controls cell protrusion extension, without affecting protrusion number in SH-SY5Y 
neuroblastoma cells 
Tumor progression and metastasis formation are dependent on remodeling of the 
actomyosin skeleton in response to environmental cues [14, 20, 52-54]. As TMOD2 controls 
cytoskeletal dynamics by stabilizing actin filaments [40], we explored the effects of TMOD2 
loss on cell behavior.  Whereas control SH-SY5Y cells consist of a mixed population of 
neuroblast-like and epithelial-like cells with few neurite-like protrusions (Fig 3A) [55], 
silencing of TMOD2 shifted SH-SY5Y cells to exhibit a mainly neuroblast-like morphology (Fig 
3A). In line with observations made by Fath et al. in mouse N2a neuroblastoma cells [44], 
TMOD2 knockdown in SH-SY5Y cells did not affect the number of protrusions per cell (Fig 3B). 
However, protrusion length significantly increased upon TMOD2 silencing (Fig 3C), resulting 
in an increase in the percentage of larger protrusions (≥ 10 µm) in SH-SY5Y shTMOD2 cells  
 
Figure 2. shRNA mediated knockdown of TMOD2 does not affect SH-SY5Y viability and proliferation. (A) Relative TMOD2 
mRNA expression in control and TMOD2 shRNA SH-SY5Y cells, determined by quantitative real-time PCR. TMOD2 expression 
of the control cells is set to 1. Values are depicted as mean ± SEM (n=3). * p < 0.05, ** p < 0.01. (B) Protein expression of 
TMOD2 after stable expression of control and TMOD2 shRNA’s in SH-SY5Y cells, determined by Western blotting. γ-Tubulin 
antibodies were used as loading control. Representative example of n=3 experiments. (C) Quantification of TMOD2 protein 
levels of control and TMOD2 shRNA SH-SY5Y cells, determined by Western blot. TMOD2 expression of the control cells is 
set to 1. Values are depicted as mean ± SEM (n=3). * p < 0.05, ** p < 0.01. Quantification of the effects of TMOD2 shRNA on 
(D) cell viability and (E) proliferation, determined by MTS assays. Viability was assessed over 4 hours, proliferation was 
assessed over 4 days. Data represents normalized mean extinction at 492 nm mean ± SEM of n=3 experiments performed 
in triplo. 
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Figure 3. TMOD2 depletion in SH-SY5Y cells results in increased protrusion length, without affecting the number of 
protrusions per cell. (A) Representative phase-contrast images of SH-SY5Y control and TMOD2 shRNA cells. Scale bar = 50 
µm. (B) Quantification of the number of protrusions per cell and (C) protrusion length of SH-SY5Y control and TMOD2 shRNA 
cells. Values are depicted as mean ± SEM of n=3 independent experiments carried out at least in duplo. Per experiment at 
least 40 cells were evaluated. * p < 0.05, ** p < 0.01. (D) Distribution of protrusion length of SH-SY5Y control and TMOD2 
shRNA cells. Values are depicted as mean ± SEM of n=3 independent experiments carried out at least in duplo. Per 
experiment at least 40 cells were evaluated. * p < 0.05. 
compared to control cells (Fig 3D). Similar results were obtained using mouse N1E-115 
neuroblastoma cells (Sup Fig 1&2). Together, these data indicate that TMOD2, rather than to 
initiate protrusions, controls their elongation. 
 
Protrusion elongation in response to TMOD2 silencing reflects changes in actin dynamics 
but is not a sign of increased neuronal differentiation 
Neuritogenesis or neurite extension is a key event during neuronal differentiation and is 
driven by cytoskeletal remodeling [56, 57]. Extensive F-actin polymerization first drives 
membrane protrusions in the form of broad lamellipodia or longer thin filopodia. 
Microtubules subsequently move into the neurite protrusion to provide transport of vesicles 




Figure 4. TMOD2 depletion does not result in neuronal differentiation in SH-SY5Y cells. (A) Protrusion elongation is the 
result of extensive actin polymerization in SH-SY5Y cells. Immunofluorescence staining of SH-SY5 control and TMOD2 
shRNA#2 cells with phalloidin to visualize the actin cytoskeleton and to α-tubulin antibodies to reveal microtubules. Hollow 
arrow heads indicate protrusions positive for both F-actin and α-tubulin, whereas filled arrows indicate thin protrusions 
formed by actin polymerization and void of α-tubulin. Scale bar = 10 µm. (B) Cell body dimensions of SH-SY5Y control and 
TMOD2 shRNA cells. Data is represented as mean ± SEM of n=3 independent experiments carried out at least in duplo. Per 
experiment at least 40 cells were evaluated. * p < 0.05. (C) Relative mRNA expression of neuronal differentiation related 
genes in SH-SY5Y control and TMOD2 shRNA cells, determined by quantitative real-time PCR. mRNA expression in control 
cells is set to 1. Values are depicted as mean ± SEM (n=3). * p < 0.05. (D) Relative mRNA expression of retinoic acid response 
related genes in SH-SY5Y control and TMOD2 shRNA cells, determined by quantitative real-time PCR. mRNA expression in 
control cells is set to 1. Values are depicted as mean ± SEM (n=3). * p < 0.05, ** p < 0.01. (E) Relative TMOD2 mRNA 
expression in control SH-SY5Y cells at different time points after induction of differentiation with 10 µM retinoic acid, 
determined by quantitative real-time PCR. TMOD2 expression in the control cells is set to 1. Values are depicted as mean ± 
SEM (n=3). * p < 0.05, ** p < 0.01. 
protrusions formed by shTMOD2 cells are the result of differentiation, we visualized the actin 
and microtubule cytoskeleton of SH-SY5Y control and shTMOD2 cells. In line with the notion  
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Figure 5. Reduced TMOD2 expression decreases the number of focal adhesions in SH-SY5Y cells. (A) Immunofluorescence 
staining of SH-SY5Y control and TMOD2 shRNA cells with phalloidin to visualize the actin cytoskeleton and pTyr118 paxillin 
antibodies to reveal focal adhesions. Scale bar = 25 µm. (B) Quantification of focal adhesion number per cell. Values are 
depicted as mean ± SEM of at least 8 images of n=1 experiment carried out in duplo. In total at least 150 cells were 
evaluated. * p < 0.05, ** p < 0.01. (C) Western blot of Triton-X 100 insoluble fractions derived from SH-SY5Y control and 
TMOD2 shRNA cells. Antibodies against pTyr118 paxillin were used to determine the amount of tyrosine phosphorylated 
paxillin as a measure for focal adhesion content. γ-Tubulin antibodies were used as loading control. Representative example 
of n=3 experiments. (D) Quantification of tyrosine phosphorylated paxillin levels of control and TMOD2 shRNA SH-SY5Y 
cells, determined by Western blot. Tyrosine phosphorylated paxillin levels of the control cells is set to 1. Values are depicted 
as mean ± SEM (n=3). * p < 0.05. 
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that TMOD2 regulates actin filament length by stabilizing pointed ends of actin filaments and 
sequestering G-actin [39], protrusions formed by shTMOD2 cells were F-actin positive (Fig 
4A). However, the majority of the protrusions formed by shTMOD2 cells were not supported 
by microtubules (Fig 4A), suggesting that protrusion elongation is a result of uncontrolled 
actin polymerization, and that TMOD2 silencing does not promote the maturation of neurites. 
In addition, while differentiation of SH-SY5Y cells coincided with a marked decrease in cell 
body size [58], TMOD2 silencing had no significant effect on cell body width and length of 
SH-SY5Y cells (Fig 4B). Expression of a panel of neuronal differentiation markers was also not 
affected in shTMOD2 cells (Fig 4C), indicating that TMOD2 silencing does not enhance 
neuronal differentiation. On the contrary, low levels of TMOD2 appear to correspond with 
the loss of neuronal differentiation, as evident from the expression changes in retinoic acid 
(RA) response genes (Fig 4D). Moreover, TMOD2 mRNA expression significantly increased 
upon RA-induced differentiation of SH-SY5Y cell (Fig 4E), suggesting that TMOD2 expression 
positively correlates with neuronal differentiation, a characteristic associated with a favorable 
clinical stage and outcome [59-61]. 
 
TMOD2 negatively regulates SH-SY5Y tumor cell migration in 2D and 3D 
Previous reports have shown that TMOD1 and TMOD3 negatively control cell migration of 
mouse fibroblasts and human endothelial cells, respectively [42, 43]. Consistently, TMOD2 
may control neuroblastoma progression by regulating adhesive and migratory properties of 
neuroblastoma cells. Indeed, shRNA mediated depletion of TMOD2 led to a reduction in the 
number of focal adhesions (Fig 5A&B), which could be confirmed by a decrease in 
Tyr118-paxillin phosphorylation, as determined by western blot (Fig 5C&D). Consistently, 
knockdown of TMOD2 significantly enhanced the migration of SH-SY5Y cells in gap-closure 
assays (Fig 6A-C), and enhanced the ability of SH-SY5Y cells to migrate towards a 
serum-gradient, as determined by transwell migration assays (Fig 6D).  
To further evaluate whether TMOD2 levels affect local invasion and dissemination, we used 
3D organotypic invasion assays. To this end, multicellular spheroids (MCS) of SH-SY5Y control 
and shTMOD2 cells were generated using hanging drops, embedded within a 3D matrix and 
followed over time. Given that the majority of primary neuroblastoma tumors arise in the 
adrenal medulla, the composition of the matrix was chosen to reflect that of the adrenal 
gland, i.e. using collagen I and collagen IV as the major matrix components [Chapter six]. 
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Figure 6. TMOD2 depletion enhances the migratory properties of SH-SY5Y cells. (A) Representative images of gap closure 
assays of SH-SY5Y control and TMOD2 shRNA cells at time points 0, 6 and 12 hours after start of the experiment. (B) 
Quantification of the percentage of gap closure over time for SH-SY5Y control and TMOD2 shRNA cells. Data represent 
mean ± SEM n=3 experiments carried out in duplo. (C) Quantification of time needed by SH-SY5Y control and TMOD2 shRNA 
cells to close 50% of the gap. Data represent mean ± SEM of n=3 experiments carried out in duplo. * p <0.05. (D) 
Quantification of serum-induced transwell migration by SH-SY5Y control and TMOD2 shRNA cells. Migration was scored 48 
hours after seeding. Data is normalized to the number of migrated SH-SY5Y control cells and are presented as mean ± SEM 
of n=4 experiments carried out in duplo. * p <0.05, ** p <0.01. (E) Representative immunofluorescence max projections of 
multicellular spheroids of SH-SY5Y control and TMOD2 shRNA cells 7 days after embedding in the 3D collagen-based matrix. 
Spheroids were fixed and stained for the cytoskeleton using phalloidin and the nucleus using Dapi. Note the presence of 
large invasive strands of TMOD shRNA spheroids. Scale bar = 100 μm. (F) Quantitative analysis of tumor border regularity 
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(circularity) of SH-SY5Y control and TMOD2 shRNA spheroids, calculated based on the perimeter of the spheroid relative to 
the area (see material and methods). Number of (G) invasive strands and (H) single cell invasions of multicellular spheroids 
in response to TMOD2 expression levels. Data are from at least n=15 spheroids/ cell line divided over n=3 experiments and 
presented as box and whisker (5-95 percentile) plots. * p < 0.05, ** p < 0.01, ***p < 0.001, two-tailed unpaired t-test with 
Welch’s correction. 
Knockdown of TMOD2 significantly decreased the tumor border regularity of MSCs, which 
coincided with a marked increase in the number of invasive strands (Fig 6E-G). The number 
of single cell invasions remained similar between control and shTMOD2 spheroids (Fig 6H), 
suggesting that TMOD2 knockdown enhances collective invasion of neuroblastoma cells 
rather than affecting single cell dissemination.  
 
Concluding remarks 
Cytoskeletal dynamics and cell-matrix interactions play pivotal roles during cancer 
progression [15, 17-21, 26, 53, 54]. We have previously put forward that TRPM7, as part of a 
large cytoskeletal complex, may affect the malignant potential of neuroblastoma cells by 
regulating actomyosin dynamics and cell-matrix interactions [38]. Here, we demonstrate that 
low levels of the TRPM7 interactor TMOD2 correspond with a poor outcome. Consistently, 
shRNA mediated depletion of TMOD2 led to dedifferentiation of neuroblastoma cells while 
promoting protrusion elongation and neuroblastoma cell migration.  
Currently, the nature of the interactions that take place between TRPM7 and TMOD2 are not 
known. However, as both high TRPM7 mRNA expression and low expression of TMOD2 are 
associated with (1) poor outcome and (2) increased neuroblastoma cell migration, and (3) the 
two proteins reside within the same complex, it is tempting to speculate that TRPM7 may 
negatively regulate TMOD2 function [33, 38]. In line with this notion, we have previously 
demonstrated that TRPM7, by phosphorylating the myosin IIA heavy chain, modulates 
adhesion dynamics by the local inhibition of actomyosin contractility [62, 63]. Similarly, 
Dorovkov et al. demonstrated that TRPM7 is able to phosphorylate TMOD1 at a residue that 
is conserved between all human TMODs, including TMOD2 (Fig 7A) [64]. Phosphorylation of 
TMOD1 by TRPM7 inhibits its actin capping ability, thereby omitting the ability of TMOD1 to 
inhibit actin polymerization [64]. Therefore, we propose that inactivation of TMOD2 by 
TRPM7-mediated phosphorylation may result in increased actin dynamics leading to 
enhanced protrusion elongation and migratory properties of neuroblastoma cells (Fig 7B-C).  
While TMOD2 is of potential prognostic value, the fact that low levels of TMOD2 predict poor 
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Figure 7. Simplified proposed model for regulation of TMOD2 by TRPM7. (A) Alignment of partial amino acid sequences 
of TMOD1-4 TMOD1 Thr54 (green) is phosphorylated by TRPM7 and conserved among the other isoforms (red) (B) TMOD2, 
as member of the TRPM7-interactome, resides in a complex linked to TRPM7. Under normal conditions, growing actin 
filaments are reversibly capped at the pointed end by TMOD2. Capping of the actin filament stabilizes the filament, reducing 
disassembly and polymerization of the actin filament. (C) Upon phosphorylation of TMOD2 by the kinase domain of TRPM7, 
TMOD2 might loose its actin capping ability, resulting in enhanced cytoskeletal dynamics by increased actin filament 
polymerization and disassembly. Consequently, this might drive enhanced protrusion elongation by extensive actin 
polymerization and enhance the migratory and invasive ability of neuroblastoma cells.  
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outcome makes it unlikely that TMOD2 can be used as a direct therapeutic target. 
Nevertheless, this manuscript provides evidence supporting the role of TRPM7-interactome 
and cytoskeletal dynamics in neuroblastoma progression. Unfortunately, as high-risk 
neuroblastoma patients already present with highly metastatic disease at diagnosis, no 
clinical benefits will be gained by targeting TMOD2 or the TRPM7 interactome with the goal 
to interfere with metastasis formation. However, apart from its key function in cell migration, 
actin dynamics is essential for a wide variety of cellular functions, including but not limited to 
cell differentiation, proliferation, transcriptional regulation and even apoptosis [65-69]. 
Therefore, understanding how the TRPM7-interactome as a whole contributes to 
neuroblastoma development and progression by regulating actin and adhesion dynamics may 
uncover novel avenues into a range of therapeutic opportunities. In line with this, other 
TRPM7-interactors, such as tropomyosin 3 isoform I (Tpm3.1), deserve a closer look. 
Tropomyosins are actin binding molecules that control actin filament function and turnover, 
for instance by enhancing the actin capping ability of TMODs [70-72]. Tpm3.1, is a non-muscle 
tropomyosin isoform whose expression is specifically upregulated in a variety of human 
cancer cells [73-76]. Moreover, anti-tropomyosin compounds targeting Tpm3.1 were shown 
to be effective in preclinical models reducing in vivo tumor growth in neuroblastoma and 
melanoma models [74, 77]. Importantly, the FDA has granted orphan drug designation for the 
treatment of neuroblastoma to the anti-Tmp3.1 compound Anisina 
(www.accessdata.fda.gov/scripts/opdlisting/oopd), suggesting that clinical evaluation of 
anti-tropomyosin compounds is under evaluation. Future efforts should address to what 
extend  other actin-binding proteins or signaling pathways regulating actin protrusion 
formation can be targeted to more effectively treat high risk neuroblastoma and improve 
patient outcome.  
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Materials and Methods 
Cell lines 
Human SH-SY5Y cells (#ATCC® CRL-2266™) were cultured in Dulbecco’s Modified Eagle Medium: Nutritient 
Mixture F-12 (Thermo Fisher, Gibco, #11320033), supplemented with 10% fetal bovine serum (FBS), 1% 
Non-Essential Amino Acids (Thermo Fisher, Invitrogen, #111400) and 1% pen/strep (Thermo Fisher, Invitrogen, 
#15140). Mouse N1E-115 cells (#ATCC® CRL-2263™) were cultured in Dulbecco’s Modified Eagle Medium + 
Glutamax (Thermo Fisher, Gibco, #31966), supplemented with 10% fetal bovine serum, and 1% pen/strep 
(Thermo Fisher, Invitrogen, #15140). Cells were cultured in a humidified incubator at 37°C and 5% CO2.  
 
Generation of cell lines 
To generate TMOD2 knockdown cell lines, scrambled, human TMOD2 and mouse TMOD2 shRNAs (obtained 
from Dr. R. Beijersbergen at The Netherlands Cancer Institute – Screening and Robotics Facility) (see 
Supplemental Table 1 for sequences) were transduced into cells using the pLKO lentiviral vector according to 
manufacturer’s protocol (Sigma-Aldrich). Cells were selected using 1 μg/ml puromycin. 
 
Quantitative real time PCR 
Total mRNA was isolated using an RNeasy minikit (Qiagen, #74106). cDNA was synthesized using an iScript cDNA 
synthesis kit (#170-8891, Bio-Rad) according to manufacturer’s protocol. q-PCR reactions were performed using 
SsoAdvanced™ Universal SYBR® Green Supermix (#1725274, Bio-Rad) on a CFX96 Touch™ Real-Time System 
(Bio-Rad) using PCR conditions as supplied by Bio-Rad. Expression levels were normalized against the 
housekeeping gene GAPDH and calculated according to the 2−ΔΔCt method [78]. For q-PCR primer sequences, see 
Supplementary Table 1. 
 
Western blotting 
Lysates were prepared as described earlier [34]. Focal adhesion-associated proteins were extracted from 
SH-SY5Y cells as described previously [79]. Proteins were separated by SDS-PAGE and blotted onto a PVDF 
membrane. Blots were incubated with rabbit polyclonal anti-pTyr118 paxillin antibody (1:750, Invitrogen, #44-
722G), mouse polyclonal anti-tropomodulin 2 antibody (1:1000, Abcam, #ab67407) or mouse monoclonal γ-
tubulin antibody (1:10000, Sigma-Aldrich, #T6557), followed by HRP-conjugated secondary antibodies (1:5000, 
Dako). Proteins were visualized using ECL detection agent (Amersham GE Healthcare, #RPN2232) and detected 
using a Fluorchem E Digital Darkroom (Proteinsimple). 
 
Cell viability and proliferation measurements 
The effect of TMOD2 knockdown on cell viability and proliferation was assessed by MTS assays using CellTiter® 
96 Aqueous One Solution Reagent (Promega, #G3580) according to manufacturer’s instructions. Absorbance 





Cells were cultured o/n at low density (10-20% confluency), after which phase-contrast images were taken on a 
Nikon Diaphot 300 microscope with Hamamatsu C8484-05G CCD Camera equipped with 10x/0.50 NA dry 
objective. Images were analyzed for protrusion length and number of protrusion/cell, and processed for 
publication using ImageJ 1.49b. 
 
Immunofluorescence 
Cells were cultured o/n on fibronectin (1mg/mL) coated glass coverslips. Cells were subsequently fixed in 3.7% 
formaldehyde, permeabilized in 0.1% Triton-X and stained for α-tubulin (1:1000; Genetex, #GTX628802), 
pTyr118 paxillin (1:100, Invitrogen, #44-722G) and actin using Alexa-568 conjugated Phalloidin (1:100, Molecular 
Probes, #A12380). Images were taken on a Leica TCS SP5 (Leica Microsystems) equipped with a 63x/1.20 NA 
water-immersion objective and LAS-AF acquisition software (Leica Microsystems). Focal adhesions were 
quantified and images were processed for publication using ImageJ 1.49b. 
Spheroids in 3D collagen matrices were fixed (3.7% formaldehyde) washed and stained using Alexa-Fluor-568 
conjugated phalloidin (1:100, Molecular Probes, #A12380) and DAPI (1:3000, Molecular Probes, #D1306). 
Spheroids were imaged on an Olympus FV1000 confocal laser scanning microscope equipped with a 20x/0.50 
NA long working distance, water immersion objective. Z-stacks were generated from images taken at 5 µm 
intervals. Maximum intensity z-projections were used to quantify the number of invasive strands, single cell 
invasions, and spheroid area and perimeter using ImageJ 1.49b. Tumor border circularity was calculated using 




Cell migration assays 
Following o/n serum starvation, cells were harvested and resuspended in medium containing 0.1% FBS. 5,0 x 
104 cells were seeded onto a transwell insert with 8 µm pore size (Corning, #3422), which was placed in degazed 
medium containing 10% FBS. Cells were allowed to migrate for 48 hours in in a humidified incubator at 37°C, 5% 
CO2. Migrated cells were fixed (75% methanol and 25% acetic acid) and stained (0.25% Coomassie Blue, 45% 
methanol, 10% acetic acid in H2O).  
Gap closure assays were performed according to manufacturer’s recommendations (Ibidi, #80209). In short, 1.0 
x 104 cells were seeded per side of the insert and cultured o/n. After removal of the insert, gap closure was 
followed for 68 hours by time lapse microscopy on a Nikon Diaphot 300 with Hamamatsu C8484-05G CCD 
Camera.  
Multicellular spheroids of SH-SY5Y cells were generated using the hanging drop method [80]. Cells were plated 
at a density of 1500 cells/drop in culture medium supplemented with 4% methyl cellulose solution 
(Sigma-Aldrich, #M6385) and allowed to aggregate o/n in a humidified incubator at 37°C and 5% CO2. Spheroids 
were washed in PBS and mixed in a Collagen-Matrigel®-solution consisting of non-pepsinized rat-tail collagen 
type I (Corning, #354249, 3.3 mg/mL), Matrigel® (Corning, #356231, 21 ug/mL), Minimum Essential Medium α 
(Gibco, #41061029, 5%) buffered with 2,5% bicarbonate. Collagen-spheroid mixtures were pipetted as a drop-
matrix and left to polymerize at 37°C. Spheroid-containing collagen lattices were maintained in a humidified 
incubator at 37°C and 5% CO2 for 7 days. 
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Neuroblastoma micro-array dataset analyses 
Two publicly available datasets were used for gene expression analyses using the R2: Genomic Analysis and 
Visualization Platform (http://r2.amc.nl). The Versteeg discovery cohort contains the gene expression profiles 
of 88 primary neuroblastoma tumors as determined by the Affymetrix Human Genome U133 Plus 2.0 platform 
(GSE16476) [49]. The SEQC validation cohort contains 498 primary neuroblastoma samples that are analyzed by 
customized 4x44k oligonucleotide microarrays from Agilent Technologies (GSE49710) [50]. Kaplan Meier curves 
based on TMOD2 expression were produced using the Kaplan Scan of the R2 platform, where the optimum 
expression cut-off for survival is determined based on statistical testing using a logrank test and corrected for 
multiple testing by Bonferroni testing. 
 
Statistical analysis 
Data are presented as mean ± SEM, unless stated otherwise. Statistics on q-PCR data were performed using 
one-sample t-test, where fold changes in expression were compared to control levels that were set to 1 in each 
independent experiment. Other statistical analyses were performed using the student’s t-test, unless stated 
otherwise. All statistical tests were two-sided and p-values < 0.05 were considered statistically significant. 
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Supplemental Materials  
 
Supplementary Figure 1. TMOD2 expression measurements on N1E-115 control and shTMOD2 cells. (A) Relative TMOD2 
mRNA expression in control and TMOD2 shRNA N1E-115 cells, determined by quantitative real-time PCR. TMOD2 
expression of the control cells is set to 1. Values are depicted as mean ± SEM (n=3). ** p < 0.01, *** p < 0.001. (B) Protein 
expression of TMOD2 after stable expression of control and TMOD2 shRNA’s in N1E-115 cells, determined by Western 
blotting. γ-Tubulin antibodies were used as loading control. Representative example of n=2 experiments. (C) 
Quantification of TMOD2 protein levels of control and TMOD2 shRNA N1E-115 cells, determined by Western blot. TMOD2 
expression of the control cells is set to 1. Values are depicted as mean ± SEM (n=2). 
 
Supplementary figure 2. Decreased TMOD2 expression in N1E-115 cells enhances protrusion length, without affecting 
the number of protrusions per cell. (A) Representative phase-contrast images of N1E-115 control and TMOD2 shRNA 
cells. Scale bar = 100 µm. (B) Quantification of the number of protrusions per cell and (C) protrusion length of N1E-115 
control and TMOD2 shRNA cells. Values are depicted as mean ± SEM of n=4 independent experiments. * p < 0.05, ** p < 
0.01, *** p < 0.001. (D) Distribution of protrusion length of N1E-115 control and TMOD2 shRNA cells. Values are depicted 
as mean ± SEM of n=4 independent experiments. * p < 0.05, ** p < 0.01 
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Supplementary Table 1 – shRNA & primer sequences 
shRNA's Sequence (5'- 3') 
Control GCTACAAGAGAAACCAAATCT 
TMOD2 shRNA#1 GCCAACAATAAAGGTGGCAAA 
TMOD2 shRNA#2 CCTGTCAGAAATGTTGTCAAA 
TMOD2 shRNA#1_mouse ATCACTGGCACTGGAATCCT 
TMOD2 shRNA#2_mouse ATCTGGGCGATCTCCATCT 
  
Primers qPCR  
CRABP2 Fwd CGAGGAATTGCTCAAAGTGCTG 
CRABP2 Rev CACAGTCTGCTCCTCAAAC 
CNTNAP2 Fwd TCCCTCCACGTCCCAAAAATG 
CNTNAP2 Rev TCTTGGCATAGCCGGGAGAA 
GAPDH Fwd CTCCTCCACCTTTGACGCTG 
GAPDH Rev TCCACCACCCTGTTGCTGTA 
ID1 Fwd GGTAAACGTGCTGCTCTACGAC 
ID1 Rev GTCCCTGATGTAGTCGATGAC 
ID2 Fwd CCTCAACACGGATATCAGCATC 
ID2 Rev CACACAGTGCTTTGCTGTC 
MAP2 Fwd AATAGACCTAAGCCATGTGACATCC 
MAP2 Rev AGAACCAACTTTAGCTTGGGCC 
RAR-β Fwd AAACGTCTGCCTGGTTTCAC 
RAR-β Rev AAGGCCGTCTGAGAAAGTCA 
TMOD2 Fwd GATCCTGGCCCTGGTAGAG 
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Chapter 5
TRPM7 controls mesenchymal 
features of breast cancer cells 
by tensional regulation of SOX4
Abstract 
Mechanically induced signaling pathways are important drivers of tumor progression. 
However, if and how mechanical signals affect metastasis or therapy response remains poorly 
understood. We previously found that the channel-kinase TRPM7, a regulator of cellular 
tension implicated in mechano-sensory processes, is required for breast cancer metastasis 
in vitro and in vivo. Here, we show that TRPM7 contributes to maintaining a mesenchymal 
phenotype in breast cancer cells by tensional regulation of the EMT transcription factor SOX4. 
The functional consequences of SOX4 knockdown closely mirror those produced by TRPM7 
knockdown. By traction force measurements we demonstrate that TRPM7 reduces 
cytoskeletal tension through inhibition of myosin II activity. Moreover, we show that SOX4 
expression and downstream mesenchymal markers are inversely regulated by cytoskeletal 
tension and matrix rigidity. Overall, our results identify SOX4 as a transcription factor that is 
uniquely sensitive to cellular tension and indicate that TRPM7 may contribute to breast 






The perception of mechanical cues from the microenvironment by cell adhesion sites is 
essential for morphogenesis during embryonic development, and for maintenance of tissue 
integrity and function in the adult [1-9]. Typically, mechanical stress triggers an immediate 
internal feedback loop that evokes cytoskeletal contraction and enforcement of adhesions 
sites to restore tensional homeostasis [10-13]. As a more sustained effect, mechano-signaling 
regulates gene expression programs that steer proliferation and differentiation [14-16]. 
Consequently, perturbed mechano-signaling contributes to a variety of pathologies, including 
tissue fibrosis and cancer [17, 18].  
In order to metastasize or escape therapy, tumor cells can re-acquire progenitor-like features. 
Soluble factors present in the tumor microenvironment such as TGF-β and Wnt proteins, as 
well as mechanical crosstalk between tumor cells and the surrounding tissue, can bring about 
this progenitor-like state [19]. For instance, mechanically-regulated signaling pathways such 
as those mediated by YAP/TAZ or myocardin-related transcription factor/serum response 
factor (MRTF/SRF) are essential in the control of stem cell development but, when spuriously 
activated by increased cellular tension, contribute to tumor progression [17, 20, 21]. More 
recently, changes in cellular tension were shown to affect epithelial-mesenchymal transition 
(EMT), a developmental transcription program co-opted by tumor cells to acquire migratory 
properties, survive outside of their niche, and resist therapy [22-25]. However, many aspects 
of these mechanically-regulated signaling pathways remain poorly understood. 
Transient receptor potential (TRP) cation channels are considered important transducers of 
mechanical signals during embryonic development and in the maintenance of tissue 
homeostasis [26]. Localized within mechano-sensory structures such as cell adhesions, 
channel opening is induced by membrane stretch and/or cytoskeletal tension [27]. The 
resulting changes in local ion concentrations not only trigger immediate cytoskeletal 
responses, but also bring about more sustained effects by regulating gene expression [26-29].  
TRPM7, a calcium-permeable TRP channel with a functional C-terminal kinase domain that 
localizes to cell adhesion sites, is required during embryogenesis and maintains stem cell-like 
features of progenitor cells [30-34]. We previously demonstrated that expression of TRPM7 is 
required for breast tumor cell migration in vitro and metastasis formation in mouse xenografts 
[35]. In addition, high TRPM7 mRNA expression at time of diagnosis predicts metastasis 
formation and poor outcome in breast cancer patients [35]. The association between high 
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TRPM7 expression and cancer progression has been confirmed in other tumor types, including 
neuroblastoma, pancreatic, nasopharyngeal and prostate cancer [36-39]. In previous studies, 
we and others demonstrated that TRPM7 activity affects cell adhesion and migration by 
reducing myosin II-based cellular tension [27, 40-42]. As TRPM7 was shown to affect cellular 
differentiation [31, 32, 39], we postulate that TRPM7-induced changes in cytoskeletal tension 
have long-term effects on the progenitor features of tumor cells by (re)activating 
developmental gene expression programs.  
Here, we report that TRPM7 contributes to the mesenchymal features of breast cancer cell 
lines by regulating expression of the transcription factor SOX4, an important driver of EMT in 
breast cancer cells that is implicated in breast cancer progression [43, 44]. We further 
demonstrate that expression of SOX4 is inversely regulated by actomyosin-based contraction 
and matrix rigidity. Consequently, our observations suggest a model in which limiting the 
contractile response to tissue stiffness activates a SOX4-mediated gene expression program. 
As SOX4 activation has been linked to metastatic progression [43, 44], TRPM7-mediated 
mechanical regulation of this transcription factor may contribute to the cellular plasticity 
observed during breast cancer progression. 
 
Results 
TRPM7 maintains the mesenchymal phenotype of breast cancer cells 
We previously showed that loss of TRPM7 expression impairs the metastatic potential of 
highly invasive MDA-MB-231 (MDA-231) breast cancer cells [35]. Knockdown of TRPM7 in 
MDA-231 cells using two independent shRNAs targeting TRPM7 resulted in a loss of the typical 
spindle-shaped morphology of these mesenchymal-type cells (Fig 1A & [35]). TRPM7 has been 
linked to the regulation of cellular differentiation and embryonic development [31, 32, 34, 45]. 
Moreover, TRPM7 was shown to regulate EMT in bladder cancer cells [46] and expression of 
the EMT marker vimentin in MDA-MB-468 breast cancer cells [47]. We therefore speculated 
that the effect of TRPM7 knockdown on the morphology of MDA-231 cells could represent a 
(partial) mesenchymal to epithelial transition (MET). Indeed, MDA-231 shTRPM7 cells showed 
increased formation of cell-cell adhesions, as observed by translocation of the tight junction 
protein ZO-1 to sites of cell-cell contacts (Fig 1B), while the expression of ZO-1 was not affected 
(Fig 1D). In addition, TRPM7 knockdown markedly increased the expression of the epithelial 




Figure 1. TRPM7 is necessary for maintenance of the mesenchymal phenotype of MDA-231 cells. (A) Phase-contrast images 
showing morphology of MDA-231 shControl, shTRPM7 and shTRPM7#2. Scale bar = 50 µM. (B) Representative 
immunofluorescence staining of F-actin (cytoskeletal protein) and ZO-1 (tight junction protein). Red arrows in ZO-1 pictures 
indicate ZO-1 localization to cell-cell adhesions. Right panels are a zoom in of middle panels. Scale bars = 20 µM for left and 
middle panels, 5 µM for right panels. (C) Relative mRNA expression of indicated EMT markers, depicted as fold changes in 
expression over MDA-231 shControl as determined by q-PCR. mRNA expression levels were determined by q-PCR. Data are 
mean ± SEM of n = 3 experiments that were performed in duplicate. Statistical significance was determined by a one-sample 
t-test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. (D) Protein expression of indicated EMT markers as determined by western 
blotting. γ-tubulin was used as loading control. Representative examples of n = 3 experiments.  
mRNA and protein level (Fig 1C-D), whereas expression of the mesenchymal markers 
fibronectin (FN1) and vimentin (VIM) decreased (Fig 1C-D & Supplementary Fig 1A). N-
cadherin (CDH2), which is known to respond in an inverse manner to E-cadherin expression, 
did not significantly decrease upon TRPM7 knockdown (data not shown). These observations 
were largely reproduced by incubating cells with the TRPM7-specific inhibitor Waixenicin A 
(Waix A) [48], which lead to an increase in CLDN1 expression and a decrease in FN1 expression 
(Supplementary Fig 1B). Unexpectedly however, CDH1 expression decreased in response to 
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Waix A treatment (Supplementary Fig 1B). TRPM7 mRNA remained unaffected by Waix A 
treatment expression (Supplementary Fig 1B), consistent with the notion that Waix A affects 
TRPM7 activity rather than gene expression. Importantly, TRPM7 knockdown as well as 
inhibition of TRPM7 with Waix A induced a similar epithelial-like transition in the 
mesenchymal-type breast cancer cell line Hs 578T (Supplementary Fig 2A-E). Taken together, 
these results indicate that TRPM7 is required for the maintenance of a mesenchymal 
phenotype of breast cancer cells, although loss of TRPM7 expression or activity is not sufficient 
to acquire a complete epithelial-like state. 
 
TRPM7 regulates expression of the EMT transcription factor SOX4 
To further investigate how TRPM7 maintains mesenchymal properties of breast cancer cells, 
we performed microarray analysis comparing MDA-231 shControl and shTRPM7 cells focusing 
on a set of transcription factors implicated in EMT or MET (EMT-TF) [49, 50]. While inducers 
of MET remained largely unaffected, we found that the transcription factor SOX4 was most 
significantly downregulated in response to TRPM7 knockdown (~6x) (Fig 2A). SOX4 was 
previously identified as an important determinant of EMT, affecting tumor cell migration and 
metastasis in mouse experimental metastasis models [43]. Moreover, and similar to TRPM7 
[35], high SOX4 expression was found to correlate with metastatic progression in breast 
cancer patients [43]. Reduced expression of SOX4 in response to TRPM7 shRNA-mediated 
knockdown was confirmed at both mRNA and protein level in MDA-231 and Hs 578T cells (Fig 
2B-C & Supplementary Fig 3A-B). To further substantiate the results from our gene expression 
profiling, we determined the expression of the well-established EMT-TFs SNAI1, SNAI2, ZEB1 
and ZEB2 by q-PCR (TWIST1 expression was not detected in MDA-231 cells) and observed that 
SNAI2 expression was only weakly (< 2-fold) downregulated by TRPM7 knockdown in MDA-
231 cells (Fig 2B), but not in Hs 578T cells (Supplementary Fig 3A). Similarly, inhibition of 
TRPM7 by treating MDA-231 and Hs 578T cells with Waix A induced a decrease in SOX4 
expression within hours after incubation with Waix A, while the expression of SNAI2 remained 
largely unaffected (Fig 2D & Supplementary Fig 3C). Together, these results indicate that SOX4 
is a common downstream transcriptional target of TRPM7 signaling in mesenchymal-type 
breast cancer cell lines. In further support of these observations, we found that TRPM7 and 
SOX4 mRNA expression are positively correlated in primary breast tumor samples, as 
determined in four independent, publicly available breast cancer patient cohorts (R2: 
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Genomics Analysis and Visualization Platform, http://r2.amc.nl) (Fig 2E). 
 
   
 
Figure 2. TRPM7 knockdown reduces expression of the EMT transcription factor SOX4. (A) Microarray results depicted in a 
heatmap containing log10 transformed intensity values of known EMT and MET inducers in MDA-231 shControl and shTRPM7 
cells. (B) Relative mRNA expression of well-established EMT-TFs, depicted as fold changes in expression over MDA-231 
shControl. (C) Protein expression of SOX4 after stable knockdown of TRPM7, determined by western blotting. Representative 
example of n = 3 experiments. (D) Effect of Waix A (3.3 µM) stimulation on SOX4 and SNAI2 mRNA expression in MDA-231 
cells at different timepoints. Waix A activity is reduced in the presence of serum [48]. Therefore, stimulation was performed 
in serum-depleted medium. (B) and (D) mRNA expression levels were determined by q-PCR. Data are mean ± SEM of n = 3 
experiments that were performed in duplicate. Statistical significance was determined by a one-sample t-test. * = p < 0.05, 
** = p < 0.01. (E) Correlation coefficients between TRPM7 and SOX4 in four breast cancer patient datasets. Patient dataset 
analysis was performed using R2 microarray analysis tools (http://r2.amc.nl). Pearsons’ correlations tests were performed to 
test for statistical significance of correlation. 
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SOX4 maintains the mesenchymal phenotype of breast cancer cells 
To test whether reduced SOX4 expression induces a similar MET-like process in MDA-231 cells, 
we performed shRNA-mediated knockdown of SOX4 using two independent SOX4 targeting 
shRNAs (Supplementary Fig 4A-B). Similar to TRPM7 knockdown cells, MDA-231 shSOX4 cells 
adopted an epithelial cell-like morphology (Fig 3A) accompanied by a translocation of ZO-1 to 
sites of cell-cell contacts (Supplementary Fig 4C). In addition, the expression of the cell-cell 
adhesion proteins E-cadherin and claudin-1 was strongly induced in MDA-231 shSOX4 cells, 
both at the mRNA and protein level (Fig 3B-C). However, although N-cadherin was previously 
reported to be induced upon SOX4-mediated EMT [43], we did not observe a significant effect 
on N-cadherin expression levels upon SOX4 knockdown (data not shown). The second hairpin 
(shSOX4#2) produced a similar but less pronounced increase in E-cadherin and claudin-1, 
which most likely reflects a less efficient knockdown of SOX4 in these cells (Fig 3B-C & 
Supplementary Fig 4A-B). Fibronectin expression decreased to a similar extent in both SOX4 
shRNA MDA-231 cell lines (Fig 3B-C). No decrease in vimentin expression was observed (Fig 
3B-C). Expression of other EMT-TFs remained unaffected by knockdown of SOX4 in MDA-231 
cells, with the exception of ZEB2, which increased in MDA-231 shSOX4 cells (< 2-fold, 
Supplementary Fig 4D). 
To determine to what extent SOX4 mediates the effects on gene expression that we observed 
in response to TRPM7 knockdown, we performed microarray analysis on MDA-231 shControl 
and shSOX4 cells, and compared the up- and downregulated genes between MDA-231 
shTRPM7 and shSOX4 cells. Using as cut-off a 2-fold change, we found a highly significant 
overlap in up- and downregulated genes (135 upregulated genes, p = 1.70e-97 and 84 
downregulated genes, p = 5.01e-40) (Fig 3D & Supplementary Table 1). Additionally, rescue of 
SOX4 activity by expression of a tamoxifen-inducible ER-SOX4 construct [51] in MDA-231 
shTRPM7, cells rescued mRNA and protein expression levels of E-cadherin, fibronectin and 
claudin-1 (Supplementary Fig 5). Together, these data identify SOX4 as a key determinant of 
the TRPM7-induced gene expression signature. Moreover, our results indicate that activation 
of a TRPM7-SOX4 axis acts to preserve a mesenchymal-like state in breast cancer cells. 
 
SOX4 expression is inversely correlated with cellular tension  
We have shown previously that the TRPM7 kinase domain phosphorylates the myosin II heavy 




Figure 3. SOX4 knockdown MDA-231 phenotypically mimic TRPM7 knockdown MDA-231. (A) Phase-contrast images 
showing morphology of MDA shControl, shSOX4 and shSOX4#2. Scale bar = 50 µM. (B) Relative mRNA expression of EMT 
markers, depicted as fold changes in expression over MDA-231 shControl as determined by q-PCR. Data are mean ± SEM of 
n = 3 experiments that were performed in duplicate. Statistical significance was determined by a one-sample t-test. * = p < 
0.05, ** = p < 0.01. (C) Protein expression of EMT markers as determined by western blotting. γ-tubulin was used as loading 
control. Representative examples of n = 3 experiments. (D) Overlapping up- and downregulated genes in shSOX4#1 (total up: 
457; total down: 445) and shT7#1 (total up: 661; total down: 727) microarray. A fold-change ≥ |2| was used as cut-off. p-
values were determined by means of a hypergeometric distribution test. 
mechanics control developmental gene expression programs [15, 52-55], we hypothesized 
that TRPM7 may regulate SOX4 expression by modulating cellular tension. 
Cellular tension is generated by contraction of the actomyosin cytoskeleton which is linked to 
the underlying substrate by cell-substrate adhesions. Typically, increased matrix stiffness 
activates an internal feedback loop that enforces sites of cell adhesion, promoting cell 
spreading and allowing active myosin to build up tension [10, 12]. We applied traction force  
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Figure 4. TRPM7 knockdown increases cytoskeletal tension in MDA-231. (A) Color maps showing the traction forces applied 
to collagen-coated polyacrylamide gels of increasing rigidity by representative shControl and shTRPM7 MDA-231 cells. (B) 
Average traction forces exerted by single cells cultured on collagen coated polyacrylamide gels of increasing rigidity. In grey, 
background noise levels show the minimum detectable force for each rigidity value. (C) Average area of shControl and 
shTRPM7 MDA-231 cells seeded on collagen-coated polyacrylamide gels of increasing rigidity. (D) Representative examples 
of cell-substrate adhesions, revealed by anti-vinculin antibodies, in shControl and shTRPM7 MDA-231 cells cultured on 
polyacrylamide gels of increasing rigidity. (E) Quantification of vinculin adhesion length of single cells cultured on collagen-
coated polyacrylamide gels of increasing rigidity. 
microscopy to quantitatively assess if and how TRPM7-mediated effects on myosin II activity 
modulate cellular tension. This technique is based on measurements of cell-induced substrate 
deformation by imaging displacements of fluorescent nanobeads embedded in the substrate 
[10, 56]. MDA-231 shControl, shTRPM7 and shTRPM7#2 cells were cultured as single cells on 
collagen-coated substrates of different rigidities, covering physiologically relevant stiffness 
regimes (1 – 30 kPA) [17]. We observed that shControl cells generated more tension and 
elongated more efficiently when substrate stiffness increased (Fig 4A-B). Supporting the 
notion that reduced TRPM7 expression increases cellular tension, MDA-231 shTRPM7 cells (n 
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> 30 cells per condition) and shTRPM7#2 cells (n > 15 cells per condition) generated 
substantially more traction forces relative to shControl cells (n > 30 cells per condition) using 
substrates stiffer than 1 kPa (Fig 4B; p < 0,0001, two-way ANOVA), without affecting cell 
surface area (Fig 4C). Consistently, we observed that shTRPM7 cells formed larger focal 
adhesions on substrates stiffer than 1 kPa, when compared to shControl cells (Fig 4D-E; p < 
0,0001, two-way ANOVA, n = 10 cells per condition). Since focal adhesion reinforcement is 
driven by cellular tension, these results support the view that TRPM7 knockdown increases 
intracellular tension, independent of substrate stiffness. 
To assess whether increased cytoskeletal tension is sufficient to reduce expression of SOX4, 
we stably transduced MDA-231 shControl cells with constitutive active RhoA (V14RhoA, 
Supplementary Fig 6A), which activates actomyosin-based contraction by stimulation of the 
myosin light chain kinase [57]. Similar to TRPM7 knockdown cells, traction force 
measurements revealed that these cells generate more tension when compared to empty 
vector-transduced cells (Fig 5A; p < 0,0001, two-way ANOVA, n > 10 cells per condition). 
Consistently, V14RhoA significantly reduced expression levels of SOX4 and fibronectin, and 
increased expression of claudin-1 (Fig 5B-D). We also treated shControl cells with 
lysophosphatidic acid (LPA), a potent activator of RhoA [58], which similarly reduced the 
protein expression of SOX4 and increased expression of claudin-1 (Supplementary Fig 6B-C). 
Since TRPM7 expression was not significantly affected by either V14RhoA or LPA, we can rule 
out the possibility that V14RhoA and LPA act by expression regulation of TRPM7. In contrast 
to TRPM7 and SOX4 knockdown (Fig 1C & 3B), but similar to what we observed following Waix 
A treatment (Supplementary Fig 1A), E-cadherin expression unexpectedly decreased in MDA-
231 V14RhoA cells and after 8h treatment with LPA (Fig. 5B & Supplementary Fig 6B). At the 
same time, expression of the EMT-TF SNAI2 remained largely unaffected by increased 
cytoskeletal tension (Fig. 5B & Supplementary Fig 6B). Together, these results demonstrate 
that increased cytoskeletal tension reduces SOX4 expression and downstream mesenchymal 
features, without bringing about a full MET. 
We next determined to what extent reducing cytoskeletal tension can rescue SOX4 expression 
in MDA-231 shTRPM7 cells. To this end, we stimulated MDA-231 shTRPM7 cells with the 
myosin II ATPase inhibitor blebbistatin. Traction force measurements indicated that treatment 
of MDA-231 shTRPM7 cells with 10 µM blebbistatin reduced traction force generation to the 
level of shControl cells (p < 0,0001, two-way ANOVA, n > 10 cells per condition), whereas  
5
TRPM7 controls mesenchymal features of breast cancer cells by tensional regulation of SOX4
125
treatment with 25 µM blebbistatin almost completely blocked force generation on pliable 
substrates (Fig 5E; p < 0,0001, two-way ANOVA, n > 10 cells per condition). This release of 
cellular tension was associated with a concordant increase in SOX4 and fibronectin expression 
levels, and reduced expression of claudin-1, whereas E-cadherin, SNAI2 and TRPM7 expression 
 
Figure 5. SOX4 is inversely regulated by cytoskeletal tension. (A-D) Effect of stable overexpression of empty vector (EV) or 
V14RhoA in MDA-231 shControl cells on traction force generation (A), mRNA (B) and protein (C) expression of indicated 
genes.(D) Quantification of SOX4 protein expression upon overexpression of V14RhoA. To enhance SOX4 protein expression, 
MDA-231 EV and V14RhoA cells were incubated in medium containing 0.1% FCS for 16 hours before protein lysate was 
harvested. (E-H) Effect of myosin II inhibition in MDA-231 shTRPM7#1 on traction force generation (E),mRNA (F) and protein 
(G) expression of indicated genes. (H) Quantification of SOX4 protein expression upon myosin II inhibition. MDA-231 shTRPM7 
cells were stimulated with DMSO vehicle or indicated concentrations blebbistatin for 2 hours to quantify effects on traction 
force generation. To measure effects of blebbistatin on mRNA and protein expression, cells were treated with 10 µM 
blebbistatin for 2 consecutive days or 16 hours, respectively. (I) Effect of matrix rigidity on SOX4, FN1 and CLDN1 mRNA 
expression in MDA-231 shControl and shTRPM7 cells. Cells were seeded onto collagen-coated substrates with indicated 
rigidities and cultured for 72h. (A & E) Traction force generation was determined by traction force microscopy on n > 10 cells 
per condition. Significance was tested using a two-way ANOVA. (B, F & I) mRNA expression levels were determined by q-PCR. 
Data are mean ± SEM of n = 3 (B & F) or n = 5 (I) experiments that were performed in duplicate. Statistical significance was 
determined by a one-sample t-test (B & F) and a two-way ANOVA (I). * = p < 0.05, ** = p < 0.01. (C & G) Protein levels of EMT 
markers were determined by Western blotting. γ-tubulin was used as loading control. Representative examples of n = 3 
experiments are shown. (D & H) SOX4 protein levels were normalized to the γ-tubulin loading control. Data are mean ± SEM 
of n = 3. Statistical significance was determined by a one-sample t-test. * = p < 0.05, ** = p < 0.01. 
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remained largely unaffected, indicating that TRPM7 controls SOX4 expression via the 
regulation of cytoskeletal tension (Fig 5F-H). Similar results were obtained when shTRPM7 
cells were treated with the Rho-kinase inhibitor Y27632 (Supplementary Fig 6D-E). Note that 
MDA-231 shControl were similarly responsive to Y27632 treatment (Supplementary Fig 6D), 
in line with the idea that expression of these genes is primarily controlled by cytoskeletal 
tension rather than by TRPM7 expression levels. Importantly, inhibition of cytoskeletal tension 
induced a comparable mesenchymal phenotype in Hs 578T cells (Supplementary Fig 6F). 
Since increased substrate stiffness allows the build-up of tension by active myosin, we 
determined how cellular tension controls the expression of SOX4, FN1 and CLDN1 by seeding 
cells onto collagen-coated substrates with different rigidities. Consistent with the previous 
experiments, SOX4 and FN1 expression in MDA-231 shControl and shTRPM7 cells gradually 
decreased on stiffer matrices (Fig 5I, p = 0,012 and p = 0,026 for SOX4 and FN1 respectively, 
two-way ANOVA, n = 5 independent experiments). Moreover, CLDN1 expression strongly 
increased on stiff substrates (Fig 5I, p < 0,0001, two-way ANOVA, n = 5 independent 
experiments). Taken together, our findings indicate that TRPM7 controls mesenchymal 
features of breast tumor cells by tensional regulation of SOX4. 
 
Discussion 
Cancer cells acquire progenitor-like features by re-activating developmental transcription 
programs such as EMT that promote metastasis and therapy resistance. There is mounting 
evidence that mechano-signaling affects such transcriptional programs. However, the 
molecular mechanisms involved remain incompletely understood [15, 54, 55]. We and others 
previously established that TRPM7, a cation channel with kinase activity and implicated in 
mechano-sensory processes, controls embryogenesis and drives tumor progression by 
regulating cytoskeletal dynamics [30-35, 39-41, 45]. Here, we show that TRPM7-induced 
cytoskeletal relaxation drives the mesenchymal features of breast tumor cells by promoting 
expression of the transcription factor SOX4, a recently identified regulator of EMT in breast 
cancer cells [43, 44, 59].  
Consistent with promoting progenitor-like features in breast cancer cells, previous studies 
revealed that TRPM7 contributes to early embryonic development and organogenesis while it 
has been implicated in the maintenance of tissue homeostasis in the adult [31, 32]. Clapham 
and colleagues reported an essential role for TRPM7 in neural crest development [32]. Neural 
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crest cells arise when epithelial-like cells from the neuro-ectoderm undergo EMT to acquire 
migratory properties, allowing them to populate distinct parts of the embryo [60]. Tissue 
specific knockout experiments in mice revealed that TRPM7 expression is required for 
maintaining neural crest cells in a progenitor-like, migratory state during embryogenesis [32]. 
In addition, we showed that TRPM7 maintains progenitor-like features of neuroblastoma cells, 
tumor cells derived from poorly differentiated neural crest cells, by promoting the expression 
of the EMT-TF SNAI2 [39]. Furthermore, our results are in accordance with findings showing 
that TRPM7 is able to regulate protein expression of the EMT marker vimentin in MDA-MB-
468 breast cancer cells [47]. Altogether, these findings point to a role for TRPM7 as a regulator 
of EMT-like transcriptional programs during embryogenesis and tumor progression. 
Based on biochemical and cell biological evidence, we previously put forward that TRPM7 
directly inhibits myosin II function by phosphorylating the myosin II heavy chain, resulting in 
disassembly of bipolar myosin II filaments [35, 40]. Here, we applied traction force microscopy 
confirming that knockdown of TRPM7 increases cellular tension. Interestingly, we find that 
the expression of SOX4, and the majority of its downstream mesenchymal effectors, is 
inversely correlated with cellular tension, while expression of other EMT-TF factors remains 
unaffected. Moreover, we were able to (partially) restore the phenotypical consequences of 
TRPM7 knockdown by inhibiting cytoskeletal contraction, indicating that TRPM7 regulates 
gene expression by modulating cytoskeletal contraction. Surprisingly however, expression of 
the epithelial marker E-cadherin (CDH1) was downregulated upon temporary inhibition of 
TRPM7 or induction of cellular tension, while E-cadherin expression was upregulated both in 
TRPM7 shRNA and SOX4 shRNA cells. We speculate that a more sustained decrease in TRPM7 
activity, as observed in response to shRNA-mediated knockdown, is required to induce CDH1 
expression. In contrast to previous studies, modulation of SOX4 expression did not affect 
N-cadherin expression in our breast cancer cell models. However, cell plasticity is not a binary 
process (on/off) but reflects context dependent activation of different gene expression 
programs that control cell survival, proliferation and cell motility [61]). Consequently, 
different cell types may respond differently to the same input.   
Since TRPM7 localizes to cell-substrate adhesions and controls cellular tension, our data 
support a model in which TRPM7 is part of a unique mechanical signalling hub that controls 
cell plasticity at the level of gene expression, and contributes to tissue development and 
maintenance. How cytoskeletal relaxation promotes SOX4 expression remains to be 
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established. Possibly, cytoskeletal relaxation maintains and/or enhances nuclear localization 
of a yet to be determined transcriptional regulator. A similar mechanism has been described 
for the transcriptional regulators YAP and TAZ, which translocate to the nucleus in response 
to increased cytoskeletal tension [14]. Alternatively, cytoskeletal tension may be transmitted 
directly to the nucleus, affecting tension on the nuclear membrane and consequently 
chromatin organization, which in turn may affect transcription [15, 62].  
It is well known that the mechanical properties of the tumor microenvironment affect the 
metastatic capabilities of tumor cells [17, 54, 55, 63]. High tumor stiffness is generally 
considered to promote tumor development and progression [22, 63, 64]. Although our 
observations need confirmation using experimental models that represent tumor progression 
in the patient, they challenge this model by showing that limiting cell contractility can also 
lead to activation of transcription programs driving metastasis and therapy resistance. In 
support of our findings, a number of papers report that low cellular tension and softness is 
correlated with metastatic features and a mesenchymal phenotype at the cellular level, as 
well as disease progression in cancer patients [65-72]. For instance, EMT induces cellular 
softness in both endometrial and breast cancer cells [68, 73]. Additionally, although high 
mammographic density increases the risk of breast cancer development [74], very low 
mammographic density (<10%) correlates with poor patient survival, prognosis and 
histological tumor grade [75-77]. It was furthermore shown in late-stage breast tumors that, 
although the periphery of primary tumors is stiffer than healthy breast tissue, the hypoxic core 
is in fact softer than healthy counterparts [66]. Consistently, migration and metastatic 
spreading were positively correlated with the low stiffness of these hypoxic core-associated 
cells [66]. Combined, these results suggest that low mammographic density and decreased 
cellular tension at later stages of tumor progression in fact promote metastasis formation and 
poor outcome. Hence, it appears that, dependent on cellular context and disease stage, both 
high and low cellular tension can contribute to tumor progression.  
In the past few years, the importance of epithelial to mesenchymal plasticity, particularly with 
respect to invasion and metastasis, has been subject to debate [61]. We observe that loss of 
cytoskeletal tension contributes to at least some mesenchymal features in our breast cancer 
model, while we have shown previously that high TRPM7 expression is correlated with 
metastatic behavior of breast cancer cells [35]. Altogether our data imply that breast 
cancer-associated plasticity is affected by both tissue rigidity and the tensional state of tumor 
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cells, which appears to involve the tensional regulation of SOX4 expression by TRPM7. In this 
cellular context, limiting the contractile response to tissue stiffness may therefore promote 
rather than inhibit metastasis formation. 
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Materials and methods 
Antibodies and reagents 
Reagents: Waixenicin A was a kind gift from David Horgen (Hawaii Pacific University, Kaneohe, U.S.A.). From 
Sigma-Aldrich: LPA (#L7260), Y-27632 (#Y0503), blebbistatin (#B0560), 4-OHT (#H6278). 
Antibodies: From Cell Signaling Technology: Claudin-1 (#4933, WB 1:1000), E-cadherin (#3195, WB 1:2000), ZO-
1 (#8193, WB 1:2000; IF 1:200). From BD Biosciences: fibronectin (#610077, WB 1:5000, IF 1:500), vimentin 
(#550513, WB 1:5000). From Sigma-Aldrich: γ-tubulin (#T6557, WB 1:10000), vinculin (#V9131, IF 1:400). From 
Diagenode: SOX4 (#C15310129, WB 1:4000). From Life Technologies -- Molecular Probes: phalloidin-Alexa-568 
(#A12380, IF 1:200). 
 
Cell culture 
MDA-MB-231 and Hs 578T (American Type Culture Collection) were cultured in Dulbecco’s Modified Eagle 
Medium + Glutamax (Life Technologies, Gibco, #31966), supplemented with 10% heat-inactivated fetal bovine 
serum and 1% pen/strep (Life Technologies, Invitrogen, #15140). Cells were cultured in a humidified incubator 
at 37 °C and 5% CO2. 
 
Generation of cell lines 
To generate knockdown cell lines control, TRPM7 [35] or SOX4 shRNAs (obtained from Dr. R. Beijersbergen at 
The Netherlands Cancer Institute - Screening and Robotics Facility) (see Supplementary Table 2 for sequences) 
were transduced into MDA-MB-231 or Hs 578T cells using the pLKO lentiviral expression vector according to 
manufacturer’s protocol (Sigma-Aldrich). Cells were selected using 1 µg/ml puromycin. To generate a stable 
constitutively active RhoA overexpressing cell line, MDA-231 shControl cells were transduced with pLZRS-
mycV14RhoA or an empty vector control. Cells were selected with 2 mg/ml G418. Stable overexpression of SOX4 
in shControl and shTRPM7 cells was obtained by expression of the pBABE-blast ER and pBABE-blast ER:SOX4 
constructs generated by the lab of Prof. P. J. Coffer (UMC Utrecht, Utrecht, The Netherlands) [51], These 
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constructs encode the hormone-binding domain of the human estrogen receptor (ER) or a fusion protein of 
mouse Sox4 with the hormone-binding domain of the human estrogen receptor, respectively. Cells were selected 
with 20 µg/ml blasticidine. For each experiment, cells were stimulated with 100 nM 4-hydroxy tamoxifen (4-OHT) 
for 24 hours. 
 
Immunofluorescence 
For staining of cell-cell contacts and fibronectin, cells were cultured o/n on glass coverslips. For quantification of 
cell-matrix adhesion size, cells were cultured on collagen-coated polyacrylamide gels. Cells were subsequently 
fixed in 4% paraformaldehyde and permeabilized in 0.1% Triton-X 100. Non-specific binding was blocked with 3% 
BSA. Cells were incubated with ZO-1, fibronectin-1 or vinculin antibodies diluted in 3% BSA. Cells were then 
incubated with phalloidin-Alexa 568 and anti-rabbit Alexa 647 conjugated antibodies diluted in 3% BSA. Images 
(2048x2048 resolution, with 6x line averaging) were taken on a Leica TCS SP5 (Leica Microsystems) equipped 
with a 63x water-immersion objective and LAS-AF acquisition software (Leica Microsystems). Images were 
processed for publication using ImageJ 1.48. 
 
Quantitative real-time PCR 
mRNA was isolated using an RNeasy minikit (Qiagen, #74106) and DNAse-treated on column (Qiagen, #79254). 
cDNA was synthesized using an iScript cDNA synthesis kit according to manufacturer’s protocol (Bio-Rad, #170-
8891). q-PCRs were performed using Power SYBR green mix (Life Technologies, Applied Biosystems, #4368708) 
on a CFX96 Touch™ Real-Time System (Bio-Rad) using PCR conditions as supplied by Applied Biosystems. Gene 
expression levels were normalized against the GAPDH housekeeping gene and calculated according to the 2-ΔΔCt 
method. For q-PCR primer sequences, see Supplementary Table 2. 
 
Western blotting 
Cells were lysed in RIPA lysisbuffer (150 mM NaCl, 1% NP40, 5 mM EDTA, 50 mM Tris pH 8.0, 0.5% deoxycholate, 
0.1% SDS) supplemented with complete protease inhibitor cocktail (Roche). After clarification, lysates were 
diluted in Laemlli’s buffer (0.25 M Tris pH 6.8, 10% glycerol, 2% SDS and 0.02% bromophenol blue), supplemented 
with 10% β-mercaptoethanol and incubated at 95 °C for 5 min. Proteins were separated by SDS-PAGE and 
subsequently blotted onto PVDF membranes. Non-specific binding was blocked with 5% BSA or 4% skim milk (for 
SOX4 blots) diluted in TBS + 0.1% Tween-20 (TBST). Blots were then incubated with primary antibodies, followed 
by HRP-conjugated secondary antibodies, diluted in TBST + 5% BSA or 0.8% skim milk (for SOX4 blots). Proteins 
were detected using ECL detection agent (Amersham GE Healthcare #RPN2232) and imaged on a Fluorchem E 
Digital Darkroom (Proteinsimple). 
 
Microarray analysis 
MDA-231 shCntrl, shTRPM7 and shSOX4#1 were subjected to microarray analysis (GEO accession number: 
GSE63958), which was performed at Genomescan B.V. (Leiden, The Netherlands). RNA concentrations were 
measured using the Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies). RNA quality and integrity 
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were determined using Lab-on-Chip analysis on the Agilent 2100 Bioanalyzer (Agilent Technologies). Biotinylated 
cRNA was prepared using the Illumina TotalPrep RNA Amplification Kit (Ambion Inc.) according to manufacturer’s 
specifications with an input of 200 ng total RNA. Per sample, 750 ng of the obtained biotinylated cRNA samples 
was hybridized onto the Illumina HumanHT-12 v4 (Illumina Inc.). Hybridization and washing were performed 
according to the Illumina Manual ‘Direct Hybridization Assay Guide’. Scanning was performed on the Illumina 
iScan (Illumina Inc.). Image analysis and extraction of raw expression data was performed with Illumina 
GenomeStudio v2011.1 Gene Expression software. Arrays were normalized in Arraystar (v. 4.03), using Robust-
Multi-Array normalization. For visualization of selected EMT/MET inducers in a heatmap (Multi Experiment 
Viewer v 4.8.1), normalized linear intensity values were log10 transformed. Statistical significance of overlapping 
up- and downregulated in MDA-231 shTRPM7 and shSOX4#1 was determined by means of a hypergeometric 
distribution test. To this end, normalized linear intensity values were log2 transformed. Log2 values < 2.5 were 
considered background and a fold change of ≥ |2| was used as cut-off. The amount of background corrected 
gene products (n = 22278) was used as total gene set for the hypergeometric distribution test. 
 
Preparation of polyacrylamide gels  
Polyacrylamide gels were prepared as previously described [10]. Briefly, glass-bottom dishes (MatTek) were 
activated with a solution of 3-(trimethoxysilyl)propyl methacrylate (Sigma-Aldrich), acetic acid and ethanol 
(1:1:14), washed with ethanol and air-dried for 10 min. To generate gels of different stiffness, different 
concentrations of acrylamide and bis-acrylamide were mixed in 10 mM HEPES supplemented with 0.5% 
ammonium persulfate, 0.05% tetramethylethylenediamine (Sigma) and 0.4% fluorescent red carboxylated 
nanobeads (Invitrogen) (see Supplementary Table 3). 10 µl of this solution was then placed on the center of the 
glass-bottom dishes and covered with 12-mm-diameter glass coverslips. After gel polymerization, top coverslips 
were removed and gels were incubated with 100 µg/ml Collagen (Nalgene) overnight at 4 °C. After washing gels 
with PBS, cells were then trypsinized and plated on gels. For traction force measurements and immunostaining, 
cells were cultured for 2-4 hrs. For mRNA expression analysis, cells were cultured for 72 hrs.  
 
Traction force microscopy 
Traction force measurements were performed as described previously [10]. Cells seeded on gels were placed on 
an inverted microscope (Nikon Eclipse Ti). Phase contrast images of single cells and fluorescence images of the 
embedded nanobeads were obtained with a 40× objective (NA 0.6). At the end of the measurements, cells were 
trypsinized and an image of bead positions in the relaxed state of the gel was acquired. By comparing bead 
positions with and without cells, a map of gel deformations caused by cells was first obtained using custom 
particle imaging velocimetry software [78]. Then, after assuming that gel displacements were caused by forces 
exerted by cells in the cell–gel contact area, the corresponding map of cell forces was calculated using a 
previously described Fourier transform algorithm [56, 79]. The average forces per unit area exerted by each cell 
were then calculated. To calculate the minimum detectable force levels for each rigidity, we followed the same 
procedure in cell-free gel areas, and calculated the resulting forces. Phase contrast images were also used to 




Statistics on q-PCR data were performed using a one-sample t-test, comparing fold changes in expression to 
control levels that were set to 1 in each independent experiment. Statistics on the effect of substrate stiffness 
on traction force generation, focal adhesion assembly and gene expression were performed using a two-way 
ANOVA. Data are represented as mean ± SEM. P-values < 0.05 were considered statistically significant. 
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Supplementary Figure 1. (A) Representative immunofluorescence staining of fibronectin in MDA-231 shControl, shTRPM7#1, 
shTRPM7#2. (B) Effect of o/n Waix A (3.3 µM) stimulation on CDH1, CLDN1, FN1 and TRPM7 expression in MDA-231 cells. 
mRNA expression levels were determined by q-PCR. Data are mean ± SEM of n = 4 experiments that were performed in 




Supplementary Figure 2. (A) Knockdown efficiency of shTRPM7 in Hs 578T cells. (B) Phase contrast images showing effect of 
TRPM7 knockdown on cell morphology in Hs 578T cells. Note the loss of long cell protrusions (indicated by white arrows in 
shControl) in shTRPM7. Scale bars = 50 µM. (C) Effect of TRPM7 knockdown on EMT marker expression, depicted as fold 
changes over shControl. CDH1 expression was not detected by q-PCR in both shControl and shTRPM7#1. (D) Effect of TRPM7 
knockdown on EMT marker expression as determined by western blotting. Black arrow indicates correct claudin-1 band 
(claudin-1 is only weakly expressed in Hs 578T). γ-tubulin was used as loading control. (E) Effect of o/n Waix A (4 µM) 
stimulation on CLDN1 and FN1 expression in Hs 578T cells. (A, C & E) mRNA expression levels were determined by q-PCR. 
Data are mean ± SEM of n = 3 experiments that were performed in duplicate. Statistical significance was determined by a 




Supplementary Figure 3. (A) Effect of TRPM7 knockdown on EMT-TF expression, depicted as fold changes over shControl, in 
Hs 578T cells. (B) Effect of TRPM7 knockdown on SOX4 protein expression as determined by western blotting. Representative 
example of n = 3 experiments. (C) Effect of o/n Waix A (4 µM) stimulation on SOX4 and SNAI2 expression in Hs 578T cells. (A 
& C) mRNA expression levels were determined by q-PCR. Data are mean ± SEM of n = 3 experiments that were performed in 
duplicate. Statistical significance was determined by a one-sample t-test. * = p < 0.05. 
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Supplementary Figure 4. (A) Knockdown efficiency of shSOX4 and shSOX4#2 in MDA-231 as determined by q-PCR. (B) 
Knockdown efficiency of shSOX4 and shSOX4#2 as determined by western blotting. Representative example of n = 3 
experiments. (C) Representative immunofluorescence staining of F-actin and ZO-1 in MDA-231 shControl and MDA-231 
shSOX4#2. Red arrows in ZO-1 pictures indicate ZO-1 localization to cell-cell adhesions. Scale bars = 20 µM. (D) Effect of SOX4 
knockdown in MDA-231 on EMT-TF mRNA expression. (A) & D) mRNA expression levels were determined by q-PCR. Data are 
mean ± SEM of n = 3 experiments that were performed in duplicate. Statistical significance was determined by a one-sample 





Supplementary Figure 5. To evaluate whether over-expression of SOX4 could rescue the effect of TRPM7 knock down in 
MDA-231 cells, a fusion protein consisting of mouse Sox4 fused to the hormone-binding domain of the human estrogen 
receptor (ER:SOX4) or solely the hormone-binding domain of the human estrogen receptor (ER) [51] was expressed in MDA-
231 shControl and shTRPM7 cells. While no longer sensitive to estrogen itself, this ER variant is extremely sensitive to the 
synthetic ligand 4-hydroxy-tamoxifen as the result of a mutation in the ligand binding domain. In the absence of 4-OHT the 
ER and ER:SOX4 fusion protein are retained in the cytoplasm and rapidly degraded. However, upon binding of the ligand, the 
ER and ER:SOX4 fusion protein translocate to the nucleus.[51] Hence, cells were stimulated with 100 nM 4-OHT for 24 hours 
to allow shuttling of the ER:SOX4 fusion protein to the nucleus and to quantify the effect of SOX4 expression in shControl and 
shTRPM7 on mRNA and protein expression. (A) Relative mRNA expression of TRPM7, SOX4 and EMT markers, depicted as 
fold change in expression over MDA-231 shControl ER as determined by q-PCR. Data are mean ± SEM of n = 3 experiments. 
Statistical significance was determined by a one-sample t-test. * = p < 0.05, ** = p < 0.01, relative to shControl ER for TRPM7 
and SOX4 and relative to shTRPM7 ER for SOX4, CDH1, CLDN1, FN1 and VIM. (B) Protein expression of ER:SOX4 and EMT 
markers as determined by western blotting. γ-tubulin was used as loading control. Representative examples of n = 3 
experiments are shown.  
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Supplementary Figure 6. (A) Expression of myc-tagged V14RhoA in MDA-231 shControl was verified by western blot using an 
anti-myc antibody. (B & C) Effect of LPA stimulation in MDA-231 shControl cells on mRNA (B) and protein (C) expression of 
indicated genes. To sensitize MDA-231 for LPA stimulation, cells were serum starved o/n. Cells were subsequently stimulated 
with 10 µM LPA (in serum-depleted medium) for 0-8 h (B) or o/n (C). (D & E) Effect of Rho-kinase inhibition in MDA-231 
shControl & shTRPM7 cells on mRNA (D) and protein (only for shTRPM7) (E) expression of indicated genes. MDA-231 
shTRPM7 were stimulated with either 5 µM or 15 µM Y-27632 for 4 days in normal culture medium. Y-27632 was replenished 
every day. (F) Effect of myosin II inhibition in Hs 578T cells on mRNA expression of indicated genes. Cells were o/n stimulated 
with indicated blebbistatin concentrations. (B, D & F) mRNA expression levels were determined by q-PCR. Data are mean ± 
SEM of n = 3 experiments that were performed in duplicate. Statistical significance was determined by a one-sample t-test. * 
= p < 0.05, ** = p < 0.01, *** = p < 0.001. (C & E) Representative examples of n = 3 experiments. 
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Supplementary Table 1. Overlapping up- and downregulated genes in shTRPM7 and 
shSOX4 microarrays. 
 
Upregulated in both shTRPM7 and shSOX4#1 
ADA FLI1 MAP3K8 NFKBIA 
ADAMTS9 GAL MATN2 NFKBIE 
AIF1L GATA2 MMP9 NLK 
ARHGEF16 GBP4 NCF2 NOSTRIN 
ATP8B1 HKDC1 OLR1 NUAK2 
BATF HS.4892 OSBP2 NUP210 
BIK HS.566661 PI16  
BIRC3 HS.582338 PLAC1  
C10ORF35 HSD11B1 PLCG2  
C15ORF48 ICAM1 PTX3  
C4BPB ICAM2 RAB15  
C4ORF26 IFIH1 RAB3IL1  
C6ORF132 IL1A RELB  
C9ORF58 IL1B RNY4  
CCL3L1 IL23A RRAD  
CCL3L3 IL24 RSAD2  
CCL4L1 IL32 SAA1  
CD83 IL6 SAA2  
CDC42EP5 IL7R SAA4  
CEACAM1 IL8 SDC4  
CGN ISG20 SEMA4D  
CH25H ISL1 SLC43A2  
CHST4 KRT17 ST6GALNAC5  
CITED4 LAMC2 TGFB2  
CLDN1 LCN2 THBD  
CLDN11 LOC100129022 TIFA  
COL17A1 LOC100129637 TMEM132A  
COL6A2 LOC100132240 TMPRSS2  
CSF2 LOC100133572 TNFAIP2  
CX3CL1 LOC339799 TNFAIP3  
CXCL1 LOC392145 TNFRSF1B  
CXCL10 LOC441395 TNFRSF9  
CXCL2 LOC644760 TRAF1  
CYP24A1 LOC645249 TRIM29  
DENND2A LOC645638 TUBAL3  
DHX58 LOC649174 UCA1  
EBI3 LOC651876 VNN1  
ECSCR LOC728463 VSTM1  
EDN2 LOC729642 WT1  
EFNA1 LOC730833 XYLB  
ERCC6 LOC732419 ZC3H12A  
FAM23B LTA ZC3H12C  
FLG LTB ZNF114  
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Supplementary Table 2 - shRNA and q-PCR primer sequences. 
shRNAs Sequence (5' - 3') 
shCntrl (scrambled shRNA) GCTACAAGAGAAACCAAATCT 
shTRPM7#1 (TRPM7 shRNA) GCGCTTTCCTTATCCACTTAA 
shTRPM7#2 (TRPM7 shRNA) GCCCGATATTATTTCCACTAT 
shSOX4#1 (SOX4 shRNA) CCTTTCTACTTGTCGCTAAAT 
shSOX4#2 (SOX4 shRNA) TGGGCACATCAAGCGACCCAT 
Primers q-PCR 
 
CDH1 Fwd TCCTGGGCAGAGTGAATTTT 
CDH1 Rev GGCGTAGACCAAGAAATGGA 
CLDN1 Fwd GGCAGATCCAGTGCAAAGTC 
CLDN1 Rev TCATCTTCTGCACCTCATCG 
FN1 Fwd TGGCACCCCACGCTCAGATACA 
FN1 Rev CTCGCCAGGCAGGTTGACGG 
GAPDH Fwd CTCCTCCACCTTTGACGCTG 
GAPDH Rev TCCACCACCCTGTTGCTGTA 
SNAI1 Fwd TCGGAAGCCTAACTACAGCGA 
SNAI1 Rev AGATGAGCATTGGCAGCGAG 
SNAI2 Fwd AAGCATTTCAACGCCTCCAAA 
SNAI2 Rev GGATCTCTGGTTGTGGTATGACA 
SOX4 Fwd GGCCTCGAGCTGGGAATCGC 
SOX4 Rev GCCCACTCGGGGTCTTGCAC 
TRPM7 Fwd TAGCCTTTAGCCACTGGAC 
TRPM7 Rev GCATCTTCTCCTAGATTTGC 
TWIST1 Fwd GTCCGCAGTCTTACGAGGAG 
TWIST1 Rev GCTTGAGGGTCTGAATCTTGCT 
VIM Fwd GAGAACTTTGCCGTTGAAGC 
VIM Rev GCTTCCTGTAGGTGGCAATC 
ZEB1 Fwd TTACACCTTTGCATACAGAACCC 
ZEB1 Rev TTTACGATTACACCCAGACTGC 
ZEB2 Fwd GACAGATCAGCACCAAATGC 
ZEB2 Rev GCTGATGTGCGAACTGTAGG 
 
 
Supplementary Table 3 - PAA gel components and volumes (µL) added. 
  1,26 kPa 5 kPa 12 kPa 30 kPa 
HEPES 10 mM 414 380,95 358 309,75 
40% Acrylamide 68,7 93 94 150 
2% BIS 12,5 11 25 37,5 
Beads (200nm) 10 10 10 10 
10x APS 2,5 2,5 2,5 2,5 
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Chapter 6
The transcriptional repressor SNAI2 
impairs neuroblastoma differentiation and 
inhibits response to retinoic acid therapy
Abstract  
Neuroblastoma is the most common extracranial solid tumor in children and originates from 
poorly differentiated neural crest progenitors. High-risk neuroblastoma patients frequently 
present with metastatic disease at diagnosis. Despite intensive treatment, patients often 
develop refractory disease characterized by poorly differentiated, therapy resistant cells. 
Although adjuvant therapy using Retinoic Acid (RA)-induced differentiation may increase 
event-free survival, in the majority of cases response to RA-therapy is inadequate. 
Consequently, current research aims to identify novel therapeutic targets that enhance the 
sensitivity to RA and induce neuroblastoma cell differentiation. The similarities between 
neural crest development and neuroblastoma progression provide an appealing starting 
point. During neural crest development the EMT-transcription factor SNAI2 plays an 
important role in neural crest specification as well as neural crest cell migration and survival.  
Here, we report that CRISPR/Cas9 mediated deletion as well as shRNA mediated knockdown 
of the EMT-transcription factor SNAI2 promotes cellular differentiation in a variety of 
neuroblastoma models. By comparing mRNA expression data from independent patient 
cohorts, we show that a SNAI2 activity-based gene expression signature significantly 
correlates with event-free survival. Loss of SNAI2 function reduces self-renewal, 3D invasion 
as well as metastatic spread in vivo, while strongly sensitizing neuroblastoma cells to 
RA-induced growth inhibition. Together, our data demonstrate that SNAI2 maintains 
progenitor-like features in neuroblastoma cells while interfering with RA-induced growth 
inhibition. We propose that targeting gene regulatory circuits, such as those controlling SNAI2 
function, may allow reversion of RA-therapy resistant neuroblastoma cells to a more 






Neuroblastoma is the second most common solid tumor in infants and young children, and 
accounts for 10% of pediatric cancer associated deaths [1, 2]. While survival rates are 
excellent for low- and intermediate-risk neuroblastoma patients, outcome is dismal for high-
risk patients, who frequently present with metastatic disease at diagnosis. These patients 
require intensive treatment, including chemo- and radiotherapy, which is often combined 
with autologous stem cell transplantation. To eradicate minimal residual disease, these 
treatments are commonly followed by retinoic acid (RA)-induced differentiation therapy 
and/or immunotherapy [3-5]. Although RA treatment was shown to reduce the risk of a 
relapse, many cases show inadequate responses to RA leading to the occurrence of relapses 
that no longer respond to therapy [3, 4]. As a consequence, there are no curative treatment 
options for relapsed neuroblastoma, resulting in an overall survival rate in high-risk patients 
that is below 40% [1, 2]. 
Neuroblastoma is derived from the neural crest, a heterogeneous cell population that arises 
at the borders of the neuro-ectoderm during early embryogenesis and contributes to the 
formation of the peripheral nervous system as well as other tissues [6]. Mechanisms 
controlling neural crest development are frequently deregulated during neuroblastoma 
progression [7-9]. For instance, MYCN, ALK and PHOX2B, genes controlling neural crest 
proliferation and differentiation, are often overexpressed or mutated in high-risk 
neuroblastomas [7, 8]. In addition, a recent study comparing the genomic landscape of 
relapsed refractory neuroblastoma with that of primary tumors, observed a specific 
enrichment of mutations in genes that activate epithelial to mesenchymal transition (EMT) in 
relapsed tumors [10]. This suggests that within these tumors, neuroblastoma cells undergo 
phenotype switching as a mechanism to escape therapy, driving the selective outgrowth of 
drug-resistant cell populations with stem cell-like features that give rise to relapsed tumors 
[7, 8, 11, 12]. 
During neural crest development, EMT is one of the key developmental programs driving the 
transition from a non-migratory epithelial-like state to a highly migratory mesenchymal state. 
This allows neural crest cells to delaminate from the neural tube and migrate through the 
developing embryo. In epithelial tumors, EMT-transcription factors such as TWIST1 and SNAI2 
are considered important determinants of cancer metastasis formation, pluripotency, and 
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therapy resistance [13-20]. In line with this notion, we recently showed that the cation 
channel TRPM7, a gene essential for normal neural crest development, promotes 
neuroblastoma self-renewal and metastasis formation most likely by regulating the 
expression of the EMT-transcription factor SNAI2 [21]. This transcriptional repressor plays a 
crucial role during neural crest specification, and expression of SNAI2 is essential during 
delamination and survival of neural crest cells outside of the neural crest niche [15, 22]. 
Consistently, we and others have suggested a role for SNAI2 in neuroblastoma development 




SNAI2 regulates a gene expression program that interferes with neuronal cell 
differentiation 
To investigate how SNAI2 contributes to neuroblastoma development and progression, we 
used established neuroblastoma cell line models SH-SY5Y, LAN-5 and N1E-115 cells. We 
performed targeted deletion of SNAI2 using CRISPR/Cas9 in human SH-SY5Y neuroblastoma 
cells. (Sup. Fig. 1A). To avoid effects of clonal heterogeneity, we focused on pools of cells 
expressing control and SNAI2 gRNA’s. Efficient targeting of the SNAI2 gene (Sup. Fig. 1B & C) 
and depletion of SNAI2 protein expression (Sup Fig. 1D) was validated by sequencing and 
western blotting, respectively.  In addition to targeted deletion in SH-SY5Y cells, expression 
of SNAI2 was modulated by expression of FLAG-tagged SNAI2 in human SH-SY5Y cells (Sup. 
Fig. 1E), RNAi mediated silencing of SNAI2 in human LAN-5 cells (Sup. Fig. 1F), and 
CRISPR/Cas9 mediated knockout of SNAI2 in mouse N1E-115 cells (Sup. Fig. 1G).  
 Loss of SNAI2 in SH-SY5Y cells was accompanied by significant changes in neuroblastoma cell 
morphology, inducing the formation of long neurite-like protrusions positive for both F-actin 
and β-tubulin (Fig 1A,B). Additionally, the percentage of neurite bearing cells was increased 
in SH-SY5Y SNAI2 gRNA cells compared to control cells (Fig 1C), suggesting that loss of SNAI2 
promotes  neuroblastoma differentiation. Surprisingly, SNAI2 depletion did not significantly 
increase neurite extension or number in LAN-5 and N1E-115 cells, most likely reflecting cell 
intrinsic differences. Nevertheless, loss of SNAI2 in SH-SY5Y and LAN-5 cells affected 
expression of a subset of genes associated with neuronal differentiation, indicative of a more 
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differentiated phenotype (Fig 2A and Sup. Fig. 2). Moreover, overexpression of FLAG-tagged 
SNAI2 in SH-SY5Y cells regulated this subset of genes in the opposite direction (Fig 2B).  
To further determine how loss of SNAI2 expression affects global gene expression, RNA 
sequencing (RNAseq) analysis was performed comparing mRNA derived from pools of control 
and SNAI2 gRNA SH-SY5Y neuroblastoma cells. We identified 206 genes in SH-SY5Y gRNA#1 
cells (199 up, 7 down) and 356 genes in SH-SY5Y gRNA#2 cells (248 up, 108 down) that were 
differentially expressed (p <1E-6, log2 fold change ≥ |2|) when compared to control cells, of 
which 180 genes were shared between both sets (Fig. 2C, Sup. Table 2). Consistent with the 
notion that SNAI2 is a transcriptional repressor [15, 25], the majority of these differentially 
expressed genes (173 of 180) were upregulated in response to SNAI2 depletion (Sup. Fig. 3A). 
Moreover, we observed a strong concordance in expression changes between SNAI2 gRNA#1 
and gRNA#2 cell lines (Sup. Fig. 3A). Log2 fold changes determined by RNAseq were confirmed 
by q-PCR for a subset of genes (Fig. 2D), including the number one most upregulated gene 
POU4F2 and two genes involved in neuronal differentiation (NRCAM and CHD5). Importantly, 
 
Figure 1. SNAI2 depletion promotes morphological differentiation of neuroblastoma cells. (A) Representative 
immunofluorescence staining of F-actin and β-tubulin. Note the increase in number of cells with neurite-like protrusions 
and length thereof in SH-SY5Y SNAI2 gRNA cells. Scale bar = 25 μm. (B) Quantification of induced neurite outgrowth in 
response to SNAI2 depletion. Data represent mean ± SEM of at least 250 cells/experiment of n=3 independent experiments 
***p < 0.001. (C) Percentage of cells presenting with neurite-like protrusions. Data represent mean ± SEM of n=3 
independent experiment with at least 250 cells/experiment ***p < 0.001.  
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Figure 2. SNAI2 controls a gene expression program involved in neuronal differentiation. Relative mRNA expression of 
neuronal differentiation related genes in SNAI2 gRNA (A) and SNAI2 over-expressing (B) SH-SY5Y cells. mRNA expression in 
control cells is set to 1. Values are depicted as mean ± SEM (n=3). * p < 0.05, ** p < 0.01, ***p < 0.001.  (C) Overlapping 
differentially expressed genes in SNAI2 gRNA#1 (total 206) and SNAI2 gRNA#21 (total 356) as determined by RNAseq. A log2 
fold-change ≥|2| and p < 1E-6 were used as cut-off values. p-value of overlap was determined by means of a Fisher’s Exact 
test. (D) Log2 fold changes of POU4F2, CHD5 and NRCAM in SH-SY5Y SNAI2 gRNA#1 and #2 cells compared to SH-SY5Y 
control gRNA cells as determined by RNAseq and validated by qPCR. Data represents mean log2 fold changes ± SEM (n = 3). 
For qPCR data expression levels are normalized to GAPDH housekeeping gene expression. **p < 0.01, ***p < 0.001. (E) 
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expression of CHD5 and NRCAM also increased in SNAI2 silenced LAN-5 neuroblastoma cells 
(Sup. Fig. 3B). 
Gene Ontology (GO)-term analysis using the 173 overlapping upregulated genes uncovered 
106 GO categories within the subroot ‘Biological Processess’ that were significantly enriched 
(p<0.01, >10 genes per category) in response to SNAI2 depletion (Sup. Table 3). In line with 
the effects we observed on neurite outgrowth (Fig. 1A-C) and the role of SNAI2 in neural crest 
development, biological processes such as neurogenesis, generation of neurons and neuron 
differentiation were among the most significantly enriched ontologies (Fig. 2E). A simplified 
directed acyclic graph showing the relationships between the most strongly enriched 
GO-terms further underscores the role for SNAI2 affected genes in neuronal differentiation 
(Fig. 2F). We conclude from these experiments that SNAI2 controls neuroblastoma 
differentiation by repressing a gene expression program involved in neuronal cell 
differentiation.  
 
A SNAI2-dependent gene expression program predicts event-free survival in neuroblastoma 
patients 
Given that overall survival of neuroblastoma patients is positively associated with the grade 
of differentiation of the tumor [26], we investigated whether SNAI2 expression correlates 
with event-free survival in a cohort of human neuroblastoma patients using online available 
microarray-based expression data (http://r2.amc.nl). However, no correlation was found 
between SNAI2 mRNA expression and patient prognosis (data not shown). We hypothesized 
that SNAI2 activity rather than SNAI2 mRNA expression would be predictive of outcome. 
Therefore, we derived a SNAI2-dependent gene expression signature based on the genes 
upregulated in response to SNAI2 knockout as determined by RNAseq. Limited by the probes 
present within the available patient datasets, 152 of the 173 upregulated genes could be 
included in the SNAI2 signature (Sup. Table 4). K-means clustering of the micro-array based 
SEQC patient dataset using the SNAI2 gene signature allowed stratification of 498 primary 
SNAI2 controls neuronal developmental gene expression programs. GO-term analysis was performed on the 173 
overlapping genes that were differentially upregulated in SH-SY5Y SNAI2 gRNA#1 and gRNA#2 cells, when compared to SH-
SY5Y control cells. Presented are the 10 most significantly enriched GO-terms within the subroot ‘Biological Process’ as 
determined by Fisher’s Exact test with False Discovery Rate (FDR) correction. Fold enrichment is the ratio between observed 
and expected genes within a category. The number of expected genes is based on the number of protein encoding genes 
within a category. (F) SNAI2 depletion affects genes controlling neuronal differentiation. Simplified representation of the 
relationship between GO-terms involved in neuronal differentiation, and the number of genes observed per category. 
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Figure 3. Expression of SNAI2 regulated genes correlates with neuroblastoma patient outcome. (A) K-means clustering of 
micro-array expression data of a cohort of 498 primary neuroblastoma tumors based on the 152 genes present within the 
SNAI2 signature. Tracks represent the k-means result (blue and red), INSS stage (light green=stage 1, dark green=stage 2, 
yellow=stage 3, red=stage 4, blue=stage 4S), risk group (red = high risk, green = low risk) and MYCN amplification status (red 
= MYCN amplified, green = non MYCN amplified). Clustering result was identified in 8/10 k-means iterations. Track below 
represent signature score for SNAI2 signature. (B) Kaplan Meier analyses of event-free survival based on the clustering 
performed in (A). (C) Kaplan Meier analyses of event-free survival based on the k-means clustering performed in the subset 
of MYCN non-amplified patients of the SEQC cohort (see Sup. Fig 4A). (D)  K-means clustering of micro-array expression 
data of a cohort of 649 primary neuroblastoma tumors based on the 152 genes present within the SNAI2 signature. Tracks 
represent the k-means result (red and blue), INSS stage (light green=stage 1, dark green=stage 2, yellow=stage 3, red=stage 
4, blue=stage 4S), risk group (red = high risk, green = low risk) and MYCN amplification status (red = MYCN amplified, green 
= non MYCN amplified). Clustering result was identified in 8/10 k-means iterations. (E) Kaplan Meier analyses of event-free 
survival of the 476 patients of which survival data was available based on the clustering performed in (B). (F) Kaplan Meier 
analyses of event-free survival based on the k-means clustering performed in the subset of 405 MYCN non-amplified 
patients of which survival data was available in the Kocak cohort (see Sup. Fig. 4B). 
neuroblastomas [27] into a group with low expression of the signature genes (n=177) and a 
group with high expression of these genes (n=321) (Fig. 3A). Consistent with the upregulation 
of these signature genes in response to SNAI2 depletion, the patient group represented by 
the cluster with high expression showed a significantly longer event-free survival when 
compared to patients in the low expression cluster (Fig. 3B). While the predictive value of the 
SNAI2 gene signature was highly significant in the subset of 401 patients without MYCN 
amplification (Fig 3C and Sup. Fig. 4A), the signature lacked statistical significance in patients 
with MYCN amplification, the strongest cytogenetic predictor of outcome in neuroblastoma, 
nor in patients diagnosed with stage 4 disease (data not shown). Similar results were obtained  
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in a second, independent micro-array based cohort representing 649 primary neuroblastomas 
[28] as well as the RNAseq based dataset corresponding to the SEQC micro-array dataset [27] 
(Fig. 3D-F and Sup. Fig. 4B-D). 
While the SNAI2-dependent gene expression signature had no additive predictive value in 
stage 4 patients and patients with a MYCN amplification, both MYCN amplification as well as 
increasing stage corresponded with a lower SNAI2 signature score indicative of a lower 
expression of genes present within the signature (Sup. fig 5 A-F). Moreover, given the lack of 
predictive value of the signature in patients with a MYCN amplification, we tested whether 
the signature might, at least in part, represent a MYCN signature. However, comparison of 
the SNAI2-dependent signature with two published neuroblastoma MYCN signatures only 
revealed a minimal overlap (Sup. Fig. 5G&H). Together, our results indicate that repression of 
this SNAI2-dependent  gene expression program is associated with an unfavorable outcome.  
 
SNAI2 promotes 3D invasion and dissemination of neuroblastoma cells 
The correlation between SNAI2 activity and event-free survival, and the prominent role of 
SNAI2 in neural crest delamination and migration [29-31], suggest that SNAI2 contributes to 
neuroblastoma progression by controlling migration and invasion of neuroblastoma cells. To 
simulate neuroblastoma tumor growth and dissemination in a 3D environment that reflects 
the in vivo situation, we evaluated the ECM composition of mouse adrenal glands, given that 
the majority of the human primary neuroblastomas arise at the adrenal gland [1]. In line with 
previous reports [32, 33], we identified collagen I and collagen IV as the major ECM 
components of the adrenal gland (Fig 4A). We subsequently set up multi-cellular spheroid 
(MCS) cultures in collagen-based 3D matrices. MCSs of SH-SY5Y SNAI2 gRNA and control cells, 
produced using the hanging drop method [34], were embedded in the organotypic 
collagen-based matrices and allowed to invade the 3D matrix (Fig. 4B). Depletion of SNAI2 
significantly increased tumor border regularity of the multicellular spheroids, by interfering 
with the formation of multicellular invasive strands (Fig. 4C&D). Moreover, SNAI2 gRNA 
spheroids presented with significantly less single cell invasions compared to MCSs derived 
from control cells (Fig. 4E). In contrast, SNAI2 over-expression in SH-SY5Y neuroblastoma cells 
significantly increased the irregularity of the invasive front of MSCs, which coincided with a 
marked increase in the number of invasive strands and single cell invasions (Fig. 4F-I). Taken  
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Figure 4. SNAI2 promotes local 3D invasion and dissemination of neuroblastoma cells. (A) Confocal imaging of mouse 
adrenal gland samples stained for the nucleus and collagen type I and type IV, revealed the abundant presence of type I 
collagen fibers (left panel) and basal membrane component type IV collagen (right panel) in both the medulla and cortex. 
Scale bar = 100 μm. Representative immunofluorescence max projections and quantifications of multicellular spheroids of 
(B-E) SH-SY5Y control and SNAI2 gRNA cells, and (F–I) SH-SY5Y control and SNAI2 over-expressing cells, respectively 10 and 
7 days after embedding in the 3D collagen-based matrix. Spheroids were fixed at designated time points and stained for 
the cytoskeleton using phalloidin and the nucleus using Dapi. Note the enhanced circular shape of SNAI2 gRNA spheroids 
and increase in single cell invasions and invasive strands of SNAI2 over-expression spheroids. Scale bar = 100 μm. 
Quantitative analysis of (C-E) SNAI2 gRNA and (G-I) SNAI2 over-expression spheroids. (C&G) Tumor border regularity 
(circularity) is calculated based on the perimeter of the spheroid relative to the area (see material and methods). Number 
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together, these results indicate that SNAI2 promotes local 3D invasion and dissemination of 
neuroblastoma cells.   
Loss of SNAI2 reduces metastatic spread of neuroblastoma cells in vivo 
During development, SNAI2 is essential for the survival of neural crest cells outside of the 
neural crest niche [22, 35]. Therefore, we investigated whether SNAI2 contributes to anoikis 
resistance in neuroblastoma cells. Consistent with the more differentiated phenotype we find 
upon SNAI2 depletion, reduced SNAI2 expression hampered the ability of SH-SY5Y, LAN-5 and 
N1E-115 cells to grow out in soft agar colony formation assays when compared to their 
control counterparts (Fig 5A-C). In contrast, overexpression of SNAI2 enhanced the number  
of invasive strands (D&H) and single cell invasions (E&I) of multicellular spheroids in response to SNAI2 expression levels. 
Data are from at least n=15 spheroids/cell line and presented as box and whisker (5-95 percentile) plots. * p < 0.05, ** p < 
0.01, ***p < 0.001, two-tailed unpaired t-test with Welch’s correction. 
 
Figure 5. SNAI2 enhances anchorage-independent growth of neuroblastoma cells. Quantification of soft agar colony 
formation by (A) SH-SY5Y control vs. SNAI2 sgRNA, (B) LAN-5  control vs. SNAI2 shRNA, (C) N1E-115 control vs. SNAI2 gRNA 
cells, and (D) SH-SY5Y control vs. SNAI2 over-expression cells 21 days after single cell seeding in a 1% agarose gel. Data 
represents mean number of colonies per experiment (n=3 independent experiments performed in triplo). * p < 0.05, ** p 
< 0.01, ** p < 0.01, *** p < 0.001. 
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Figure 6. Loss of SNAI2 reduces in vivo colonization and growth of neuroblastoma cells. (A) Representative 
bioluminescent images of mice 32 days after intravenous injections with SH-SY5Y control or SNAI2 gRNA cells (n = 10 mice 
in each group, divided over 2 independent experiments that show highly reproducible results). Photon fluxes are set to 
the same scale (photons/s/cm2/sr). (B) Quantification of bioluminescence between day 7 and day 32 post-injection. Data 
are modelled using a Linear Mixed effects model (see material and methods). Data are mean ± SEM of n=10 mice per 
group. (C) Representative images of livers of mice intravenously injected with SH-SY5Y control or SNAI2 gRNA cells at day 
32. (D) Quantification of liver weight at day 32 post-injection. (E) Quantification of number of liver tumors per mouse, 
measured in resected liver tissue from mice injected with SH-SY5Y control or SNAI2 gRNA cells. (F) Quantification of mean 
liver tumor size in mice injected with SH-SY5Y control or SNAI2 gRNA cells. Data are mean ± SEM of n=10 livers/group for 
control and gRNA#2 and n=9 livers for gRNA#1). ***p < 0.001, two-tailed unpaired t-test with Welch’s correction. (G) 
SNAI2 protein expression in SH-SY5Y control and SNAI2 gRNA cells pre-injection, and resected liver tumors of mice 
injected with SH-SY5Y control or SNAI2 gRNA cells, determined by Western blotting. The additional SNAI2 bands in the 
tumor samples most likely represent additional post-translational modifications that occur in vivo.  
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of colonies (Fig. 5D), indicating that SNAI2 promotes anchorage-independent growth of 
neuroblastoma cells.  
To further substantiate these findings, we performed tail vein injections of luciferase 
expressing SH-SY5Y neuroblastoma cells in NOD-scid IL2Rgammanull (NSG) mice. Pilot 
experiments revealed that similar to human primary neuroblastoma [1], SH-SY5Y cells 
selectively colonized the adrenal medulla, liver and bone marrow (Sup. Fig. 6A-C), while no 
infiltration in the lungs was seen. Tumor cell dissemination of intravenously injected SH-SY5Y 
neuroblastoma SNAI2 gRNA and control gRNA cells was monitored by non-invasive 
bioluminescence imaging. Bioluminescence could be observed from 7 days post-injection 
onwards, increasing over time, indicating survival and colonization of the injected cells (Fig. 
6A&B). The bioluminescence signal observed in the SH-SY5Y SNAI2 gRNA injected mice was  
significantly lower from day 14 (gRNA#2) and day 17 (gRNA#1) onwards, as determined by 
using a Linear Mixed-effects model. Upon autopsy of the sacrificed mice, we observed a 
marked increase in liver size and weight of livers derived from mice injected with control gRNA 
cells (Fig. 6C&D). Image analysis of liver paraffin sections revealed that the number of tumors 
was significantly higher in mice injected with control cells vs. mice injected with SNAI2 gRNA 
cells (Fig. 6E), consistent with the premise that SNAI2 expression promotes survival of tumor 
cells at ectopic sites. Although proliferation of SNAI2 depleted SH-SY5Y was not affected in 
vitro (Sup. Fig. 6D&E), tumors derived from SNAI2 gRNA cells were significantly smaller (Fig. 
6F), indicating that SNAI2 depletion also hampers tumor growth in vivo.  
Given the fact that the injected pool of SNAI2 gRNA cells showed heterogeneous expression 
of SNAI2, the tumors appearing in the SNAI2 knockout pools may represent cells that 
managed to maintain sufficient levels of SNAI2 expression. Indeed, all tumors derived from 
either control or gRNA cell injected mice expressed SNAI2 protein, indicating that only 
SH-SY5Y cells expressing SNAI2 are able to colonize the liver (Fig. 6G). Unexpectedly, we 
observed that also in the control cells, expression of SNAI2 was significantly higher in SH-SY5Y 
cells isolated from liver metastasis when compared to cells prior to injection (Fig. 6G). 
Although we cannot rule out that specific interactions between the tumor cells and the liver 
microenvironment contribute to this effect, our results suggest that high expression of SNAI2 
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SNAI2 depletion sensitizes neuroblastoma cells to retinoic acid 
In a variety of neuroblastoma cell lines, exposure to the vitamin A metabolite retinoic acid 
(RA) leads to a proliferation arrest, terminal differentiation and the induction of apoptosis. 
Moreover, RA is used in the clinic to treat minimal residual disease [36, 37]. Given the 
observation that loss of SNAI2 expression promotes differentiation, we tested whether 
reduced expression of SNAI2 would enhance the sensitivity of neuroblastoma cells to RA. 
Indeed, proliferation of SNAI2 gRNA cells was strongly reduced and reached a plateau when 
SNAI2 gRNA cells were treated with 1 µM of RA, whereas proliferation of SH-SY5Y control cells 
 
Figure 7. SNAI2 controls retinoic acid sensitivity of neuroblastoma cells. (A) Representative images of SH-SY5Y control and 
SNAI2 gRNA cells grown in the absence or presence of RA (1 µM). Cells were fixed, stained and photographed after 10 days. 
(B) Proliferation curves of SH-SY5Y control and SNAI2 gRNA cells in the presence or absence of 1 µM RA over the period of 
56 days. (C) Representative images of LAN-5 control and SNAI2 shRNA cells grown in the absence or presence of RA (1 µM). 
Cells were fixed, stained and photographed after 14 days. (D) Quantification of cell number of LAN-5 control and SNAI2 
shRNA cells after 14 days in the presence or absence of 1 µM RA. Data represent mean number of cells ± SEM (n=3). (E) 
Representative images of mouse N1E-115 control and SNAI2 gRNA cells grown in the absence or presence of RA (10 µM). 
Cells were fixed, stained and photographed after 10 days. (F) Quantification of cell number of mouse N1E-115 control and 
SNAI2 gRNA cells after 10 days in the presence or absence of 10 µM RA. Data represent mean number of cells ± SEM (n=4). 
** p < 0.01, as determined by t-test with Welch’s correction. 
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was only marginally inhibited (Fig. 7A&B). Similar effects were observed in LAN-5 SNAI2 
shRNA cells (Fig. 7C&D) and mouse N1E-115 neuroblastoma cells expressing mouse specific 
SNAI2 gRNA’s (Fig. 7E&F). In contrast, SNAI2 overexpression in SH-SY5Y neuroblastoma cells 
slightly enhanced basal proliferation rates, but did not significantly enhance RA resistance of 
these cells (Sup. Fig. 7). As basal SNAI2 protein levels may be correlated to response to RA, 
we determined the SNAI2 protein expression in a panel of neuroblastoma cell lines and 
compared this with the effect of RA on proliferation. However, we did not find a consistent 
relation between basal SNAI2 protein levels and RA sensitivity (Sup. Fig. 8 A-C), nor did we 
find evidence that SNAI2 expression is repressed in response to RA (Sup. Fig. 8D). We conclude 
from these data that while SNAI2 depletion enhances the response of our neuroblastoma 
models to RA, its expression does not appear to be subject to regulation by RA.   
 
Discussion 
The transcriptional repressor SNAI2 is a key determinant of neural crest development [15] 
and its expression has been linked to tumor progression and therapy resistance in a variety 
of tumor types [17-20]. By RNA sequencing we observed that targeted deletion of SNAI2 leads 
to derepression of a gene expression program involved in neuronal differentiation. Consistent 
with the fact that overall survival of neuroblastoma patients is dependent on the 
differentiation status of the tumor [38], high expression of these SNAI2 responsive genes is 
correlated with an increased event-free survival probability in two independent 
neuroblastoma patient cohorts. Consistently, MYCN amplification as well as increased stage 
correspond to a lower expression of the SNAI2-dependent gene expression program. While 
this SNAI2-dependent gene signature is highly predictive in non-MYCN amplified tumors, the 
signature has no additive predictive value in MYCN amplified tumors, which was to be 
expected as MYCN-amplification is already strongly predictive of poor outcome.  
Although the SNAI2-dependent gene signature corresponds well with event-free survival, 
SNAI2 mRNA expression itself does not. Therefore, we postulate that SNAI2 protein level or 
activity rather than mRNA expression determines outcome. Consequently, activation of a 
SNAI2-dependent gene expression program may be controlled by regulating SNAI2 protein 
expression or activity.  In line with such a mode of action, it was shown that phosphorylation 
of specific residues can alter SNAI2 activity or mark the protein for ubiquitination and 
proteasomal degradation [39-41].  
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Although we cannot rule out a role for other members of the SNAI family in neuroblastoma 
pathogenesis, we have focused our studies on SNAI2, based on our previous studies involving 
the channel kinase TRPM7 that showed that expression of SNAI2, but not that of other SNAI 
family members, was correlated with neuroblastoma self renewal and metastasis formation 
[21]. Consistent with a role for SNAI2 as a regulator of stemness, cell survival, and cell motility, 
we observed that SNAI2 expression is essential for maintaining neuroblastoma 
anchorage-independent growth as well as the ability to disseminate and invade in vitro and 
metastasize in vivo. In fact, all tumors isolated from mice injected with SH-SY5Y SNAI2 gRNA 
cell pools were found to express SNAI2 protein, suggesting that only cells having functional 
SNAI2 protein expression were able to survive in vivo. Strikingly, also in tumors from mice 
injected with SH-SY5Y control cells expression was higher than in the injected cell pool, 
suggesting that high SNAI2 expressing cells within this population have a selective growth 
advantage in vivo. 
In high-risk neuroblastoma patients, RA is used as an adjuvant to differentiate or eliminate 
remaining tumor cells after intensive multimodal therapy [5]. However, many patients fail to 
respond to the differentiation-inducing effects of this drug [3, 4]. While no direct link has been 
described between RA signaling and SNAI2, it was shown that SNAI2 expression is 
downregulated in response to RA during embryonic development [42, 43]. Although we did 
not find that RA modulates SNAI2 expression, targeted deletion of SNAI2 strongly sensitizes 
both human MYCN-amplified LAN-5 and non-MYCN amplified SH-SY5Y cells [44] as well as 
mouse N1E-115 neuroblastoma cells to RA-induced growth inhibition. However, as the gene 
expression changes observed in response to RA treatment were highly cell type specific, we 
were unable to define uniform SNAI2 responsive genes responsible for repressing the 
response to RA. Moreover, forced SNAI2 over-expression did not further enhance resistance 
of the SH-SY5Y cell line to RA. Since SNAI2 is part of large transcriptional complexes[45-51], 
forced expression of SNAI2 may lead to a stoichiometric imbalance between SNAI2 and its 
binding partners [52]. As a consequence, SNAI2 overexpression may not be sufficient to fully 
reproduce the responses seen in reaction to physiologically enhanced expression or activity 
of SNAI2. Nevertheless, our data indicate that targeting (regulators of) SNAI2 in 
neuroblastoma may reduce malignant behavior and promote the response to RA-therapy. 
While no specific inhibitors are currently available for SNAI2, recent studies have identified 
SNAI2 as part of different transcriptional complexes. For instance, a physical and functional 
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interaction has been described for SNAI2 with the transcriptional co-activators YAP and TAZ 
[45, 46]. Moreover, inhibition of SNAI2 function using a p53-SNAIL binding inhibitor mimics 
SNAI2 knockdown and reduces growth of therapy resistant ER+ breast cancer cells [47]. 
Additionally, the SNAG repressor-domain of SNAI2 was found to interact with the 
chromatin-modifying proteins, such as lysine specific demethylase 1 (LSD1) [48, 49]. Blocking 
the interaction between SNAI2 and LDS1 by using the LSD1 inhibitor Parnate, or by means of 
a cell-permeable peptide targeting the SNAG domain of SNAI2, significantly suppressed the 
malignant behavior of a variety of tumor cell types [50]. Moreover, LSD1 inhibition using 
Parnate was shown to reactivate RA-induced differentiation in acute myeloid leukemia [51]. 
However, in our hands targeting SNAI2 by LSD1 inhibition, using the LSD1 inhibitor 
GSK2879552, did not measurably enhance the response of SH-SY5Y neuroblastoma cells to 
RA (data not shown). Therefore, future research should focus on identifying targetable SNAI2 
interactors in neuroblastoma cells to effectively inhibit SNAI2 mediated repression and 
enhance RA-mediated growth inhibition. 
While SNAI2 has mainly been described as an EMT-activating transcription factor, we have 
found no evidence that depletion of SNAI2 influences the expression of canonical epithelial 
or mesenchymal markers, or results in a more epithelial-like morphology in our 
neuroblastoma cell models. Our results, on the other hand, do indicate that SNAI2 promotes 
malignant behavior of neuroblastoma cells by maintaining a progenitor-like transcriptional 
program in neuroblastoma cells. Hence, interfering with differentiation by activation of 
developmental programs may thus contribute to neuroblastoma disease progression. 
Consistently, targeting regulatory networks that control these developmental programs may 
help promote neuroblastoma differentiation and enhance response to therapy. For instance, 
recent studies have shown that ALKF1174L driven neuroblastomas develop resistance to ALK 
inhibitors by activation of AXL [53], a tyrosine kinase that promotes EMT. Inhibition of AXL 
using small-molecule inhibitors strongly increased the sensitivity of ALK mutated 
neuroblastoma cells to treatment [53, 54]. Going forward, future efforts should determine to 
what extend targeting regulatory networks controlling developmental programs, such as 
those interfering with SNAI2 function, can revert therapy resistant neuroblastoma to a more 
differentiated, therapy responsive phenotype.  
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Materials and Methods 
Cell lines 
Human SH-SY5Y, SK-N-AS and mouse N1E-115 cell lines were obtained from ATCC (#ATCC® CRL-2266™, RRID: 
CVCL_0019; #ATCC® CRL-2137™ RRID: CVCL_1700 and #ATCC® CRL-2263™, RRID CVCL_0451). Human LAN-5 and 
IMR-32 cells were derived from DSMZ (#ACC 673, RRID: CVCL_0389 and #ACC 165, RRID: CVCL_0346). The SH-
EP2 cell line was obtained from J. Molenaar, Princess Máxima Center, Utrecht, The Netherlands.  All cell lines 
were cultured according to the guidelines described by ATCC and DSMZ in a humidified incubator at 37 °C and 
5% CO2. The SH-EP2 cell line was cultured as described previously [21]. 
 
Generation of cell lines 
To generate SNAI2 knockout cell lines, control and SNAI2 gRNAs (see Supplementary Table 1 for sequences) 
were transduced in SH-SY5Y and N1E-115 cells using the lentiviral expression vector pLentiCRISPRv1. To generate 
knockdown cell lines, non-targeting control and SNAI2 shRNAs (obtained from Dr. R. Beijersbergen at The 
Netherlands Cancer Institute - Screening and Robotics Facility) (see Supplementary Table 1 for sequences) were 
transduced into LAN-5 cells using the pLKO lentiviral expression vector according to manufacturer's instructions 
(Sigma-Aldrich). Cells were selected using 1 μg/ml puromycin. For bioluminescent imaging, SH-SY5Y control and 
SNAI2 gRNA cells were co-transduced with a retroviral pLZRS luciferase reporter construct [21] and selected with 
250 µg/mL Zeocin. Stable overexpression of SNAI2 was obtained by transducing SH-SY5Y cells with 
pPGS-hSLUG.fl.flag (a gift from Eric Fearon (Addgene plasmid #25696)). Cells were selected using 1 mg/mL G418. 
 
Cell proliferation and viability 
The effect of SNAI2 expression levels on cell viability and proliferation was assessed by MTS assays using 
CellTiter® 96 Aqueous One Solution Reagent (#G3580, Promega) according to manufacturer’s instructions. 
Absorbance was acquired using a plate reader (Infinite F50, TECAN). 
 
Quantitative real time PCR 
Total mRNA isolation using an RNeasy minikit (#74106, Qiagen) was followed by cDNA synthesis using an iScript 
cDNA synthesis kit (#170-8891, Bio-Rad) according to manufacturer’s protocol. q-PCR reactions were performed 
using SsoAdvanced™ Universal SYBR® Green Supermix (#1725274, Bio-Rad) on a CFX96 Touch™ Real-Time 
System (Bio-Rad) using PCR conditions as supplied by Bio-Rad. Expression levels were normalized against the 
housekeeping gene GAPDH and calculated according to the 2−ΔΔCt method [55]. For q-PCR primer sequences, see 




PCR and mutational analyses 
Genomic DNA was isolated using DNeasy Blood & Tissue kit (#69504, Qiagen). SNAI2 target regions were 
amplified by PCR using FastStart™ Taq DNA Polymerase (#12032937001, Roche). For PCR primer sequences, see 
Supplementary Table 1. PCR products were analyzed by Sanger sequencing and subjected to mutational analysis 
using Surveyor® mutation detection kit (#706020, IDT) according to manufacturer’s protocol. 
 
Western blotting 
Lysates were prepared as described earlier [56]. Proteins were separated by SDS-PAGE and blotted onto 
nitrocellulose membranes. Non-specific binding was blocked with 1% Fatty acid free BSA (#P6156, Bio-West) for 
SNAI2 blots or 2% skim milk for γ-tubulin blots diluted in TBS + 0.1% Tween-20 (TBST). Proteins were detected 
by immunoblotting using anti-SNAI2 (1:1000, #9585, Cell Signalling Technology, RRID:AB_2239535) and anti-γ-
tubulin (1:10.000, #T6557, Sigma-Aldrich, RRID:AB_477584) followed by HRP-conjugated secondary antibodies 
(1:5000, Dako) or IRDye® 800CW and 680RD secondary antibodies (1:2000, LICOR). When HRP-conjugated 
secondary antibodies were used, proteins were visualized using ECL detection agent (#RPN2232, Amersham GE 
Healthcare) and detected using a Fluorchem E Digital Darkroom (Proteinsimple). In the case of IRDye-conjugated 
antibodies, membranes were scanned using an Odyssey CLx Near-Infrared Fluorescence Imaging System 
(Biosciences). 
 
RNA sequencing analysis 
RNA sequencing and differential expression analysis of SH-SY5Y SNAI2 control and gRNA cells was performed by 
GenomeScan B.V. (Leiden, The Netherlands) on triplicate samples.  
Sample preparation – RNA samples of SH-SY5Y SNAI2 control and gRNA cells were prepared and analyzed as 
three independent experiments. mRNA was purified from cell cultures using an RNeasy minikit (#74106, Qiagen) 
with on column DNAse (#79254, Qiagen) treatment. Quality and integrity of the RNA was determined using 
Fragment AnalyzerTM (Advanced Analytical Technologies). Samples were processed using the NEBNext® UltraTM 
Directional RNA Library Prep kit for Illumina® (#E7420S, NEB) according to manufactures instructions. In short, 
after isolation of mRNA from total RNA using the oligo-dT magnetic beads, mRNA was fragmented and cDNA 
synthesis was performed for ligation with the sequencing adapters and PCR amplification of the resulting 
product. Quality and yield were measured with the Fragment AnalyzerTM. Clustering and DNA sequencing using 
the Illumina cBot and HiSeq 4000 was performed according to manufacturer’s protocols using DNA 
concentrations of 3.0 nM.  
Primary data analysis - Image analyses, base calling, and quality check was performed using the Illumina data 
analysis pipeline RTA v2.7.7 and Bcl2fastq v2.17 (Illumina). 
Adapter clipping - Prior to alignment, reads were trimmed for adapter sequences using Trimmomatic v0.30. 
Presumed adapter sequences were removed from the read when the bases matched a sequence in the adapter 
sequence set (TruSeq adapters) with 2 or less mismatches and an alignment score of at least 12. All forward and 
reverse reads were pooled for each sample after trimming.  
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Mapping of reads - Reads were mapped to the reference sequence, GCCh37.75 reference for Homo sapiens, 
using a short read aligner based on the Burrows-Wheeler Transform. The default mismatch rate of 2% was used. 
Frequency of reads mapping to a transcript was determined based on the mapped locations.  
RNAseq data have been submitted to the NCBI Gene Expression Omnibus database, accession code: GSE126332. 
Differential expression analysis was performed with the read counts using the DESeq package v 1.10.1 on the R 
platform v2.15.3. Genes were considered differentially expressed when their 2log fold change ≥ |2|with a P < 
1E-6. Statistical significance of overlapping up- and downregulated genes in SH-SY5Y gRNA#1 and gRNA#2 was 
determined by means of a Fisher’s Exact test. GO-term analysis was performed using PANTHER 
(http://www.pantherdb.org/geneListAnalysis.do; GO Ontology database Released 2019-07-03) on genes that 
were differentially upregulated in both gRNA cell lines.  
 
3D multicellular spheroid invasion assays 
Multicellular spheroids of SH-SY5Y cells were generated using the hanging drop method [57]. Cells were plated 
at a density of 1500 cells/drop in culture medium supplemented with 4% methyl cellulose solution (#M6385, 
Sigma-Aldrich) and allowed to aggregate o/n in a humidified incubator at 37°C and 5% CO2. Spheroids were 
washed in PBS and mixed in a Collagen-Matrigel®-solution consisting of non-pepsinized rat-tail collagen type I 
(#354249, Corning, 3.3 mg/mL), Matrigel® (#356231, Corning, 21 µg/mL), Minimum Essential Medium α (# 
41061029, Gibco, 5%) buffered with 2,5% bicarbonate. Collagen-spheroid mixtures were pipetted as a drop-
matrix and left to polymerize at 37 °C. Spheroid-containing collagen lattices were maintained in a humidified 
incubator at 37 °C and 5% CO2 for 7-10 days. 
 
Immunofluorescence 
For visualization of neurite-like protrusions and quantification of protrusion length, SH-SY5Y cells were cultured 
o/n on fibronectin (1 mg/mL, Roche) coated glass coverslips. Coverslips were fixed (3.7% formaldehyde) washed 
and stained using β-Tubulin antibodies (1:1000, #T4026, Sigma-Aldrich, RRID:AB_477577) and phalloidin 
Alexa-Fluor 568- (1:200, #A12380, Molecular Probes) and anti-mouse Alexa-Fluor 488-conjugated antibodies 
(1:1000, #A-11001, Life Technologies, RRID:AB_2534069). Images were taken on a Leica TCS SP5 (Leica 
Microsystems) equipped with a 63× water-immersion objective or 20× dry objective and LAS-AF acquisition 
software (Leica Microsystems). Images were processed for publication and analyzed using ImageJ 1.49b. For 
neurite length and percentage of cells with neurites at least 250 cells/ experiment were quantified from 3 
independent experiments. Analyses of neurite length were done using NeuronJ plugin in ImageJ 1.49b. 
Spheroids in 3D collagen matrices were fixed (3.7% formaldehyde) washed and stained using Alexa-Fluor 
568-conjungated phalloidin (1:100, #A12380, Molecular Probes) and DAPI (1:3000, #D1306, Molecular Probes, 
RRID:AB_2629482). Spheroids were imaged on an Olympus FV1000 confocal laser scanning microscope 
equipped with a 20×/0.50 NA long working distance, water immersion objective. Z-stacks were generated from 
images taken at 5 µm intervals. Maximum intensity z-projections were used to quantify the number of invasive 
strands, single cell invasions, and spheroid area and perimeter using ImageJ 1.49b. Tumor border circularity was 





Mouse kidneys with adrenal glands were fixed in 4% PFA for 24 h at 20°C, after which thick tissue slices (200 μm) 
were obtained by vibratome sectioning (Leica, VT1000s). After antigen retrieval in Tris-EDTA buffer (pH 9) for 7 
min at 97 °C, tissue slices were incubated with primary human-specific Nestin (1:500; #ABD69, Millipore, 
RRID:AB_2744681), Collagen I (1:200, #ab34710, Abcam, RRID:AB_731684) or Collagen IV (1:200, #PA1-28534, 
Sigma-Aldrich, RRID:AB_1956972) antibodies followed by Alexa-Fluor 488-conjugated goat anti-rabbit (cross-
adsorbed, 1:200, #A-11008, Thermo Fisher Scientific, RRID:AB_143165) secondary antibodies and DAPI (4’,6-
diamidino-2-phenylindole; 2.5 μg/ml, #10236276001, Roche Diagnostics). Confocal microscopy (Olympus 
FV1000) was performed using 20×/0.50 NA and 40×/0.80 NA long working distance objectives. 
 
Soft agar colony assay 
35 mm dishes were coated with a base layer of culture medium with 1% UltraPure™ Low Melting Point Agarose 
(#16520050, Invitrogen) in PBS. SH-SY5Y and LAN-5 cells were seeded as single cells at a density of 15.000 cells 
per dish in culture medium containing 0.4% UltraPure™ Low Melting Point Agarose for 21 and 28 days, 
respectively. N1E-115 cells were seeded at a density of 2500 cells per dish for 16 days. After incubation for the 
indicated number of days, colonies were counted manually. Experiments were performed 3 times in triplicate.  
 
Retinoic acid assays 
Cells were seeded in 35 mm dishes (SH-SY5Y: 6.5·104, LAN-5: 1.0·105) or 6 wells plates (SH-SY5Y, SK-N-AS and 
SH-EP2: 3.0·104, IMR-32 and LAN-5: 1.0·105) in the presence of 0.1 and/or 1 µM retinoic acid (#R2625, 
Sigma-Aldrich) or vehicle control DMSO (#1029521011, Merck) for the indicated time points. N1E-115 cells were 
pre-treated with 0.1, 1 and/or 10 µM retinoic acid or vehicle control for 4 days in medium containing 2% FCS, 
after which treatment was continued for 2.5·104 cells in 35 mm dishes or 1.5·104 cells in 6 well plates for 6 days. 
Medium was replaced every 4-5 days. After the incubation period samples were either fixed, stained with crystal 
violet and photographed or harvested and counted. For long term proliferation assays, 7.5·104 SH-SY5Y cells 
were seeded into 6 well plates in triplicate in the presence of retinoic acid (#R2625, Sigma-Aldrich) or vehicle 
control DMSO (#1029521011, Merck). Medium was refreshed every 4-5 days. Cells were counted when passaged 
and reseeded at a density of 7.5·104 cells per well. To determine the effect of retinoic acid on SNAI2 protein 
levels, cells were seeded in 6 wells plates (SH-SY5Y and SK-N-AS: 3.0·105, IMR-32 and LAN-5: 5.5·105, and SH-EP2 
and N115: 1.5·105) in the presence of 0.1, 1 and 10 µM retinoic acid or vehicle control DMSO. After an incubation 
period of 4 days, protein lysates were harvested as described earlier [56]. 
 
Mouse xenograft experiments 
Mouse xenograft experiments were carried out in accordance with protocols approved by the Radboud 
University’s Animal Experiment Committee (DEC-2014-004). Trypsinized SH-SY5Y cells were washed 3 times with 
PBS. 200 µL PBS containing 5·105 cells were injected into the tail vein of female NOD-scid IL2Rgammanull gamma 
(NSG) mice of 8-10 weeks. The amount of cells injected was analyzed 3 h post-injection by bioluminescence 
imaging. Tumor growth was followed using bioluminescence imaging. To this end, animals were anaesthetized 
with 2–3% isoflurane and a solution of 200 µL sterile PBS containing 3.6 µg XenoLight D-Luciferin - K+ Salt 
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Bioluminescent Substrate (#122799, Perkin Elmer) was injected i.p.. Light emission was measured 10 min later, 
using a cooled CCD camera (IVIS; Xenogen) coupled to Living Image acquisition and analysis software over an 
integration time of 1 min. Signal intensity was quantified as the Flux (photons/s) measured over the whole 
mouse. Mouse Xenograft bioluminescence data was log transformed, after which it was analyzed using a Linear 
Mixed-effects model, where the factors ‘experimental group’, ‘time’ and ‘experimental group*time’ were fixed 
factors and the mouse identifier was the random factor.  
Organs and tissues were collected at day 32 after injections. Tumors were excised from one liver per group to 
prepare protein lysates as described [56]. Adrenal glands and kidneys were fixed in 4% paraformaldehyde for 24 
h, while other organs and tissues were fixed in 4% buffered formaldehyde. All organs were stored in 70% EtOH. 
For quantification of tumor size and number in the liver, the large lobs of the livers were sliced transversally in 
4 parts, serial embedded in paraffin and 5 µm sections were cut and stained with a standard Haematoxylin and 
Eosin staining (H&E). Four liver sections per animal were quantified using Pannoramic Viewer software 1.15.4 
(3DHISTECH Ltd.).  
 
Gene-expression dataset analyses 
A predictive gene-signature, based on genes upregulated in response to SNAI2 depletion, was established using 
the k-means clustering module of the R2 genomics analyses and visualization platform (department of 
Oncogenomics, Academic Medical Center of the University of Amsterdam (http://r2.amc.nl)). K-means 
clustering was performed using two independent neuroblastoma patient cohorts (SEQC-498; GSE49710 [27] and 
Kocak-649; GSE45547 [28]) based on the expression values of the upregulated genes. Limited by the availability 
of probes in both datasets, only 152 out of the 173 upregulated genes were included in signature (Sup Table 4). 
The number of draws was set to 10×10. Heatmaps represent z-score normalized expression. Survival curves 
based on the clusters were generated using event-free survival (EFS) as endpoints.  
 
Statistical analyses  
Data are presented as mean ± SEM, unless stated otherwise. Statistics on q-PCR data were performed using 
one-sample t-test and fold changes in expression were presented relative to control levels. Other statistical 
analyses were performed using the student’s t-test, unless stated otherwise. All statistical tests were two-sided 
and p values <0.05 were considered statistically significant. 
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Supplementary figure 1. Manipulation of SNAI2 expression in human SH-SY5Y, human LAN-5 and mouse N1E-115 cells. 
(A) Schematic representation of the targeting locations of human SNAI2 gRNA#1 and gRNA#2 on the human SNAI2 gene. 
(B) Sanger sequencing (left) and Surveyor nuclease assay (right) results of exon 1 of SH-SY5Y control and gRNA#1 cells 
indicating efficient targeting of exon 1 by gRNA#1. (C) Sanger sequencing (left) and Surveyor nuclease assay (right) results 
of exon 2 of SH-SY5Y control and gRNA#2 cells indicating efficient targeting of exon 2 by gRNA#2. (D) Protein expression 
of SNAI2 after stable expression of control and SNAI2 gRNA’s in SH-SY5Y cells, determined by Western blotting. 
Representative example of n=3 experiments. (E) Protein expression of SNAI2 after stable overexpression of FLAG-tagged 
SNAI2 in human SH-SY5Y cells, determined by Western blotting. Representative example of n=3 experiments. (F) Human 
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SNAI2 mRNA expression in human LAN-5 control and SNAI2 shRNA cells, determined by quantitative RT-PCR (left). Human 
SNAI2 expression in the control cells is set to one. Values are depicted as mean ± SEM (n=3). ** p < 0.01, ***p < 0.001. 
(Right) Protein expression of SNAI2 after stable expression of SNAI2 shRNA’s in human LAN-5 cells, determined by Western 
blotting. Representative example of n=3 experiments. (G) Protein expression of SNAI2 after stable expression of control 




Supplementary figure 3. Efficient targeting of SNAI2 in SH-SY5Y cells using 2 independent guideRNA’s results in strong 
concordance in differentially expressed genes. (A) Log2 fold changes of overlapping differentially expressed genes in 
SH-SY5Y SNAI2 gRNA cells as determined by RNAseq using DESeq v1.10.1 algorithm for analyses. A log2 fold-change ≥|2| 
and p < 1E-6 were used as cut-off values. Data represents mean log2 fold changes per differentially expressed gene (n = 
3). (B) Log2 fold changes of POU4F2, CHD5 and NRCAM in LAN-5 SNAI2 shRNA#1 and #2 cells compared to LAN-5 control 
shRNA cells as determined by qPCR. Data represents mean log2 fold changes ± SEM (n = 3). For qPCR data expression levels 
are normalized to GAPDH housekeeping gene expression. * p < 0.05, ***p < 0.001. 
 
Supplementary figure 2. siRNA mediated depletion of SNAI2 in LAN-5 cells similarly affects the expression of neuronal 
differentiation genes compared to SNAI2 knock out in SH-SY5Y cells. Relative mRNA expression of differentiation related 
genes in LAN-5 SNAI2 shRNA and control cells. mRNA expression in control cells is set to 1. Values are depicted as mean 
± SEM (n=3). * p < 0.05, ** p < 0.01, ***p < 0.001.  
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Supplementary figure 4. K-means clustering of non-MYCN amplified patients based on SNAI2 gene signature. (A) 
K-means clustering of micro-array expression data of a cohort of 401 primary neuroblastoma tumors without MYCN 
amplification based on the 152 genes present within the SNAI2 signature. Tracks represent the k-means result (blue and 
red), INSS stage (light green=stage 1, dark green=stage 2, yellow=stage 3, red=stage 4, blue=stage 4S), risk group (red = 
high risk, green = low risk) and MYCN amplification status (red = MYCN amplified, green = non MYCN amplified). Clustering 
result was identified in 7/10 k-means iterations. Track below represent signature score for SNAI2 signature. (B) K-means 
clustering of micro-array expression data of a cohort of 550 primary neuroblastoma tumors without MYCN amplification 
based on the 152 genes present within the SNAI2 signature. Tracks represent the k-means result (red and blue), INSS 
stage (light green=stage 1, dark green=stage 2, yellow=stage 3, red=stage 4, blue=stage 4S), risk group (red = high risk, 
green = low risk) and MYCN amplification status (red = MYCN amplified, green = non MYCN amplified). Clustering result 
was identified in 7/10 k-means iterations. (C) K-means clustering and accessory Kaplan Meier analyses of RNAseq 
expression data of a cohort of 498 primary neuroblastoma tumors based on the 125 annotated genes of the 152 genes 
present within the SNAI2 signature. Tracks represent the k-means result (blue and red), INSS stage (light green=stage 1, 
dark green=stage 2, yellow=stage 3, red=stage 4, blue=stage 4S), risk group (red = high risk, green = low risk) and MYCN 
amplification status (red = MYCN amplified, green = non MYCN amplified). Clustering result was identified in 7/10 k-means 
iterations. Track below represent signature score for SNAI2 signature. (D) K-means clustering and accessory Kaplan Meier 
analyses of RNAseq expression data of a cohort of 401 primary neuroblastoma tumors without MYCN amplification based 
on the 125 annotated genes of 152 genes present within the SNAI2 signature. Tracks represent the k-means result (blue 
and red), INSS stage (light green=stage 1, dark green=stage 2, yellow=stage 3, red=stage 4, blue=stage 4S), risk group (red 
= high risk, green = low risk) and MYCN amplification status (red = MYCN amplified, green = non MYCN amplified). 





Supplementary Figure 5. SNAI2-dependent gene expression signature score corresponds with severity of disease and does 
not overlap with MYCN signatures. (A-C) Box and whiskers plots of the SNAI2-dependent gene expression signature score 
in non-MCYN amplified vs. MYCN amplified patients in the micro-array datasets (A) SEQC and (B) Kocak as well as the (C) 
SEQC RNAseq dataset. Significance of the differences between the means were assessed by two-tailed unpaired t-test. (D-F) 
Box and whiskers plots of the SNAI2-dependent gene expression signature score in patient groups categorized by INSS stage 
in the micro-array datasets (D) SEQC and (E) Kocak as well as the (F) SEQC RNAseq dataset. Significance of the differences 
between the means were assessed by two-tailed unpaired t-test with Welch’s correction. (G & H) Comparison of SNAI2-
dependent gene expression signature with published neuroblastoma MYCN signatures. (G) Schematic representation of the 
overlap between genes within the SNAI2 signature and genes within a MYCN activity signature based on in vitro identified 
MYCN targets that correlate with MYCN expression in a neuroblastoma patient gene expression dataset [58]. (H) Schematic 
representation of the overlap between genes within the SNAI2 signature and genes within a MYCN activity signature based 
on the gene expression pattern associated with MYCN amplification in two neuroblastoma gene expression datasets [59].   
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Supplementary figure 6. Tail vein injected SH-SY5Y cells home to organs classically affected by human neuroblastoma 
cells and SNAI2 depletion does not affect the viability and proliferative capacity of SH-SY5Y cells. Schematic 
representation of (A) kidney, (B) liver, (C) bone marrow matched to bioluminescent images of the target organs 35 days 
after intravenous injection of NSG mice with SH-SY5Y cells. Scalebar = 5 mm. Effect of SNAI2 gRNA#1 and gRNA#2 on (D) 
viability and (E) proliferation of SH-SY5Y cells. Quantification of cell viability and proliferation was determined by MTS 
assays. Viability was assessed over 4 hours; proliferation was assessed over 4 days. Data represents normalized mean 




Supplementary figure 7. SNAI2 overexpression does not significantly enhance sensitivity of SH-SY5Y neuroblastoma 
cells to retinoic acid. (A) Representative images of SH-SY5Y control and SNAI2 overexpressing cells grown in the absence 
or presence of RA (1µM). Cells were fixed, stained and photographed after 10 days. (B) Proliferation curves of SH-SY5Y 






Supplementary figure 8. Basal SNAI2 protein expression does not correlate with response to Retinoic Acid, nor does 
retinoic acid show consistent effects on SNAI2 protein levels. (A) Protein expression of SNAI2 in a panel of neuroblastoma 
cell lines, as determined by Western blotting. Representative example of n=2 experiments is shown. (B) Representative 
images of neuroblastoma cell lines grown in the absence or presence of RA (0.1 or 1µM). Cells were fixed, stained and 
photographed after 10 days. (C) Quantification of cell numbers in a panel of neuroblastoma cell lines after 10 days in the 
presence of 0.1 or 1 µM RA relative to their DMSO vehicle treated controls. Data represent number of cells relative to 
DMSO vehicle treated controls ± SD (n=2). (D) Protein expression of SNAI2 in the same neuroblastoma panel after 4 days 
in the presence or absence of 0.1, 1 or 10 µM RA relative to their vehicle treated controls, as determined by Western 
blotting. Representative example of n=2 experiments is shown. 
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Supplementary Table 1 – gRNA, shRNA & primer sequences 
gRNA's Sequence (5'- 3') 
Control GTAGCGAACGTGTCCGGCGT 
SNAI2 gRNA#1 CGTTGAAATGCTTCTTGACC 
SNAI2 gRNA#2 GAGTAACTCTCATAGAGATA 
SNAI2 gRNA#1_mouse AAGTCCCATTAGTGACGAAG 







SNAI2 shRNA#2 CCCGTATCTCTATGAGAGTTA 
  
Primers qPCR  
ASCL1 Fwd GGAGCTTCTCGACTTCACCA 
ASCL1 Rev AACGCCACTGACAAGAAAGC 
CHD5 Fwd GATGGAGAATGAGGACGAGATG 
CHD5 Rev TCCGCTTCCCTTTACACTTG 
CNTNAP2 Fwd TCCCTCCACGTCCCAAAAATG 
CNTNAP2 Rev TCTTGGCATAGCCGGGAGAA 
DCX Fwd AAGCTTAGGTGCCTGCGTTA 
DCX Rev AAGGGGCACTTGTGTTTGTC 
GAP-43 Fwd GTGCCACTAAAGCTTCCACTG 
GAP-43 Rev GGGCACTTTCCTTAGGTTTGG 
GAPDH Fwd CTCCTCCACCTTTGACGCTG 
GAPDH Rev TCCACCACCCTGTTGCTGTA 
MAP2 Fwd AATAGACCTAAGCCATGTGACATCC 
MAP2 Rev AGAACCAACTTTAGCTTGGGCC 
NRCAM Fwd TCCAACCATCACCCAACAG 
NRCAM REV CCAGAGGGTCTTTATCGATGTC 
Pou4F2 Fwd CAGAGGCAGAAACAGAAAAGAATG 
Pou4F2 Rev CCAAAAGTGAAAAGAGGCAGAAG 
RAR-β Fwd AAACGTCTGCCTGGTTTCAC 
RAR-β Rev AAGGCCGTCTGAGAAAGTCA 
RET Fwd CGTGTACGACGAGGACGAC 
RET Rev TGATGCAGGTACCACGTCTG 
SNAI2 Fwd AAGCATTTCAACGCCTCCAAA 
SNAI2 Rev GGATCTCTGGTTGTGGTATGACA 
  
Primers PCR  
SNAI2 Exon1 Fwd (human) GGGAGGAGCTGAAATCTGAA 
SNAI2 Exon1 rev (human) AGCTCCCTTTCAGGACACTG 
SNAI2 Exon2 Fwd (human) ATGCCCTCCTAAATGGGTCT 




Supplementary Table 2 - Overlapping up- and downregulated genes in both SH-SY5Y SNAI2 
gRNA#1 and gRNA#2 compared to SH-SY5Y control cells in alphabetical order 
AC012065.7 CPLX2 HRH3 NFASC SERPINA5 
ACHE CPNE4 HRK NMNAT2 SEZ6 
ACTL6B CRMP1 IFITM10 NNAT SEZ6L 
AFF3 CRTAC1 IGDCC3 NOS2 SFMBT2 
ALK CUX2 IGF2-AS NRCAM SGK1 
AMER3 CXCR4 IGLON5 NRSN1 SHANK1 
ANK1 DCX IQSEC3 NRXN1 SHANK2 
APBA1 DHRS2 JPH3 NRXN2 SLC35F3 
ARC DIO3 KCNA3 NTNG2 SLC6A11 
ARHGAP20 DIO3OS KCNJ3 NYAP2 SLC7A14 
ASPDH DLG3 KCNJ9 OPRM1 SMPD3 
ASTN1 DLGAP3 KCNK3 PAX5 SNAP91 
ATCAY DNER KCNK9 PDE4C SNCB 
ATP1A3 DPP10 KCNQ3 PDZK1 SPOCK2 
ATP2B2 DPP10-AS1 KCNT1 PHACTR1 SRRM4 
B3GAT1 EDIL3 KIF1A PHF21B ST8SIA3 
BMP7 EGR1 KIF21B PLCH2 SVOP 
BRINP2 EPHA10 LHFPL3 PLCXD3 SYN1 
BRSK2 FAM135B LINC00599 PLEKHA7 SYT13 
C22orf34 FAM155B LINC00890 PNCK T 
CACNA1B FAT3 LMO3 PNMA3 TBC1D30 
CACNA1C FEZ1 LRFN2 POU4F2 TMEM178B 
CACNG2 FSTL5 LRRTM2 PPP2R2C TNFAIP6 
CADPS GABRB3 LYPD1 PRKCA TNFRSF19 
CALB1 GABRD MAP6 PRNP TOX2 
CAMK2N1 GALNT14 MARCH11 PTCHD2 TRIM67 
CDH4 GDAP1L1 MARCH4 PTPRK TSSC2 
CDKN2A GDF7 MGST1 RIMS2 TUBB4A 
CELF2 GOLGA7B MMP24 RP11-19O2.2 UNC5A 
CELF4 GPR158 MPPED2 RP11-314B1.2 UNC5D 
CELF5 GRIN1 MSN RP11-3N2.13 UNC79 
CHD5 GRIP2 MYT1L RP11-561N12.5 VIP 
CLVS1 GRM8 NAT16 RP11-738O11.13 WSCD2 
CNTN2 GYG2 NCAN RPH3A XKR7 
CNTNAP5 HMX1 NCKAP5 SCRT1 ZDHHC22 
CPLX1 HR NEFM SCRT2 ZNF662 
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Supplementary Table 3 – GO-term analysis on genes upregulated within SNAI2 gRNA SH-
SY5Y cells 
GO-term analysis using PANTHER yields 81 significantly enriched categories as determined by Fisher’s Exact test with False Discovery Rate 
(FDR) correction. Fold enrichment is the ratio between observed and expected genes within a category. Number of expected genes is based 
on the number of protein encoding genes within a category.  
 
GO-term GO term Observed Expected Fold enrichment  FDR 
nervous system development GO:0007399 64 19.15 3.34 1.10E-14 
generation of neurons GO:0048699 48 12.55 3.82 3.86E-12 
neurogenesis GO:0022008 49 13.36 3.67 5.74E-12 
synapse organization GO:0050808 21 2.22 9.44 1.27E-10 
neuron development GO:0048666 32 6.65 4.81 8.77E-10 
plasma membrane bounded cell 
projection morphogenesis GO:0120039 25 3.98 6.28 9.75E-10 
regulation of trans-synaptic signaling GO:0099177 24 3.61 6.65 1.01E-09 
cell projection morphogenesis GO:0048858 25 4.02 6.23 1.05E-09 
neuron differentiation GO:0030182 35 8.23 4.25 1.12E-09 
modulation of chemical synaptic 
transmission GO:0050804 24 3.6 6.67 1.24E-09 
neuron projection morphogenesis GO:0048812 25 3.95 6.33 1.37E-09 
cell part morphogenesis GO:0032990 25 4.19 5.97 2.31E-09 
neuron projection development GO:0031175 28 5.45 5.14 2.78E-09 
cell morphogenesis involved in 
neuron differentiation GO:0048667 23 3.53 6.52 3.02E-09 
anterograde trans-synaptic signaling GO:0098916 22 3.38 6.51 8.51E-09 
chemical synaptic transmission GO:0007268 22 3.38 6.51 9.08E-09 
regulation of membrane potential GO:0042391 22 3.48 6.33 1.36E-08 
trans-synaptic signaling GO:0099537 22 3.53 6.24 1.66E-08 
regulation of nervous system 
development GO:0051960 31 7.59 4.08 3.26E-08 
synaptic signaling GO:0099536 22 3.74 5.89 4.37E-08 
multicellular organism development GO:0007275 80 40.82 1.96 7.78E-08 
behavior GO:0007610 24 4.69 5.12 7.84E-08 
system development GO:0048731 73 35.94 2.03 1.40E-07 
regulation of neurogenesis GO:0050767 28 6.71 4.17 1.62E-07 
cell morphogenesis involved in 
differentiation GO:0000904 23 4.54 5.07 2.07E-07 
regulation of transport GO:0051049 43 15.19 2.83 2.37E-07 
regulation of localization GO:0032879 54 22.44 2.41 2.57E-07 
anatomical structure development GO:0048856 82 43.97 1.86 3.40E-07 
multicellular organismal process GO:0032501 96 56.55 1.7 4.26E-07 
developmental process GO:0032502 85 46.82 1.82 4.40E-07 
axon guidance GO:0007411 16 2.11 7.59 4.48E-07 
neuron projection guidance GO:0097485 16 2.13 7.5 5.08E-07 
axon development GO:0061564 19 3.3 5.76 8.09E-07 
cell morphogenesis GO:0000902 25 5.87 4.26 8.14E-07 
plasma membrane bounded cell 
projection organization GO:0120036 31 9 3.44 9.50E-07 
signal release from synapse GO:0099643 11 0.84 13.11 9.59E-07 
neurotransmitter secretion GO:0007269 11 0.84 13.11 9.87E-07 




signal release GO:0023061 13 1.38 9.39 1.31E-06 
cell development GO:0048468 38 13.36 2.84 1.87E-06 
regulation of cell development GO:0060284 28 7.7 3.63 1.87E-06 
cell projection organization GO:0030030 31 9.35 3.32 2.01E-06 
regulation of neuron differentiation GO:0045664 23 5.36 4.29 2.58E-06 
adult behavior GO:0030534 12 1.22 9.82 2.99E-06 
regulation of neuron projection 
development GO:0010975 20 4.08 4.9 3.11E-06 
regulation of plasma membrane 
bounded cell projection organization GO:0120035 23 5.47 4.2 3.53E-06 
regulation of cell projection 
organization GO:0031344 23 5.55 4.15 4.29E-06 
cellular developmental process GO:0048869 62 30.93 2 6.84E-06 
regulation of ion transport GO:0043269 23 5.7 4.03 6.88E-06 
cellular component morphogenesis GO:0032989 25 6.73 3.72 7.27E-06 
cell differentiation GO:0030154 61 30.16 2.02 8.22E-06 
regulation of ion transmembrane 
transport GO:0034765 19 3.95 4.81 8.49E-06 
cell-cell signaling GO:0007267 29 9.02 3.22 1.00E-05 
central nervous system development GO:0007417 27 8 3.38 1.18E-05 
neurotransmitter transport GO:0006836 12 1.47 8.19 1.54E-05 
regulation of transmembrane 
transport GO:0034762 20 4.61 4.34 1.65E-05 
regulation of neurotransmitter levels GO:0001505 16 2.92 5.49 1.79E-05 
regulation of biological quality GO:0065008 63 32.91 1.91 2.32E-05 
regulation of synaptic plasticity GO:0048167 12 1.55 7.75 2.47E-05 
regulation of system process GO:0044057 20 4.79 4.18 2.77E-05 
localization GO:0051179 79 46.72 1.69 3.97E-05 
brain development GO:0007420 22 6.04 3.64 5.79E-05 
cognition GO:0050890 14 2.47 5.67 7.17E-05 
learning or memory GO:0007611 13 2.13 6.09 8.78E-05 
positive regulation of neuron 
differentiation GO:0045666 15 3.02 4.96 1.31E-04 
head development GO:0060322 22 6.4 3.44 1.37E-04 
positive regulation of nervous system 
development GO:0051962 18 4.42 4.07 1.50E-04 
cation transmembrane transport GO:0098655 19 5.01 3.79 1.99E-04 
inorganic cation transmembrane 
transport GO:0098662 18 4.54 3.96 2.08E-04 
regulation of signaling GO:0023051 55 28.86 1.91 2.10E-04 
locomotory behavior GO:0007626 11 1.63 6.75 2.31E-04 
regulation of cation transmembrane 
transport GO:1904062 14 2.81 4.98 2.57E-04 
metal ion transport GO:0030001 19 5.16 3.68 2.73E-04 
inorganic ion transmembrane 
transport GO:0098660 19 5.23 3.63 3.23E-04 
ion transport GO:0006811 29 11.08 2.62 4.01E-04 
regulation of multicellular organismal 
process GO:0051239 50 25.49 1.96 4.18E-04 
positive regulation of neurogenesis GO:0050769 16 3.88 4.13 4.42E-04 
cell adhesion GO:0007155 23 7.55 3.05 4.45E-04 
biological adhesion GO:0022610 23 7.6 3.03 4.84E-04 
establishment of localization GO:0051234 65 37.9 1.72 5.06E-04 
regulation of cell communication GO:0010646 53 28.52 1.86 7.13E-04 
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positive regulation of neuron 
projection development GO:0010976 12 2.3 5.22 8.17E-04 
regulation of transporter activity GO:0032409 12 2.3 5.21 8.38E-04 
cation transport GO:0006812 21 6.75 3.11 8.43E-04 
cellular localization GO:0051641 41 19.98 2.05 1.09E-03 
ion transmembrane transport GO:0034220 22 7.68 2.86 1.68E-03 
regulation of multicellular organismal 
development GO:2000026 36 16.59 2.17 1.71E-03 
chemotaxis GO:0006935 16 4.45 3.6 1.97E-03 
positive regulation of cell 
development GO:0010720 16 4.46 3.58 1.99E-03 
transport GO:0006810 62 36.82 1.68 1.99E-03 
export from cell GO:0140352 23 8.41 2.74 2.00E-03 
taxis GO:0042330 16 4.46 3.58 2.00E-03 
regulation of ion transmembrane 
transporter activity GO:0032412 11 2.14 5.14 2.04E-03 
transmembrane transport GO:0055085 26 10.47 2.48 2.59E-03 
regulation of transmembrane 
transporter activity GO:0022898 11 2.21 4.98 2.59E-03 
cell-cell adhesion GO:0098609 15 4.07 3.68 2.61E-03 
movement of cell or subcellular 
component GO:0006928 29 12.52 2.32 3.01E-03 
protein localization to membrane GO:0072657 15 4.14 3.63 3.02E-03 
forebrain development GO:0030900 13 3.19 4.07 3.29E-03 
regulation of cell differentiation GO:0045595 32 14.77 2.17 3.75E-03 
nervous system process GO:0050877 27 11.24 2.4 3.75E-03 
biological regulation GO:0065007 127 100.6 1.26 3.76E-03 
system process GO:0003008 33 15.95 2.07 6.65E-03 
regulation of cellular localization GO:0060341 20 7.47 2.68 7.87E-03 
locomotion GO:0040011 25 10.6 2.36 8.71E-03 
positive regulation of cell projection 





Supplementary Table 4 –SNAI2 gene expression signature of upregulated genes, and genes 
upregulated upon SNAI2 depletion not present in micro-array expression datasets 
 
Genes in SNAI2 gene expression signature 
ACHE CNTNAP5 HR NNAT SFMBT2 
ACTL6B CPLX1 HRH3 NOS2 SGK1 
AFF3 CPLX2 IGLON5 NRCAM SHANK1 
ALK CPNE4 IQSEC3 NRSN1 SHANK2 
AMER3 CRMP1 JPH3 NRXN1 SLC35F3 
ANK1 CRTAC1 KCNA3 NRXN2 SLC6A11 
APBA1 CUX2 KCNJ3 NTNG2 SLC7A14 
ARC CXCR4 KCNJ9 NYAP2 SMPD3 
ARHGAP20 DCX KCNK3 OPRM1 SNAP91 
ASPDH DHRS2 KCNK9 PAX5 SNCB 
ASTN1 DLG3 KCNQ3 PDE4C SPOCK2 
ATCAY DLGAP3 KCNT1 PDZK1 SRRM4 
ATP1A3 DNER KIF1A PHACTR1 ST8SIA3 
ATP2B2 DPP10 KIF21B PHF21B SVOP 
B3GAT1 EDIL3 LHFPL3 PLCH2 SYN1 
BMP7 EGR1 LINC00599 PLCXD3 SYT13 
BRSK2 EPHA10 LMO3 PLEKHA7 T 
CACNA1B FAM135B LRFN2 PNCK TBC1D30 
CACNA1C FAM155B LRRTM2 PNMA3 TNFAIP6 
CACNG2 FAT3 LYPD1 POU4F2 TNFRSF19 
CADPS FEZ1 MAP6 PPP2R2C TOX2 
CALB1 FSTL5 MARCH4 PRKCA TUBB4A 
CAMK2N1 GABRB3 MGST1 PRNP  
CDH4 GABRD MMP24 PTCHD2 UNC5A 
CDKN2A GALNT14 MPPED2 RIMS2 UNC5D 
CELF2 GDAP1L1 MSN RPH3A UNC79 
CELF4 GPR158 MYT1L SCRT1 VIP 
CELF5 GRIN1 NCAN SCRT2 WSCD2 
CHD5 GRIP2 NCKAP5 SERPINA5 ZDHHC22 
CLVS1 GRM8 NEFM SEZ6  
CNTN2 HMX1 NMNAT2 SEZ6L  
     
Genes not present in micro-array expression datasets 
AC012065.7 MARCH11 TMEM178B   
BRINP2 NAT16 TRIM67   
C22orf34 NFASC TSSC2   
DPP10-AS1 RP11-19O2.2 XKR7   
GDF7 RP11-314B1.2 ZNF662   
GOLGA7B RP11-3N2.13    
IFITM10 RP11-561N12.5    
LINC00890 RP11-738O11.13   
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Neuroblastoma is a developmental tumor originating from poorly differentiated neural crest 
cells. Consequently, disruption of programs controlling normal neural crest development and 
differentiation contribute to neuroblastoma development and progression. During 
development, neural crest cells detach from the neural tube and migrate to distant locations 
within the embryo. In order to delaminate and migrate, an essential program known as 
epithelial-to-mesenchymal transition (EMT) is activated [1-4]. This developmental program 
not only confers migratory properties upon cells, but promotes stem-cell like properties, 
including self-renewing ability, apoptosis prevention and anoikis resistance [5-8]. While 
neuroblastomas find their origin in neural crest cells and divert developmental programs 
during disease progression, cancer cells in general share many characteristics observed during 
neural crest development, such as EMT and migratory ability [9, 10]. Therefore, cancer cells 
are thought to reactivate or hijack the molecular mechanisms and regulatory networks 
underlying neural crest development and EMT as a means to metastasize and develop therapy 
resistance [9, 10].   
Neural crest development as well as cancer progression are strongly dictated by the 
interactions between the cell and its environment. Next to a diverse set of biochemical 
signals, the mechanical properties of the (tumor) microenvironment strongly influence cell 
behavior and regulate developmental gene expression programs, induce EMT and steer cell 
migration [4, 5, 11-14]. As a consequence, molecular sensors that integrate these 
environmental cues play pivotal roles during development, oncogenesis and tumor 
progression.  
Members of the mammalian Transient Receptor Potential (TRP) channel family are known for 
their ability to transduce a large variety of environmental signals. In response to specific cues, 
TRP channels modify their ion-conducting properties to steer downstream signaling cascades 
[15-18]. By doing so, TRP channels modulate many cellular processes, such as cell division, 
EMT, migration and even transcription [16, 17, 19, 20]. In addition, TRP channels can 
modulate cell behavior in manners supplementary to their ion-conducting function (Chapter 
2 & [21]). Consequently, TRP channels are critical during development and homeostasis, as 
well as oncogenesis and cancer progression.  
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TRPM7 is a distinctive member of the TRP channel family, consisting of a bivalent cation 
channel fused to a C-terminal α-kinase domain. Next to being essential during embryonic 
development, expression of the protein is associated with the clinical stage and presence of 
metastasis in a variety of tumor types [22, 23]. Our group previously demonstrated that 
TRPM7 is required for metastasis formation of both breast cancer and neuroblastoma [24, 
25]. In addition, we have shown that TRPM7 maintains the expression of the EMT-
transcription factor SNAI2 [25]. In this thesis, we examined how TRPM7 contributes to the 
malignant potential of neuroblastoma cells. We demonstrated that TRPM7 is part of a 
cytoskeletal complex that appears to regulate the malignant properties of neuroblastoma 
cells by modulating cell-matrix interactions and actomyosin dynamics. In addition, we reveal 
that TRPM7 controls developmental gene expression programs that contribute to cancer 
progression. Together our data suggest that TRPM7 is a unique protein that controls 
(neuroblastoma) cell behavior and contributes to cancer progression, metastasis formation 
and therapy resistance by interconnecting mechanotransduction with cytoskeletal dynamics 
and ultimately activation of developmental transcriptional programs.  
 
TRPM7 is part of a large cytoskeletal protein complex linked to neuroblastoma progression  
TRPM7 controls malignant properties as part of a cytoskeletal complex 
Cell migration, invasion and metastasis formation strongly depend on the spatiotemporal 
regulation of the actin cytoskeleton and actomyosin mediated tension [26, 27]. In addition, 
the actomyosin cytoskeleton plays an important role in a variety of cellular processes 
including intracellular transport, proliferation, differentiation and neuritogenesis [28]. 
Consistently, proteins involved in actin dynamics and adhesion remodeling are essential 
during (neural crest) migration, and neuronal as well as neuroblastoma differentiation [29-
33]. A recent study by Molenaar et al. demonstrated that mutations in genes encoding 
regulators of cytoskeletal dynamics are associated with aggressive high-stage 
neuroblastomas [34].  
Our group previously showed that TRPM7 localizes to adhesion structures in neuroblastoma 
cells and controls adhesion remodeling and cellular tension [35, 36]. However, the 
mechanisms by which TRPM7 controls cytoskeletal tension, adhesion dynamics and migration 
remain incompletely understood. By performing mass-spectrometry on TRPM7 immune 
complexes, we show in Chapter 3 that TRPM7 not only interacts with the actomyosin 
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cytoskeleton, but is part of a large multi-protein complex. Within this complex TRPM7 may 
affect cell behavior through various mechanisms. For instance, similar to TRP channels in 
Drosophila photoreceptors, TRPM7 may function as a protein scaffold to physically assemble 
relevant proteins and localize proteins to specific regions within the cell, such as adhesion 
sites [37, 38]. By acting as a scaffold TRPM7 could also increase the local concentration of 
enzymes and substrates, promote efficient interaction between specific proteins and 
enhance signal transduction [39]. Next to being a scaffold, TRPM7 also conducts ions to locally 
activate signaling cascades [40]. Connecting both channel and scaffolding moieties may 
further increase the rate of signal transduction. Additionally, as TRPM7 possesses a C-terminal 
kinase domain [41, 42], TRPM7’s kinase activity may modulate the activity of the components 
within the complex. Lastly, massive auto-phosphorylation of TRPM7 facilitates substrate 
recruitment and kinase-substrate interactions [43-45]. Therefore, by controlling the 
composition of the complex, TRPM7 may regulate and shape signaling transmission and 
ultimately cell behavior.  
In-depth analyses of the ‘TRPM7 interactome’ revealed that the complex is strongly enriched 
in proteins involved in the regulation of actomyosin function, adhesion formation and 
protrusion dynamics (Chapter 3). Accordingly, we hypothesize that TRPM7 affects 
cytoskeletal remodeling, actin myosin contractility and adhesion dynamics by regulating and 
localizing specific cytoskeletal components and functionally modulating the activity of these 
cytoskeletal interactors. Consistently, we have demonstrated previously that the interaction 
of TRPM7 with the TRPM7 interactome member myosin IIA depends on both TRPM7 
mediated Ca2+-conduction as well as its kinase activity [35]. Consecutively, TRPM7-induced 
relaxation of the actomyosin cytoskeleton and remodeling of adhesions results from TRPM7 
kinase-dependent phosphorylation of the myosin IIA heavy chain [35].  
Apart from myosin IIA, TRPM7 may modulate actin dynamics through several other TRPM7 
interactome members. For example, TRPM7 also phosphorylates the assembly domains of 
the TRPM7 interactors myosin IIB and IIC [46]. Additionally, annexin A1 was recognized as a 
TRPM7 kinase substrate [47, 48]. While annexin A1 was not identified as a member of the 
interactome, its family member annexin A2 is part of the complex. Several family members of 
the annexin family, including A1 and A2, are known to associate with actin bundles and are 
suggested to integrate Ca2+ signaling with actin dynamics at the cell membrane [49]. Lastly, 
TRPM7 was shown to directly phosphorylate and control the activity of the actin binding 
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proteins cofilin and tropomodulin 1 [50, 51]. Whereas cofilin and tropomodulin family 
members 2 and 3 are part of the TRPM7 interactome, tropomodulin 1 was not identified 
within this complex. However, the position of TRPM7 mediated phosphorylation of 
tropomodulin 1 is conserved amongst all tropomodulin family members (Chapter 4). This 
suggests that TRPM7 phosphorylates and controls the actin capping ability of tropomodulin 2 
and 3 similar to tropomodulin 1. Taken together, there is ample evidence supporting the 
hypothesis that TRPM7 controls cytoskeletal dynamics and adhesion remodeling by directly 
regulating the composition of the interactome and the activity of its constituents.  
  
TRPM7 interactors predict neuroblastoma disease progression 
While only a few members of the TRPM7-interactome had previously been implicated in 
neuroblastoma disease progression, we revealed in Chapter 3 that mRNA expression of about 
30% of the TRPM7-interactors identified by us accurately predict disease progression in two 
independent neuroblastoma patient cohorts. This suggests a regulatory role for TRPM7 and 
its cytoskeletal complex in neuroblastoma progression. Even though high TRPM7 expression 
in general is associated with poor patient prognosis and/or advanced disease, components of 
the interactome were found to both positively and negatively associate with disease 
progression. While this may be surprising, it is very well possible that, depending on the 
protein, TRPM7 either positively or negatively regulates its interactors.  For example, TRPM7 
mediated phosphorylation of cofilin and myosin IIA, respectively, inhibits cofilin function and 
prevents myosin IIA filament formation [50, 52]. On the other hand, TRPM7 mediated 
phosphorylation of the eEF2-kinase increases its stability and consequently activity, while 
autophosphorylation of TRPM7 itself facilitates substrate interactions and kinase activity [43-
45, 53]. Likewise, TRPM7 interactors themselves may influence malignant neuroblastoma cell 
features either positively or negatively.  
 
The TRPM7 interactor tropomodulin 2 inhibits malignant potential of neuroblastoma cells 
To gain more insight into the function of the TRPM7 interactome in neuroblastoma 
progression, we set out to evaluate if and to what extend the TRPM7 interactor tropomodulin 
2 contributes to the malignant phenotype of neuroblastoma cells, given its exceptional 
correlation with patient survival (Chapter 3). More elaborate evaluation of the relationship 
between tropomodulin 2 mRNA expression and patient prognosis (Chapter 4) revealed that 
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high tropomodulin 2 expression positively correlates with favorable clinical characteristics 
and event free survival probability in two independent neuroblastoma patient cohorts. 
Moreover, consistent with previous reports that tropomodulin 1 and 3 negatively control cell 
migration [54, 55], knockdown of tropomodulin 2 significantly enhanced the malignant 
character of neuroblastoma cells by enhancing migratory and invasive properties, while 
reducing the number of focal adhesions of neuroblastoma cells (Chapter 4). Consequently, by 
inhibiting neuroblastoma cell migration, tropomodulin 2 may negatively affect 
neuroblastoma disease progression by impairing metastasis formation.  
While we do not have direct evidence that TRPM7 controls tropomodulin 2 activity, it is very 
likely that tropomodulin 2 is a substrate for the TRPM7 kinase, as TRPM7 is able to 
phosphorylate tropomodulin 1 at a residue conserved in tropomodulin 2 as well. 
Phosphorylation at this specific residue, Thr54, inhibits the ability of tropomodulin 1 to cap 
actin filaments, thereby enhancing the rate of actin polymerization at the pointed (-) end [51]. 
By similarity, TRPM7-mediated phosphorylation of tropomodulin 2 at this residue may also 
increase actin dynamics, thereby promoting protrusion elongation followed by enhanced 
migration of neuroblastoma cells. Consequently, these data further underline the idea that 
TRPM7 may control the malignant and invasive behavior of neuroblastoma cells by regulating 
actin dynamics through the activity of TRPM7-interactome constituents. Future investigations 
should further uncover the role of the interactome and its individual members in the 
regulation of neuroblastoma aetiology. 
 
TRPM7 controls developmental transcriptional programs  
TRPM7 controls developmental transcriptional programs involved in migratory and invasive 
behavior 
To enhance their malignant potential and metastatic properties, cancer cells reactivate 
developmental programs such as EMT. In order to develop novel therapeutic approaches, it 
is key to understand which mechanism and constituents underly the activation of such 
developmental programs. In Chapter 5 we demonstrate that shRNA mediated depletion of 
TRPM7 results in loss of mesenchymal features of breast cancer cells, while epithelial 
properties become more prominent. Loss of TRPM7 may thus result in a (partial) 
mesenchymal-to-epithelial transition (MET), the opposite of EMT. Consistently, we and others 
suggest that TRPM7 may be a regulator of EMT, where TRPM7 promotes migratory and 
Chapter 7
188
invasive properties through the induction of EMT ([25, 56, 57] & Chapter 5). In Chapter 5, we 
also show that these phenotypical MET changes coincide with and can be mimicked by a 
reduction in the expression of SOX4, a transcription factor recently identified as a master 
regulator of EMT in breast cancer [58]. This suggests that TRPM7 controls EMT in breast 
cancer cells through expression regulation of SOX4. Similarly, our group has demonstrated 
that TRPM7 maintains progenitor-like features in neuroblastoma cells most likely by 
regulating the expression of the neural crest EMT-transcription factor SNAI2 [25]. 
Consequently, TRPM7 not only controls cell behavior by directly modulating cytoskeletal 
dynamics, but also has a more sustained influence by regulating developmental 
transcriptional programs in a cell type specific manner. Likewise, others have demonstrated 
that different TRP channels control developmental and pathological processes by activating 
Ca2+-sensitive transcription factors, such as NFAT, NF-κB and STAT3 [21]. TRPM8 was even 
shown to transcriptionally control EMT in breast cancer cells by inhibiting the degradation of 
the EMT-transcription factor SNAI1 [59]. 
 
Control of progenitor-like features through expression regulation of EMT-transcription factor 
SNAI2 
Our group previously demonstrated that TRPM7 expression positively associates with the 
migratory and metastatic abilities of neuroblastoma cells [25]. Moreover, TRPM7 was shown 
to maintain neuroblastoma cells in a progenitor-like state at the transcriptional level. Micro-
array analysis pointed towards the EMT-transcription factor SNAI2 as most likely candidate 
by which TRPM7 controls malignant features of neuroblastoma cells, since SNAI2 is an 
important driver of neural crest formation and migration, and a determinant of cancer 
stemness and metastasis formation [25]. In Chapter 6 we evaluated if and how SNAI2 
contributes to neuroblastoma cell behavior. Expression analyses of SNAI2 knockout as well as 
TRPM7 knockdown neuroblastoma cells revealed that differentially expressed genes in 
response to loss of either TRPM7 or SNAI2 are significantly enriched for biological processes 
linked to cell differentiation and development ([25] & Chapter 6). Consistent with the 
hypothesis that TRPM7 acts upstream of SNAI2 and loss may result in more divergent and 
widespread effects, TRPM7 depletion impacted expression of genes involved in a broader 
range of biological processes, including blood vessel development and glycan biosynthesis. 
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On the contrary, biological processes affected by SNAI2 are restricted to neuronal 
development and differentiation.  
Functionally, loss of SNAI2 mimics that of TRPM7. Similar to depletion of TRPM7 [25], SNAI2 
loss significantly reduced the invasive and metastatic behavior of neuroblastoma cells. 
Moreover, loss of SNAI2 promoted the sensitivity of different neuroblastoma cell models to 
the clinically used differentiation agent retinoic acid (Chapter 6). Consistently, preliminary 
results indicate that shRNA mediated knockdown of TRPM7 also enhances retinoic acid 
induced growth inhibition of human SH-SY5Y neuroblastoma cells (unpublished data). 
Together these data suggest that TRPM7 may (at least in part) promote neuroblastoma 
progression by preventing neuroblastoma differentiation and maintaining neuroblastoma 
cells in a progenitor-like state through transcriptional regulation of SNAI2. Future research 
should determine to what extent other transcription factors contribute to TRPM7 mediated 
neuroblastoma progression and how expression of these factors is regulated by TRPM7. 
 
How does TRPM7 regulate gene expression? 
Tensional regulation of gene expression 
Cellular tension, be it derived from the microenvironment or a resultant of intracellular 
cytoskeletal tension, plays an important role during embryonic development, tissue 
homeostasis and pathological processes. Increasing evidence indicates that these mechanical 
forces can be the driving forces controlling transcriptional programs contributing to processes 
such as the maintenance of pluripotency, cell migration and differentiation [60]. Previous 
reports suggest that loss of TRPM7 promotes phenotypical cell contractility, while 
over-expression causes actomyosin relaxation as apparent by increased cell spreading [24, 
35]. In Chapter 5 we demonstrate by physical measurements that knockdown of TRPM7 leads 
to increased intracellular tension. In addition, we reveal that expression of SOX4 is inversely 
correlated with cytoskeletal tension. Taken together, this suggests that high levels of TRPM7 
maintain SOX4 expression by promoting actomyosin relaxation. Consequently, TRPM7 could 
maintain breast cancer cells in a mesenchymal, migratory state through tensional regulation 
of SOX4. In a broader view, as TRPM7 is suggested to relay mechanical signals [61-64], TRPM7 
may play a key role in integrating physical changes of the microenvironment, through 
cytoskeletal remodeling, into the (de)activation of transcriptional programs.  
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It remains to be determined whether a similar mechanism is accountable for 
TRPM7-controlled expression regulation of SNAI2 in neuroblastoma cells. Interestingly, 
though, SNAI2 protein (and to a lesser extend mRNA) expression was shown to increase in 
human breast cancer associated fibroblasts when cultured on stiff substrates [65]. This 
suggests that SNAI2 expression may indeed be tensionally regulated. However, this study only 
compares two stiffnesses, where soft is defined as 80-120 kPa and stiff as >120 kPa. With the 
exception of bones, tissues are typically much softer with stiffnesses below 15-20 kPa [66]. 
Hence, the investigated stiffnesses do not resemble physiological conditions, making 
interpretation and extrapolation of the tensional regulation of SNAI2 expression difficult.   
 
The question remains how TRPM7-mediated cytoskeletal relaxation drives the expression of 
SOX4. Currently, a number of mechanisms by which cellular tension influences gene 
transcription have been described. One of the most well-known and studied pathways 
involves the transcriptional co-activators YAP and TAZ. In response to increases in tension, 
YAP and TAZ translocate from the cytosol into the nucleus where they regulate the 
transcription of target genes [67]. Similarly, actin polymerization in reaction to mechanical 
stimuli promotes nuclear translocation of the transcription factor MRTF by reducing the pool 
of monomeric (G-) actin that binds and masks the nuclear localization signal of MRTF. In the 
nucleus, MRTF subsequently activates SRF-dependent transcription [68, 69]. However, both 
activation of YAP/TAZ and MRTF/SRF by increased tension are associated with the induction 
of EMT as well as enhanced metastasis formation [67, 70]. Consequently, as TRPM7 maintains 
mesenchymal and metastatic properties of tumor cells by promoting tensional relaxation 
instead of enhancing cellular tension, it is unlikely that these pathways are responsible for 
TRPM7 controlled transcription. Be that as it may, while currently not described, there may 
be transcriptional regulators that translocate to the nucleus upon cytoskeletal relaxation or 
are excluded from the nucleus following increases in cellular tension. Hence in theory, TRPM7 
may control transcription through yet unidentified transcriptional regulators that are 
oppositely regulated compared to YAP/TAZ and MRTF/SRF.  
Alternatively, TRPM7-controlled cytoskeletal tension may be directly transmitted to the 
nuclear membrane, influencing nuclear stiffness and chromatin organization [71-73]. In line 
with this notion, Le et al. recently demonstrated that mechanical strain influenced lineage 
commitment of primary epidermal keratinocytes by bringing about large-scale chromatin  
7
General discussion & future perspectives
191
 
Figure 1. TRPM7 controls cell behavior through immediate effects on the cytoskeleton as well as more sustained effects 
by modulating transcription. In response to external stimuli from the (tumor) microenvironment, both TRPM7-mediated 
ion-conduction and kinase activity are modulated. By activation of Ca2+ sensitive proteins, TRPM7-mediated Ca2+-influx can 
induce cytoskeletal and adhesion remodeling. In addition, Ca2+-influx promotes the interaction of the kinase with its 
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rearrangements and silencing of genes involved in lineage commitment [74]. Moreover, in 
response to mechanical strain, perinuclear actin polymerization was enhanced, thereby 
reducing the pool of nuclear actin and interfering with nuclear actin-induced transcription. 
Interestingly, increased tension also resulted in a small increase in H3K27me3 silencing marks 
at SOX1 and SOX2 promotors in primary epidermal keratinocytes [74]. Consequently, a similar 
mechanism may reduce transcription of SOX4 in response to increased cellular tension upon 
TRPM7 loss in breast cancer cells.  
 
TRPM7 – one protein to control all – a working model 
Taken together, TRPM7 is implicated in controlling embryonic development, as well as 
malignant neuroblastoma- and cancer cell features ([22] & Chapter 1). However, the 
molecular mechanisms by which TRPM7 regulates (malignant) cell behavior in general, and 
that of neuroblastoma cells in specific, are still incompletely understood. Based on the results 
presented in this thesis, we propose two modes of action by which TRPM7 may affect 
malignant potential (Fig. 1). On the one hand, the direct interactions of TRPM7 and its kinase 
domain with the actomyosin cytoskeleton and cytoskeletal proteins allows TRPM7 to 
integrate signals into immediate effects by regulating local assembly and activation of the 
cytoskeletal proteins, and remodeling of the actomyosin cytoskeleton. In addition to these 
effects, TRPM7 exerts more sustained effects by controlling transcriptional programs involved 
in cellular differentiation to maintain progenitor-like features. As these two branches are not 
isolated from each other, it is likely that there is a significant interplay between both 
immediate and sustained modes. Direct effects on the cytoskeleton or other 
TRPM7-interactors may be required for transcriptional regulation, whereas changes in 
transcription could influence cytoskeletal remodeling and TRPM7 activity.  
substrates. On the other hand, the TRPM7 kinase-domain can modulate channel opening. The TRPM7 kinase domain 
furthermore induces cytoskeletal relaxation by phosphorylating myosin II heavy chain, thereby inducing the dissociation of 
myosin II from the actin cytoskeleton. The kinase additionally regulates protrusion formation, adhesion and migration by 
modulating the assembly and activity of components of the TRPM7 interactome. TRPM7-mediated Ca2+-influx may have 
more sustained effects on cell behavior by activating Ca2+-sensitive transcription factors/regulators. Similarly, 
phosphorylation of transcription factors or regulators by the kinase domain may influence transcription, whereas 
cytoskeletal relaxation may influence transcription by tensional regulation of nuclear localization of transcription factors, 
or by affecting chromatin remodeling through changing nuclear membrane tension. Moreover, cleaved TRPM7 kinase 
domain can translocate to the nucleus to phosphorylate histone residues and modulate transcription. Collectively, by 
modulating transcription of factors such as SNAI2 and SOX4, TRPM7 plays an important role in controlling developmental 
gene expression programs, thereby negatively contributing to disease outcome by maintaining progenitor-like features of 
neuroblastoma cells as well as mesenchymal features of breast cancer cells.   
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While the ion conduction and kinase activity of TRPM7 may exert different functions by 
activating different proteins or pathways leading to both early and sustained effects, it is very 
likely that there is crosstalk between the channel- and kinase-domains and they may act in 
conjunction. Consistently, the TRPM7 kinase-domain is proposed to modulate channel 
opening [75, 76], while Ca2+ is essential for the interaction of the kinase with its substrates, 
indicating that ion conduction by TRPM7 also modulates substrate phosphorylation [35, 48, 
77].  
  
Clinical implications and future directions 
TRPM7 as a therapeutic target? 
While TRPM7 expression and activity have been linked to poor prognosis in a variety of 
different tumor types, including breast cancer, no correlation between TRPM7 mRNA 
expression and patient outcome has been demonstrated for neuroblastoma [23]. 
Nevertheless, we have previously shown that TRPM7 does strongly impact the malignant 
potential of neuroblastoma cells by controlling progenitor-like features as well as migratory 
abilities [25]. Moreover, TRPM7 expression was shown to be essential for metastasis 
formation of mouse neuroblastoma cells in vivo [25]. Taken together, these data suggest that 
it is TRPM7 activity or protein levels, rather than mRNA expression that contribute to 
neuroblastoma progression.  
Given its important role in cancer and neuroblastoma biology, along with its accessibility as a 
membrane protein and its molecular targetability TRPM7 may be considered an attractive 
therapeutic target. Currently, however, there are only few potent TRPM7 channel blockers 
identified of which none have reached the clinical stage of drug development [23]. The most 
promising and potent TRPM7 channel blockers are WaixenicinA and NS8593 [78]. Channel 
blockage by WaixenicinA is irreversible, whereas inhibition by NS8593 is reversible [78]. Both 
inhibitors were shown to impair cell proliferation [79-81], whereas NS8593-mediated channel 
blocking also reduces cell motility [82, 83]. In addition to channel inhibitors, TRPM7 kinase 
inhibitors are of significant interest as the channel and kinase moiety may play different roles 
in controlling cell behavior. Consistently, the recently identified TRPM7 kinase inhibitor 
TG100-115 was able to inhibit cell migration and invasion, as well as myosin IIA 
phosphorylation in MDA-MB-231 breast cancer cells without significantly impacting cell 
viability [84]. However, while prevention of metastasis formation may be beneficial for 
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(breast cancer) patients with localized disease at risk to develop metastatic disease, this will 
not aid high-risk neuroblastoma patients as these patients present with highly metastatic 
disease at diagnosis. Taken together, further characterization of TRPM7 channel and kinase 
inhibitors will help determine channel- and kinase-specific signaling modules and lead to the 
development of drugs that can be used to selectively inhibit specific TRPM7 modules in cancer 
cells. However, caution is warranted, as general TRPM7 inhibition may lead to severe side 
effects, given the importance of TRPM7 channel activity in for example magnesium 
homeostasis [85, 86] and the automaticity of specific myocardial cell types of the adult mouse 
heart [87]. 
 
Targeting downstream effectors of TRPM7 
As mentioned in Chapter 4, despite the fact that mRNA expression of tropomodulin 2 strongly 
correlates with neuroblastoma event free and overall survival, the protein itself is unlikely to 
be a direct therapeutic target. However, targeting the TRPM7-interactome component 
tropomyosin 3.1 has been shown to effectively reduce neuroblastoma and melanoma tumor 
outgrowth in preclinical models [88-90]. Moreover, many of the TRPM7-interactome 
components associate significantly well with neuroblastoma disease progression (Chapter 3). 
Hence, functional characterization of the TRPM7-interactome as a whole and in relation to 
TRPM7 may offer additional targeting possibilities and therapeutic opportunities to treat 
patients with metastatic disease at time of diagnosis.  
In Chapter 6 we have demonstrated that loss of the neural crest related EMT-transcription 
factor SNAI2 relieves the repression of a neuronal differentiation related expression program 
in neuroblastoma cells. This was accompanied by a reduction in the malignant behavior of 
neuroblastoma cells in vitro and in vivo, and sensitized neuroblastoma cells to the clinically 
used agent retinoic acid. Moreover, a gene expression signature based on the expression of 
the SNAI2-dependent genes correlated very well with event free survival of neuroblastoma 
patients. These data suggest that targeting regulatory networks that control neuroblastoma 
differentiation may help reduce the malignant character of neuroblastoma cells and enhance 
therapy response. Unfortunately, and consistent with the fact that inhibition of transcription 
factors is notoriously difficult [91-93], there are no specific inhibitors for SNAI2 available to 
date. As SNAI2 is part of different (transcriptional) complexes, SNAI2 activity may be inhibited 
by targeting SNAI2 coregulators or the interaction between SNAI2 and its coregulators [94-
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97]. However, as SNAI2 is part of multiple complexes, inhibition of these coregulators may 
not completely block all activity of SNAI2. Additionally, coregulators such as the lysine specific 
demethylase LSD1, are also part of other signaling complexes. Consequently, inhibition of 
these coregulators may be rather unspecific and affect additional pathways. Therefore, we 
propose that unbiased CRISPR screens may aid in the identification of novel upstream targets 
that modulate SNAI2 expression or activity in order to effectively inhibit SNAI2 mediated gene 
repression, and enhance neuroblastoma differentiation and therapy sensitivity.  
 
Concluding remarks 
In this thesis we further characterized the role of TRPM7 in cancer and more specifically in 
neuroblastoma progression. We demonstrate for that TRMP7 is part of a large protein 
complex linked to cytoskeletal remodeling and neuroblastoma disease progression. 
Moreover, we reveal that the TRPM7 effectors tropomodulin 2 and SNAI2 significantly 
contribute to the malignant character of neuroblastoma cells, whereas TRPM7 controls 
mesenchymal features of breast cancer cells by tensional control of the transcription factor 
SOX4. Therefore, based on current literature and this thesis, we propose that TRPM7 plays a 
central role in controlling cancer progression and metastasis formation by directly regulating 
migration through cytoskeletal and adhesion dynamics. Additionally, TRPM7 further 
contributes to the malignant character and therapy sensitivity of tumor cells by maintaining 
progenitor- and mesenchymal-like features through transcriptional control of developmental 
gene expression programs. Consequently, targeting regulatory networks that control 
developmental programs, such as the TRPM7-SNAI2 axis, may revert therapy resistant 
neuroblastoma cells into a more differentiated, therapy responsive phenotype.  
Future research should determine to what extend TRPM7 presents an attractive and feasible 
therapeutic target. In addition, unbiased CRISPR screens may help identify targetable 
signaling cascades, such as those controlling SNAI2 activity/expression, to promote 
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Neuroblastoom is de op twee na meest voorkomende tumor bij kinderen. Jaarlijks wordt er 
in Nederland bij zo’n 25 kinderen neuroblastoom vastgesteld. Hoewel de ziekte bij een groot 
deel van de patiënten goed te behandelen is, overlijdt 30% van de kinderen met 
neuroblastoom binnen 5 jaar na diagnose. Dit is het gevolg van het uitgroeien van tumorcellen 
die ongevoelig zijn voor therapie. Om nieuwe behandelmethoden te kunnen ontwikkelen 
voor deze patiëntengroep, is het van groot belang dat we inzicht krijgen in de moleculaire 
processen die leiden tot het ontstaan en de progressie van neuroblastomen, en hoe deze 
bijdragen aan de ontwikkeling van therapie ongevoeligheid. 
Neuroblastomen zijn kwaadaardige tumoren van het sympathische zenuwstelsel. Deze 
tumoren kunnen al ontstaan tijdens de ontwikkeling van het embryo als gevolg van een 
verstoorde uitrijping (differentiatie) van de neurale lijst cellen. Tijdens de embryonale 
ontwikkeling verplaatsen deze snel delende cellen zich door het embryo naar specifieke 
locaties, waar ze differentiëren tot verschillende weefsels, waaronder het sympathische 
zenuwstelsel. Door een blokkade in de differentiatie van deze neurale lijst cellen behouden 
deze cellen hun delende vermogen en ontstaan neuroblastomen. Daarnaast behouden 
neuroblastoomcellen de eigenschappen die neurale lijst cellen in staat stellen om zich te 
verplaatsen naar verschillende locaties in het lichaam. Bovendien lijkt verstoorde 
differentiatie bij te dragen aan het ongevoelig worden van neuroblastoomcellen voor 
therapie.  
De ontwikkeling, migratie en differentiatie van neurale lijst cellen wordt sterk beïnvloed door 
fysieke en chemische signalen. Deze signalen zijn afkomstig uit de directe omgeving van de 
cellen. Ionkanalen van de zo genoemde TRP-familie hebben een sleutelrol in het waarnemen 
en vertalen van omgevingssignalen naar het gedrag van cellen. Onder invloed van specifieke 
signalen beïnvloeden deze kanalen dan ook een grote verscheidenheid aan processen, 
waaronder het delend vermogen en de bewegelijkheid van cellen.  
TRPM7 is een opmerkelijk lid van de TRP-familie. Naast zijn kanaalfunctie beschikt TRPM7 ook 
over een kinase domein. Dit domein stelt het eiwit in staat de interactie met en de activiteit 
van andere eiwitten te beïnvloeden door deze te markeren. Voorgaand onderzoek binnen 
onze groep heeft aangetoond dat TRPM7 een directe interactie aangaat met het cytoskelet 




heeft onze groep laten zien dat TRPM7 bijdraagt aan het uitzaaien van zowel borstkanker- als 
neuroblastoomcellen. Echter, hoe TRPM7 het kwaadaardige gedrag van tumorcellen 
beïnvloedt blijft tot op heden onduidelijk. In dit proefschrift hebben wij geprobeerd meer 
inzicht te krijgen in de mechanismen waarmee TRP-kanalen het (kwaadaardige) gedrag van 
cellen reguleren. Onze aandacht richt zich hierbij vooral op de rol van TRPM7 in 
neuroblastoom. 
In Hoofdstuk 1 van dit proefschrift geven we een algemene inleiding over processen die 
belangrijk zijn tijdens de ontwikkeling en differentiatie van neurale lijst cellen en hoe deze in 
verband gebracht worden met de ontwikkeling en progressie van neuroblastoom en kanker 
in het algemeen. Daarnaast wordt een overzicht gegeven van de reeds bekende functies van 
TRPM7 tijdens normale fysiologische processen en in pathologische condities. In hoofdstuk 2 
bespreken we hoe TRP-kanalen, waaronder TRPM7, bijdragen aan normale ontwikkeling en 
het handhaven van fysiologische evenwichten, en hoe misregulatie van deze ionkanalen kan 
bijdragen aan de ontwikkeling van ziekten, zoals kanker. Hierbij wordt naast hun 
conventionele rol als ionkanalen ook aandacht besteed aan additionele, niet-conventionele 
mechanismen. 
In hoofdstuk 3 tonen wij aan dat TRPM7 deel uitmaakt van een groot eiwitcomplex, dat we 
het TRPM7-interactoom noemen. Het merendeel van de componenten in dit complex is 
betrokken bij de vorming van celadhesiestructuren en regulatie van het cytoskelet. Daarnaast 
associeert de mRNA expressie van verscheidene van deze componenten, in primair 
neuroblastoom weefsel op het moment van diagnose, zeer sterk met de het ziekteverloop 
van neuroblastoom patiënten. Dit impliceert dat het TRPM7-interactoom mogelijk betrokken 
is bij de progressie van neuroblastoom. In hoofdstuk 4 gaan wij dieper in op deze bevindingen. 
Hier laten wij in twee onafhankelijke cohorten van neuroblastoom patiënten zien dat een 
verhoogde mRNA expressie van Tropomodulin 2, één van de componenten van het TRPM7-
interactoom, sterk geassocieerd is met gunstige moleculaire karakteristieken van de tumor 
en een goede, uitzaaiingsvrije prognose. Verlaging van Tropomodulin 2 expressie in 
neuroblastoomcellen vermindert het aantal celadhesies, terwijl de lengte van celprotrusies 
en de bewegelijkheid van neuroblastoomcellen significant toeneemt. Ook laten we met 
behulp van bioinformatische analyses zien dat Tropomodulin 2 mogelijk een direct substraat 
is voor het kinase domein van TRPM7.  
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In hoofdstuk 5 onderzoeken we de hypothese dat TRPM7, door het controleren van de 
contractiliteit van cellen, genexpressie beïnvloed en daarmee het (kwaadaardige) gedrag van 
cellen reguleert. Terwijl onze groep eerder heeft aangetoond dat een verhoogde TRPM7 
expressie de contractiliteit van neuroblastoomcellen verlaagt, laten we hier zien dat het 
verlies van TRPM7 de contractiliteit van borstkankercellen verhoogt. Deze toename in 
contractiliteit gaat gepaard met een afname in de expressie van de transcriptiefactor SOX4, 
een belangrijke regulator van een genexpressie programma dat de bewegelijkheid en de 
migratie van cellen bevordert. Net als het verlies van TRPM7, leidt het verlagen van SOX4 
expressie tot borstkankercellen met een minder kwaadaardig fenotype. Tezamen suggereren 
deze resultaten dat TRPM7 bijdraagt aan de progressie van borstkanker door het behouden 
van kwaadaardige cel eigenschappen. De veranderingen in SOX4 expressie lijken een direct 
gevolg te zijn van veranderingen in contractiliteit die ontstaan na TRPM7 activatie. 
 Uit eerder onderzoek van onze groep is gebleken dat TRPM7 neuroblastoomcellen in een 
minder uitgerijpt, voorloper-achtig stadium houdt, door de expressie van de 
transcriptiefactor SNAI2 hoog te houden. In hoofdstuk 6 tonen we aan dat SNAI2 de 
differentiatie van neuroblastoomcellen reguleert door het onderdrukken van een 
genexpressie programma dat neuronale differentiatie bevordert. Een expressiepatroon 
gebaseerd op de expressie van de SNAI2-onderdrukte genen laat zien dat hoge expressie van 
SNAI2-onderdrukte genen sterk correleert met een goede, uitzaaiingsvrije prognose van 
neuroblastoompatiënten. Verder laten we zien dat in neuroblastoomcellen het verlies van 
SNAI2 leidt tot een vermindering van het kwaadaardige gedrag in een 3D omgeving en het 
vermogen van deze cellen om uit te zaaien in een muismodel. Bovendien maakt SNAI2 verlies 
neuroblastoomcellen veel gevoeliger voor behandeling met Vitamine A. Dit is een onderdeel 
van de therapie voor hoog-risico patiënten die de kans op terugkeer van de ziekte verkleint 
door de differentiatie van neuroblastoomcellen te bevorderen. Samenvattend concluderen 
wij uit deze resultaten dat SNAI2 bijdraagt aan neuroblastoom progressie door de 
differentiatie van neuroblastoomcellen te onderdrukken. 
In hoofdstuk 7 worden de resultaten van dit proefschrift in relatie tot de literatuur besproken. 
Daaruit volgend integreren we onze bevindingen tot een model dat beschrijft hoe TRPM7 zou 
kunnen bijdragen aan het kwaadaardige gedrag van (neuroblastoom)cellen. Daarnaast 
bespreken we hoe de hier opgedane kennis gebruikt kan worden voor de ontwikkeling van 








Daar zit je dan, na jaren van pipeteerwerk een heel boekwerk geschreven en dan aan het 
einde zoekende naar woorden om dit laatste, maar wel heel belangrijke, stuk te schrijven. 
Want laten we wel wezen, voor velen van jullie zal dit namelijk zo ongeveer het enige 
hoofdstuk zijn dat jullie daadwerkelijk lezen en interessant vinden. Begrijp me niet verkeerd, 
geen verwijten hier, niet iedereen kan zich verliezen in de wonderlijke wereld van TRPM7, 
maar ik voel de druk wel op mijn schouders.  
Of misschien, heel misschien speelt er toch ook nog iets anders. Misschien voelt dit als de 
definitieve afsluiting van een belangrijke, bewogen en vormende periode. Een periode met 
ups en downs, waarin ik niet alleen veel heb geleerd als onderzoeker, maar ook over mijzelf 
als persoon. Een periode waar ik mijn steentje heb mogen bijdragen aan een mooi onderzoek 
doorgegeven van PhD op PhD en waarin ik de warmte heb mogen voelen van de hulp, 
ondersteuning en gezelligheid van collega’s, lotgenoten, vrienden en familie. Want zoals 
velen van jullie weten (en daar is het cliché), een PhD doe je niet alleen. Ik wil dan ook graag 
mijn dankbaarheid uiten aan eenieder hieronder aangeschreven, maar ook zeker aan hen die 
ik onbedoeld ben vergeten.    
 
Beste prof. Dr. Hoogerbrugge, beste Peter. Wij hebben elkaar gedurende mijn PhD misschien 
niet veel gezien en gesproken, en jouw recht door zee persoonlijkheid en soms onverbloemde 
taalgebruik boezemde mij in den beginne ook een beetje angst in. Maar jouw directheid 
tijdens onze gesprekken en discussies heeft mij veel geleerd, want het is allemaal wel heel 
leuk wat wij in onze biologie bubbel bedenken, maar wat betekent dat nu echt voor de kliniek, 
voor de patiëntjes die ziek zijn. Door te vragen vanuit jouw point of view en geen genoegen 
te nemen met initiële antwoorden, liet jij me dieper nadenken over het belang van de materie 
en hoe je deze communiceert. Peter, ik wil je graag bedanken voor het klinisch inzicht dat jij 
mij hebt gebracht en je begeleiding en inzet om deze PhD tot een mooi einde te brengen.  
 
Frank, 8 jaar geleden klopte ik voor het eerst op jouw kantoordeur. Ik zou graag mijn 
masterstage lopen, maar niet op het leukemie onderzoek hoor, nee, op het neuroblastoma 
project mét microscopie. En zogezegd, zo gedaan. Wat begon als een masterstage monde uit 




graag bedanken voor de kansen die jij mij hebt geboden en dat (strenge) duwtje in de rug om 
toch dat proposal te schrijven. Ik heb met veel plezier in jouw groep gewerkt. Naast jouw 
onuitputbare bron van kennis en no-nonsense houding zal ik ook nooit vergeten dat jij tijdens 
een lab-etentje gierend van het lachen de te veel bestelde sushi onder bordjes en servetjes 
verstopte en altijd al dubbel ligt van het lachen voordat je überhaupt begonnen bent met het 
geven van je speech. Nogmaals bedankt en gelukkig zullen wij elkaar nog vaak zien en spreken 
op het Prinses Máxima. 
 
Jeroen! Ons TRPM7 team was helaas van korte duur, maar toch hebben we een heel leuke 
tijd gehad samen op dit project en volgens mij ook best mooi werk afgeleverd. Ook toen jij je 
volgende roeping had gevonden als leraar bij de HU, hebben wij nog veel gesproken en 
gespard, en ik ben je dan ook dankbaar dat je in je drukke schema ook nog tijd voor mij kon 
vinden. Daarnaast vond ik het ook supertof om op de HU gezamenlijke gastcolleges te geven. 
Helaas doe ik met deze thesis wel het licht uit bij Team TRPM7 en kan ik mijn rol als 
ambassadeur van ‘the most important protein of the world’ aan niemand overdragen. 
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niet vergeten. We hebben maar even tegelijk bij LKO/Team TRPM7 gewerkt en ik heb je zelfs 
van je bureau verdreven (hopelijk kun je het me vergeven). Bedankt voor jouw altijd snelle 
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maar dat mocht de pret niet al te veel drukken. Met jouw vrolijke karakter en flinke dosis 
doorzettingsvermogen heb ook jij bergen met werk verzet. Special thanks voor jouw hulp met 
de rebuttal van hoofdstuk 6. En natuurlijk Suzanne, wat was het supertof om te zien hoe jij je 
ontwikkelde tijdens jouw stage! Helaas heeft jouw werk geen plek kunnen vinden in dit 
proefschrift, toch ben ik erg blij met het werk dat jij hebt gedaan. Ik wil jullie alle vier graag 
bedanken dat jullie je met hart en ziel hebben ingezet voor ‘mijn’ onderzoek. Het was een eer 
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Xenia, I cherish our awesome time in Hamburg and our honest talks. You girls gave me a lot 
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jij natuurlijk ook heel erg bedankt hiervoor! Daarnaast nogmaals dank voor het supersnel 
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lockdown. En Kadem! Bedankt voor de gezellige praatjes en jouw hulp aan ons lab.   
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collega’s Aida, Dedeke, Pauline, Ronald, Tamara en Susan bedanken voor hun steun tijdens 
de laatste loodjes. 
 
En dan natuurlijk mijn paranymfen. Miriam, hoewel jij en Steffi in mijn afwezigheid hadden 
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dat dat toch wel meeviel. Ik wil je bedanken voor de super tijd die we samen hebben gehad 
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kerstmarkt, koekjes bakken en ‘water’ drinken tijdens de vierdaagse feesten, we hebben onze 
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Hoewel pipeteren natuurlijk van levensbelang is, moet de nodige ontspanning in een lab-vrije 
omgeving absoluut niet worden onderschat. Alba, Dorine, Kiki en Ronald, bedankt voor de 
gezellige etentjes, drankjes, lunches en avondjes. Kwaliteit over kwantiteit! En ook Dries, 
Marthe en de kleine Kasper, de biertjes, BBQ’s en wandelingen zijn altijd supergezellig!   
 
Antoine, many thanks to you for letting me use one of your beautiful pieces of art as the cover 
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Naast begeleiders, collega’s en vrienden, is de steun van familie erg belangrijk. Mama en 
Alfons, bedankt voor jullie onvoorwaardelijke steun en dat jullie er altijd voor mij zijn, ook al 
had ik niet altijd evenveel tijd voor jullie. Papa en Wilma, bedankt voor de ontspannen 
gesprekken, deze spaarzame tijd kwam vaak op het juiste moment en deed mij altijd goed. 
Nanouk, Joost en Kalle, Daan en Lieke, en Eline, geheel op jullie eigen manier hebben jullie 
mij bewust en onbewust weten te ondersteunen; soms met kopjes thee, een knuffel, 
exotische, wilde verhalen of juist een thesis-vrije zone. Jullie weten niet half hoe belangrijk 
dat is. Martin en Jeanne, Hanneke en Robin, Maartje en Ivo, Hubine en Quincy, bedankt voor 
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minder dan muggen. Samen met jou zijn dingen altijd mooier en leuker. Bedankt voor jouw 
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Research Data Management 
The experimental procedures as well as analysed data in the form of graphs and images 
obtained during this PhD project at the Radboudumc and described in this thesis have been 
carefully written down in paper lab journals until September of 2016. These lab journals are 
stored in the department archive (Radboudumc, room M357.-2.118G). From September 2016 
onwards, experimental procedures and analysed data have been captured and stored on the 
digital lab book client Labguru. This lab book client is centrally stored and daily backed-up to 
the local Radboudumc server. Both paper labjournal and Labguru entries reference the 
specific digital location paths where raw data of the experimental entry is located. Upon the 
migration of the laboratory from the Radboudumc to the Princess Màxima Center for 
Pediatric Oncology, Labguru entries were exported as read only onto a mobile portable disk 
stored in the office of Dr. F. N. van Leeuwen, as well as on the read only partition of the 
department server at the Princess Màxima Center. Similarly, all raw and analysed data was 
remained in original folders but transferred to the mobile portable disk and read only 
partition of the department server at the Princess Màxima Center. 
Mouse studies described in Chapter 6 were approved by the Central Animal Laboratory and 
the Animal Ethics Board of the Radboudumc.  
Gene-expression dataset analyses described in Chapters 3, 4 and 6 are performed using 
published expression data sets publicly available via the Gene Expression Omnibus. Analyses 
were performed on the publicly accessible, web-based R2 genomics analysis and visualization 
platform.  
All raw and processed micro-array data displayed in Chapter 5 and RNA-seq data displayed in 
Chapter 6 is available in the Gene Expression Omnibus, accession codes GSE63958 and 







Voor het bijwonen van de 
openbare verdediging van het 
proefschrift:
TRPM7: 
Integrating signal transduction, 
cytoskeletal dynamics and 
transcription in neuroblastoma 
progression  
Op woensdag 4 november 2020 
om 10:30 uur precies
De plechtigheid zal live 
te volgen zijn via: 
www.ru.nl/aula/livestream
Kirsten Vrenken
Komijnweg 29
3541 RK Utrecht
k.vrenken@gmail.com
Paranimfen:
Miram Butler
M.Butler@prinsesmaximacentrum.nl
Britt Vervoort
B.M.T.Vervoort@
prinsesmaximacentrum.nl
